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ABSTRACT OF THE DISSERTATION 
NEW ORGANOGERMANIUM SUBSTRATES FOR PD-CATALYZED CROSS-
COUPLING REACTIONS. APPLICATION OF ORGANOGERMANES TOWARDS 
THE SYNTHESIS OF CARBON-5 MODIFIED URIDINE ANALOGUES 
by 
Jean-Philippe Pitteloud 
Florida International University, 2010 
Miami, Florida 
Professor Stanislaw F. Wnuk, Major Professor 
 The diverse biological properties exhibited by uridine analogues modified at 
carbon-5 of the uracil base have attracted special interest to the development of efficient 
methodologies for their synthesis. This study aimed to evaluate the possible application 
of vinyl tris(trimethylsilyl)germanes in the synthesis of conjugated 5-modified uridine 
analogues via Pd-catalyzed cross-coupling reactions. The stereoselective synthesis of 5-
[(2-tris(trimethylsilyl)germyl)ethenyl]uridine derivatives was achieved by the radical-
mediated hydrogermylation of the protected 5-alkynyluridine precursors with 
tris(trimethylsilyl)germane [(TMS)3GeH]. The hydrogermylation with Ph3GeH afforded 
in addition to the expected 5-vinylgermane, novel 5-(2-triphenylgermyl)acetyl 
derivatives. Also, the treatment with Me3GeH provided access to 5-vinylgermane uridine 
analogues with potential biological applications. 
 Since the Pd-catalyzed cross-coupling of organogermanes has received much less 
attention than the couplings involving organostannanes and organosilanes, we were 
prompted to develop novel organogermane precursors suitable for transfer of aryl and/or 
  v
alkenyl groups. The allyl(phenyl)germanes were found to transfer allyl groups to aryl 
iodides in the presence of sodium hydroxide or tetrabutylammonium fluoride (TBAF) via 
a Heck arylation mechanism. On the other hand, the treatment of allyl(phenyl)germanes 
with tetracyanoethylene (TCNE) effectively cleaved the Ge-C(allyl) bonds and promoted 
the transfer of the phenyl groups upon fluoride activation in toluene.  
 It was discovered that the trichlorophenyl,- dichlorodiphenyl,- and 
chlorotriphenylgermanes undergo Pd-catalyzed cross-couplings with aryl bromides and 
iodides in the presence of TBAF in toluene with addition of the measured amount of 
water. One chloride ligand on the Ge center allows efficient activation by fluoride to 
promote transfer of one, two or three phenyl groups from the organogermane precursors. 
The methodology shows that organogermanes can render a coupling efficiency 
comparable to the more established stannane and silane counterparts. Our coupling 
methodology (TBAF/moist toluene) was also found to promote the transfer of multiple 
phenyl groups from analogous chloro(phenyl)silanes and stannanes. 
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1. INTRODUCTION 
1.1. Nucleosides and nucleotides as targets for antiviral and anticancer therapy 
The initial studies on the synthesis of nucleosides and nucleotides were intended 
to demonstrate the structure of adenosine and other naturally occurring ribo- and 
deoxyribonucleosides. Further developments have been devised as an opportunity to 
synthesize nucleoside/nucleotide analogues that might serve as specific inhibitors of 
enzymes involved in cell metabolism and proliferation. Moreover, the key role of such 
molecules as building blocks of nucleic acids (DNA and RNA) has promoted the design 
of many efficient methodologies to create synthetic oligonucleotides of great importance 
in the elucidation of the human genome, study of DNA-protein interactions, gene 
modulation, RNA catalysis, and DNA/RNA structure and stability. Although, it remains 
less costly to obtain the major nucleosides by simple degradation of nucleic acids, 
decades of efforts have been dedicated to discover more efficient strategies for their total 
synthesis. Such methodologies led to the preparation of very interesting modified 
nucleosides, which exhibited wide range anticancer and antiviral activity.1  
Anticancer nucleoside analogues: 
The most common cancer treatments currently in use are based on the inhibition 
of cell DNA replication and/or interference of its important functions. An important 
rationale applied on targeting such cellular processes was the fact that most of the cells in 
adults are in a quiescent state in which replication of its DNA is not in full activity. 
However, some specific tissues (e.g., hair follicles, gastrointestinal, bone marrow) are 
always in a replicative state. In addition, since all cells are repairing their often damaged 
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DNA, exposure to long-term treatments leads to important toxicity levels in cancer 
patients.2  
Presently, the U.S. Food and Drug Administration (FDA) has approved around 14 
nucleoside-based drugs for the treatment of cancer (Table 1). Noteworthy, this number 
represents approximately 20% of the drugs in use to treat cancer, and three of these have 
been approved during the last 6 years.2 These important events have promoted the 
investigation of base/sugar-modified nucleosides as novel leads in cancer treatment. In 
general, many of the purine and pyrimidine antimetabolites share very similar metabolic 
pathways within the cell but it is the inhibition of certain enzyme(s), which confers them 
the activity against a particular cancer.  
Table 1: FDA approved anticancer purine and pyrimidine nucleoside analogues.2 
 
Drug Date of approval
6-mercaptopurine 1953 
5-fluorouracil 1962 
6-thioguanine 1966 
Arabinofuranosylcytosine (cytarabine) 1969 
5-fluoro-2'-deoxyuridine (floxuridine) 1970 
2'-deoxycoformycin (pentostatin) 1991 
Arabinofuranosyl-2-fluoroadenine (fludarabine) 1991 
2-chloro-2'-deoxyadenosine (cladribine) 1992 
2,2-difluoro-2'-deoxycytidine (gemcitabine) 1996 
N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (capecitabine) 1998 
5-aza-cytidine (vidaza) 1998 
2'-fluoro-2'-deoxyarabinofuranosyl-2-chloroadenine (clofarabine) 2004 
O6-methylarabinofuranosyl guanine (nelarabine) 2005 
5-aza-2'-deoxycytidine (decitabine) 2006 
 
Surprisingly, as noted by some authors3, “one of the most remarkable features of 
purine and pyrimidine nucleoside analogues that remain unexplained is how drugs with 
such similar structural features, share metabolic pathways and elements of their 
mechanism of action show, such diversity in their clinical activities”. This certainly 
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serves as a driving force for the rational design and synthesis of novel modified 
nucleoside analogues, looking for the most potent and less toxic anticancer drugs. 
In most cases, nucleoside drugs are required as substrates of certain enzymes in 
order to generate the active metabolite responsible for their biological activity. 
Phosphoribosyl transferases are responsible for the activation of the three base analogues, 
mercaptopurine, thioguanine, and fluorouracil, and there are five other enzymes 
accountable for the first phosphorylation of most of the nucleoside analogues.4-6 
Conversion of the monophosphate nucleoside is followed by a second phosphorylation by 
the appropiate monophosphate kinases7 giving the corresponding diphosphate. The last 
phosphorylating event occurs after the participation of the nucleoside diphosphate 
kinases. Later, the triphosphate nucleoside analogue usually interacts with the DNA 
polymerases. There are three modes of interaction between the triphosphate nucleoside 
and the DNA polymerases: 1) compete with the natural substrate without acting as a 
substrate; 2) substitute for the natural substrate with a small effect on DNA synthesis; or 
3) substitute for the natural substrate and interfere with DNA synthesis by chain 
termination. Among these three, the latter two have been proposed as the most likely for 
the interaction of most of the tri-phosphorylated nucleoside drugs with the DNA 
polymerases. On the other hand, the selectivity and effectiveness of the various approved 
anticancer drugs can be attributed to 1) how easily the DNA chain is extended after the 
incorporation of the drug and 2) how easily they may be removed by the proof-reading 
exonucleases. Some representative examples of nucleoside drugs approved for the 
treatment of cancer are presented as follows.  
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a) Thiopurine analogues: 
In 1953 the FDA approved 6-mercaptopurine (MP) (Figure 1) as one of the first 
drugs for the treatment of childhood acute lymphocytic leukemia.8 Being an analogue of 
hypoxanthine makes it an excellent substrate for hypoxanthine/guanine phosphoribosyl 
tranferase. Subsequently, the 6-thio-inosine monophosphate (T-IMP) acts as a substrate 
of IMP dehydrogenase and is converted to the guanine nucleotide. Therefore, 
ribonucleotide reductase converts it to the corresponding 6-thio-2'-deoxyguanosine-5'-
triphosphate, which is easily incorporated into DNA. Although, its incorporation does not 
result in the inhibition of DNA polymerase, it is believed to cause important DNA 
damage accounting for its antitumor activity. 
 Similarly, thioguanine (TG) is straightforwardly converted to its corresponding 
nucleotide (T-GMP) by hypoxanthine/guanine phosphoribosyl transferase. The following 
incorporation of T-GMP into DNA is also suggested to cause DNA damage in analogous 
fashion to T-IMP.9 The FDA approved thioguanine (TG) in 1966 as a treatment for 
myelogenous leukemia. 
NH
NNH
N
S
NH
NNH
N
S
NH2
Mercaptopurine Thioguanine
Figure 1. Thiopurines with anticancer activity.  
b) Cytidine analogues:  
Many deoxynucleoside derivatives have been reported as important anticancer 
agents. Their clinical use is relatively new and most of them share very similar 
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mechanisms of action based on the inhibition of DNA polymerases and/or ribonucleotide 
reductase. However, subtle modifications of their structures have resulted in their 
different properties and unique clinical activities (Figure 2). 
 Cytarabine (arabinocytidine, AraC) is a good substrate for deoxycytidine 
kinase, and its fundamental metabolite inside the cell is its corresponding tri-phosphate 
AraCTP. After AraCTP incorporation in the 3'-end of the new DNA strand, further 
elongation is drastically inhibited.10 
 Gemcitabine (2'-difluoro-2'-deoxycytidine, dFdC) is also a good substrate for 
the DNA polymerases as its tri-phosphorylated analogue dFdC-TP.11 In contrast to AraC, 
after its incorporation into DNA, the chain extension is only interrupted after the 
integration of the next nucleoside. It must be mentioned that a much greater percentage of 
dFdC-TP was incorporated in internal positions (>90%) compared to araCTP. Moreover, 
the proof-reading exonucleases associated with DNA polymerase  were not capable to 
remove dFdC from the newly damaged DNA, which is not likely the case with araC.12 
Another difference that accounts for the increased potency of Gemcitabine compared to 
Cytarabine is its ability to inhibit ribonucleotide reductase.13 Blocking this enzyme results 
in a considerable reduction of the availability of natural substrates for DNA replication, 
thus enhancing its anticancer activity. The FDA approved Gemcitabine in 1996 for the 
treatment of non-small cell lung cancer and pancreatic cancer. 
  Decitabine (aza-dCyd) and Vidaza (aza-Cyd) are both excellent substrates for 
the successive phosphorylations via deoxycytidine kinase14-17 and uridine/cytidine kinase 
to form the aza-dCTP and aza-CTP, respectively. In contrast to Cytarabine and 
Gemcitabine, aza-dCTP is easily incorporated and extended into the internal positions of 
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the new DNA.18 Upon its incorporation, inhibition of the methylation of the DNA chain 
was suggested to be responsible for its observed activity. On the other hand, aza-CTP is a 
ribonucleotide metabolite, which is readily converted to the corresponding deoxycytidine 
analogue by ribonucleotide reductase and incorporated into DNA. Although aza-CTP is 
also integrated into RNA, its antitumor activity is attributed to the inhibition of DNA 
methyltransferase once present in DNA.  
Deoxycytidine AraC Gemcitabine
Decitabine Vidaza
Figure 2. Cytidine analogues with anticancer activity.
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c) Purine nucleoside analogues:  
Since 1991 the FDA has approved five purine deoxynucleosides for their clinical 
use as anticancer agents (Figure 3). 
 Fludarabine (F-araA), was approved by the FDA in 1991 for the treatment of 
chronic lymphocytic leukemia as its monophosphorylated nucleotide F-araAMP.19,20 The 
design of F-araA analogue was based on the previous discovery of the effect of 
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substituting the 2-hydrogen atom of adenosine with a halogen, hampering its inactivation 
by adenosine deaminase.21,22 Nelarabine is a pro-drug of araG approved for the treatment 
of T-cell malignancies.23 It is used instead of araG because of the low solubility of the 
latter. Incorporation of either F-araAMP or araGMP results in the inhibition of the DNA 
replication by chain termination.24-26 F-araATP was also reported as a weak inhibitor of 
ribonucleotide reductase.27 
Fludarabine
Pentostatin
Cladribine
Clofarabine
Figure 3. Purine nucleoside analogues with anticancer activity.
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 Cladribine (Cl-dAdo) is a 2'-deoxyadenosine derivative used for the treatment of 
hairy-cell leukemia after approval in 1992.28 It is efficiently converted by the action of 
deoxycytidine kinase and nucleotide kinase to Cl-dATP, which is an excellent substrate 
for the DNA polymerases. It is only after the incorporation of three successive Cl-dAdo 
residues that the DNA replication is stopped.28 Cladribine is also a more potent inhibitor 
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of ribonucleotide reductase than Fludarabine.24,28 The presence of the Cl atom at position 
2 of the adenine base confers special stability to deamination by adenosine deaminase.  
 Clofarabine (Cl-F-araA) has almost the same structure as Cladribine with the 
introduction of a fluorine atom in position 2' of the deoxyribose moiety. It was approved 
for clinical use against relapsed and refractory pediatric lymphoblastic leukemia in 
2004.29,30 The 2'-fluoro unit confers unique stability to the glycosidic bond in the 
presence of acids producing very good oral bioavailability. The mechanism of action may 
be seen as a combination of that described for Fludarabine and Cladribine, resulting in 
the potent inhibition of both DNA polymerase and ribonucleotide reductase.24,31,32 
Pentostatin (deoxycoformycin) like Cl-dAdo has also been approved treatment 
for hairy-cell leukemia since 199133,34, but with a different way of action. Pentostatin 
inhibits adenosine deaminase, causing the accumulation of high levels of dATP, which 
subsequently inhibits ribonucleotide reductase and further DNA synthesis. 
These examples of approved anticancer drugs (figures 1-3) are certainly the 
product of many years of close collaboration between synthetic organic chemists and 
biologists. In a similar fashion, such collaboration resulted in the discovery of very 
important modified nucleosides that exhibit interesting cytotoxic profiles against a wide 
range of pathogenic viruses in humans (e.g., rhabdoviruses (rabies), filoviruses (Ebola), 
arenaviruses (Junin, Tacaribe), reoviruses (rota), paramyxoviruses (parainfluenza, 
measles), retroviruses (HIV), herpesviruses, poxiviruses (variola), etc.). Some examples 
are presented as follows. 
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Antiviral nucleoside analogues: 
a) Purine nucleoside analogues. Via inhibition of (S)-adenosylhomocysteine hydrolase:  
 Soon after the discovery of the antiherpes virus properties of Acyclovir, (S)-9-
(2,3-dihydroxypropyl)adenine (DHPA) (Figure 4) appeared as broad-spectrum antiviral 
agent. Specific phosphorylation of the drug by the herpes simplex virus (HSV)-encoded 
thymidine kinase accounted for the initial metabolism of Acyclovir.35,36 A similar 
metabolic pathway was proposed for the alternative DHPA. Many years later, DHPA was 
demonstrated to be an inhibitor of S-adenosylhomocysteine (SAH) hydrolase, which 
causes accumulation of S-adenosylhomocysteine, leading to suppression of the 
conversion from S-adenosylmethionine (SAM) to SAH.37 This last step is responsible for 
the methylation (capping) of viral mRNAs, which results in their maturation and further 
replication.37  
 In the search for other adenosine analogues in which either acyclic or carbocyclic 
residues have replaced the sugar moiety, 3-deazaadenosine (C-c3Ado) and 3-
deazaneplanocin A offered interesting profiles. Both analogues were found to be 
protective to the Ebola virus-infected mouse.38,39 After finding substantial amounts of 
interferon in the infected mice, it was suggested that 3-deazaneplanocin A prevents the 
release of mature mRNAs after inhibiting the capping of viral mRNAs. The resulting 
accumulated mRNAs promote formation of double-stranded RNA, known to induce 
production of interferon. 
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X=N Carbocyclic adenosine (C-Ado)
X=CH Carbocyclic 3-deazaadenosine (C-c3Ado)
Figure 4. Purine nucleoside analogues with antiviral activity by inhibition of S-
adenosylhomocysteine (SAH) hydrolase.
X=N Neplanocin A
X=CH 3-deazaneplancin A
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b) Purine and pyrimidine nucleoside analogues. Via inhibition of reverse trancriptase 
(NRTIs): 
At the present, seven 2',3'-dideoxynucleoside analogues (ddN) have been 
approved for the clinical treatment of HIV infections: zidovudine (AZT), didanosine 
(ddI), zalcitabine (ddC), stavudine (d4T), lamivudine (3TC), emtricitabine ((-)FTC), 
and abacavir (ABC) (Figure 5).40 They all share the action mechanism first postulated 
for AZT.41 Successive phosphorylations result in the formation of the corresponding 5'-
triphosphate ddN analogues, which are readily incorporated into DNA by the HIV-
encoded reverse transcriptase. The lack of a 3'-hydroxyl group results in the DNA chain 
termination and subsequent inhibition of the reverse transcription process. 
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Figure 5. Purine and pyrimidine nucleoside analogues with antiviral activity 
by inhibition of reverse trancriptase (NRTIs)
Didanosine (ddI)Zidovudine (AZT) Zalcitabine (ddC)
Stavudine (d4T) R=H Lamivudine (3TC)R=F Emtricitabine ((-)FTC)
Abacavir (ABC)
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1.1.1. 5-Modified pyrimidine nucleosides 
1.1.1.1. 5-Fluorouracil (FUra), a potent inhibitor of thymidylate synthase 
Approved by the FDA in 1962, fluorouracil or 5-fluorouracil (FUra) may be one 
of the most important anticancer drugs (Figure 6). Initially, the design of FUra was based 
on important principles; 1) a fluorine and a hydrogen atom have approximately the same 
size; 2) a C-F bond is much stronger than a C-H bond; 3) thymidylate synthase 
substitutes the H5 on uracil base for a methyl group from methylene tetrahydrofolate; and 
4) rat hepatoma cells use uracil, but not normal liver cells. Consequently, Heidelberger et 
al. proposed that FUra would selectively kill cancer cells through inhibition of 
thymidylate synthase.42 Later on, the proposed hypotheses were confirmed and FUra 
started to be used in the treatment of colorectal, breast, stomach, and pancreatic cancers.43 
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 The metabolic cascade of FUra starts with the conversion of the administered 
drug (FUra) into the corresponding mono phosphorylated nucleoside analogue (F-UMP) 
by orotate phosphoribosyl transferase. Subsequently, the corresponding nucleotide 
kinases convert F-UMP to F-UTP, which acts as a competitive substrate in the synthesis 
of RNA and promotes the incorporation of high levels of FUra in many different types of 
RNA. Although the effect of FUra on novel functions of RNA has not been yet 
elucidated, its incorporation into RNA is suggested to contribute to its high potency. 
Capecitabine
Figure 6. 5-Fluorouracil (FUra) and its derivatives.
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Furthermore, 5-fluorouridine-5'-diphosphate (F-UDP) acts as a substrate for 
ribonucleotide reductase and is converted to the corresponding F-dUDP by the removal 
of the 2'-OH group. Action of the nucleoside diphosphate NDP kinase transforms F-UDP 
into F-UTP, which is readily incorporated into DNA by the DNA polymerases. 
Recognition of the defective 5-Ura fragment in the new DNA is efficiently performed by 
uracil glycosylase, resulting in its further removal. The apurinic/apyrimidinic 
endonuclease I readily identifies the empty site in DNA, causing a single strand break. 
The DNA repair enzymes finally recognize the broken strand, and trigger the repair and 
re-synthesis of DNA known to set up a cycle that promotes inhibition of DNA synthesis 
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and cell death. In addition, competition between F-UMP with the natural 2'-deoxyuridine 
mono-phosphate (dUMP) results in the inhibition of thymidilate synthase because of its 
inability to remove the fluorine atom. Consequently, the incapacity of thymidilate 
synthase to produce thymidine triphosphate (TPP) fosters (no competition) the 
incorporation of F-UTP into DNA with concomitant cell death.44,45 
In summary, the high potency of FUra as an anticancer drug may be attributed to 
the symbiotic inhibition of two related metabolic pathways by its corresponding 
nucleotide derivatives: 1) considerable depression of the availability of TPP for DNA 
synthesis, and 2) cell death after incorporation of the defective FUra-containing monomer 
into DNA. 
Later on, capecitabine and floxuridine (Figure 6) emerged as effective prodrugs of 
FUra. The former, administered orally, is converted to FU after three enzymatic steps.46 
Because of the overexpresion of thymidine phosphorylase in tumor tissues, capecitabine 
is assumed to have increased selectivity compared to FUra. Althugh it is not widely 
employed, floxuridine readily undergoes a similar coversion to FUra by thymidine 
phosphorylase.47 
1.1.1.2. Bromovinyldeoxyuridine (BVDU), an important antiviral drug 
Collaborative efforts between the laboratories of Dr. Erick De Clercq (Rega 
Institute for Medical Research, Belgium) and Dr. Richard Walker (Chemistry Department 
of the University of Birgminham, U.K.) led to the discovery of [(E)-5-(2-bromovinyl)-2'-
deoxyuridine] (BVDU), a highly potent antiviral drug with specific activity against 
herpes simplex virus type 1 (HSV-1) and varicella zoster virus (VZV).48,49 The unique 
(E)-5-(2-bromovinyl) moiety, attached to carbon 5 in the uracil base, was suggested to be 
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the source of the shown specificity of BVDU, thus promoting the synthesis of congeners 
containing such a fragment. Among the various BVDU analogues prepared, BVaraU 
(sorivudine) presented similar activity against HSV-1 and, particularly, VZV (Figure 7).49 
BVaraU (sorivudine)
Figure 7. (E)-5-(2-bromovinyl) containing uridine analogues BVDU 
and BVaraU. Potent antiviral agents.
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Specific phosphorylation of the nucleoside analogue by the HSV-1 or VZV-
encoded thymidine kinase (TK) affords the corresponding 5'-diphosphate (BVDU-DP). A 
third phosphorylating event, by nucleoside diphosphate kinase (NDP), results in BVDU-
TP, which competes with deoxythymidine triphosphate dTPP for the viral DNA 
polymerase. The efficient incorporation of several BVDU-TP units into the viral DNA 
renders a structurally and functionally inoperative DNA (Scheme 1).49 Interestingly, 
herpes simplex virus type 2 (HSV-2) encoded thymidine kinase (TK) cannot transform 
the corresponding 5'-monophosphate-BVDU to its 5'-diphosphate, resulting in a 
decreased activity compared to HSV-1 and VZV. The antiviral activity spectrum of 
BVDU has been extended to suid herpesvirus type 1 (SHV-1), bovid herpes virus type 1 
(BHV-1), simian varicella virus (SVV), herpesvirus saimiri, and herpesvirus 
platyrrinhae.50 In comparison with other approved antiviral agents such as acyclovir, 
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valaciclovir, and famciclovir; BVDU can be administered orally at smaller dosage (125 
mg) and less frequently (once per day).51 
 
Scheme 1: Mechanism of action of BVDU.49 
On the other hand, BVDU should not be administered to patients under treatment 
with the 5-fluorouracil (FUra, see section 1.1.1.1). Thymidine phosphorylase converts 
BVDU to its free base (E)-5-(2-bromovinyl)uracil (BVU), which is a potent inhibitor of 
dehydropyrimidine dehydrogenase (DPD). Similarly, the same enzyme is also in charge 
of the degradation of 5-fluorouracil.52 
Recently, bicyclic furo[2,3-d]pyrimidine nucleoside analogues (BCNAs) have 
emerged as a new generation of potent antivirals with activity against varicella zoster 
virus (VZV).53,54 Among the BCNAs, Cf 1742 and Cf 1743 (Figure 8) showed high anti-
VZV replication activity at subnanomolar concentrations (EC50:0.1-1 nM), which in 
comparison is about 10-fold lower than for BVDU, and 10,000-fold lower than 
acyclovir.55 Although, the mechanism of action of the BCNAs has not been fully 
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resolved, it was proved they inhibit VZV replication as its triphosphorylated derivative 
BCNA-TP. The latter is suspected to act as a competitive inhibitor/alternate substrate in 
the viral DNA synthesis.  
n=5  Cf 1742
n=4  Cf 1743
Figure 8. Bicyclic furo[2,3-d]pyrimidine nucleoside analogues 
with anti-VZV activity.55
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In addition, and likely not the case with BVDU, the BCNAs are not substrates for 
thymidine phosphorylase and thus do not obstruct the catabolism of 5-fluorouracil 
(FUra).52 Therefore, BCNAs are the therapy of choice for VZV infections in patients 
under 5-fluorouracil treatment. 
The search for new, therapeutically useful, modified purine and pyrimidine 
nucleoside analogues has promoted the development of many different approaches for 
their efficient synthesis. The known versatility, selectivity, and relatively mild reaction 
conditions necessary for palladium-catalyzed coupling reactions have engendered their 
application in the synthesis of many important metabolites.56 Therefore, the second part 
of this introduction will be focused on a general description of the palladium-catalyzed 
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coupling reaction, emphasizing the new developments and the use of Group 14 metals as 
well as the role of hypervalent species as reactive intermediates (see 1.2). The third part 
will review various applications of the palladium-catalyzed coupling reaction in the 
synthesis of 5-modified pyrimidine nucleoside analogues (see 1.3). 
1.2. An overview of the palladium-catalyzed coupling reactions 
Many combinations of palladium complexes and organometallic substrates have 
been successfully employed for the generation of new C-C bonds.57 The Pd-catalyzed 
cross-coupling was first studied by Murahashi in the reaction of aryllithiums and vinyl 
halides (Scheme 2).58 Later on, Negishi reported efficient coupling of alkenylaluminum, -
zinc, and -zirconium reagents with vinyl and aryl halides (Negishi reaction).59 Reaction 
of alkenyl copper(I) precursors with alkenyl halides was also reported by Normant.60 The 
use of organic tin compounds as coupling precursors was introduced by Migita and 
Kosugi and extensively followed by Stille (Stille-Migita-Kosugi reaction).61,62 Suzuki and 
Miyaura initiated the application of organoboron compounds, which easily undergo 
cross-coupling after activation with base (Suzuki-Miyaura reaction).63 Strategies 
involving the use of organosilanes have been widely exploited in the last decade 
(Hiyama-Denmark reaction).64 Terminal alkynes were also found to undergo coupling 
with halides in the presence of Cu (I) and palladium catalyst (Sonogashira reaction).65 
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R M
Scheme 2. Common organometallic precursors employed in Pd-
catalyzed cross-coupling reactions.
R R'
Pd catalyst
X=I, Br, Cl, OTf
R' X
M= Li (Murahashi)
       Al, Zn, Zr (Negishi)
       Cu (R=alkenyl, Normant)
       Sn (Stille-Migita-Kosugi)
       B (Suzuki-Miyaura)
       Si (Hiyama-Denmark)
       Cu (R=alkynyl, Sonogashira)
 
The alkenylation of organic electrophiles, also known as the Heck reaction, is 
often included in the family of coupling process, even though there is no transmetallation 
step.66 The cross-coupling reactions may be seen as a very diverse family of processes, in 
which most of the mechanistic aspects are shared despite the different activation 
requirements for the organometallic nucleophiles. Important mechanistic information has 
been mostly obtained from the study of the coupling of organostannanes with organic 
electrophiles in the presence of palladium and the conclusions extended to other coupling 
reactions.67 A general mechanism proposed for the coupling of organostannanes (Scheme 
3) consists of an initial oxidative addition of Pd(0) to the corresponding halide to form 
the cis-PdL2R1 complex (1) followed by fast isomerization to the more stable trans-
complex (2). Transmetallation involving the organometallic nucleophile and the trans-
complex (2) via an associative substitution (SE2 reaction) give the cyclic intermediate (3). 
Such a complex is assumed to directly afford the cis-PdLR1R2 complex (4) from which 
the cross-coupled product (R1-R2) is obtained after reductive elimination of palladium as 
the reactive PdL2 complex.68,69 
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Scheme 3. Proposed mechanism for the Stille reaction via a cyclic associative 
transmetallation.68,69
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The cyclic associative transmetallation model is applicable to the Stille reaction 
under the most common conditions consisting of moderately coordinating solvents, 
palladium complexes with monodentate ligands, and ratios L/Pd >2:1. Investigation of 
the coupling under different conditions promoted the appearance of different models such 
as the dissociative and the open associative transmetallation.70,71 
 Because the extensive methodologies developed for the Pd-catalyzed cross-
coupling reactions are the subject of numerous excellent reviews,67 in the next part of the 
introduction I will concentrate on those aspects of the Pd-catalyzed cross-coupling which 
are either less developed/understood or have become major subjects of my dissertation. 
1.2.1. Group 14 metals (Sn, Si, Ge) in Pd-catalyzed cross-coupling reactions 
Among all different organometallic reagents efficiently employed in the Pd-
catalyzed cross-coupling reactions, organostannanes (Stille-Migita-Kosugi) and 
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organoboranes (Suzuki-Miyaura) have been extensively used due to their reactivity and 
tolerance to a wide variety of functional groups. Nevertheless, the sensitivity of 
organoboranes and the toxicity associated with tin-containing byproducts have led to the 
search for more reliable alternatives. Thus, improvements of Stille-Migita-Kosugi and 
Hiyama-Denmark reactions have gained special attention in the last decade, as well as the 
development of new organogermanium coupling partners. 
Recent advances on Stille-Migita-Kosugi (Sn) reaction: 
Significant advances have been made on the use of more economical and 
environmentally friendly reaction media when using organotins in Pd-catalyzed cross-
coupling reactions. The ability to successfully perform the coupling reaction in aqueous 
media,72 supercritical carbon dioxide,73 and room-temperature ionic liquids (1-butyl-3-
methylimidazolium tetrafluoroborate, BMIM BF4)74 has notably expanded the scope of 
the Stille-Migita-Kosugi reaction.  
Novel Pd/ligand combinations have increased the reactivity of the less reactive 
organic bromide and chloride electrophiles (Scheme 4).75-77 More stable and efficient 
catalytic systems have been also successfully developed.78 The fluoride-activated 
organotins have been used as transmetallating agents, presumably acting via the 
corresponding hypervalent tin species (see 1.2.1.2).79-81 
Scheme 4. Coupling of aryltri(butyl)tin with arylchlorides.77
Pd(P(t-Bu)3)2
dioxane
100oC
ClSnBu3
X Y
X
Y
CsF
(76-94%)
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Recent advances on the Hiyama-Denmark (Si) reaction: 
Hiyama et al. reported the positive effect of fluoride ion on the nucleophilicity of 
certain substituents attached to trialkylsilanes 5 (Figure 9) because of the formation of 
pentavalent silicon species (see 1.2.1.2).82 However, transfer of alkenyl and allyl groups 
from the silane was not efficient. In order to overcome this drawback, Hiyama and co-
workers83 found that the presence of an electron-withdrawing ligand on the silicon center 
efficiently promoted nucleophilic activation by fluoride ions to afford the corresponding 
pentavalent silicate. Consequently, aryl(halo)silanes 6 were successfully used in the Pd-
catalyzed cross-coupling with less reactive arylchlorides.84,85 As with fluorosilanes, the 
presence of two chloro ligands was shown to give optimal results. Interestingly, such 
chloro-substituted silanes were also efficiently activated by hydroxide ions to give the 
corresponding cross-coupling products from the in situ generated silanol.86 
R Si(CH3)3
R=alkyl, aryl, alkenyl or alkynyl
5 76
8
Figure 9. Organosilanes employed in Pd-catalyzed cross-coupling 
reactions.
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In view of the apparent need for the generation of pentavalent silicon species, 
Denmark et al. explored the use of silacyclobutanes (siletanes) 7 as the nuclephilic 
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coupling partners.87 The use of such strained structures was based on the manifested 
increase of their Lewis acidity resulting from a change in the coordination geometry 
(strain-release Lewis acidity) from tetra- to penta-coordinated silicon species.88 However, 
further investigations evidenced the formation of silanol and/or siloxanes upon treatment 
of the corresponding silacyclobutane with TBAF3H2O. These products were evaluated 
as coupling substrates showing reactivity levels comparable to the parent 
silacyclobutanes.89 These important discoveries rapidly triggered the study of the Pd-
catalyzed cross-coupling of many structurally diverse oxygen-substituted silanes 
including, silanols 8, siloxanes 9, and polysiloxanes 10.64 Moreover, alternative use of 
base and Ag2O to activate the silanol precursors was demonstrated to be equally effective 
as the typical fluoride activation.64,90 Important mechanistic implications arose from the 
pioneering work by Denmark regarding silanol activation with potassium 
trimethylsilanolate (TMSOK). Kinetic studies revealed initial pre-equilibrium between 
the corresponding silanol 11 and a newly formed silanolate 12. Subsequently, 
nucleophilic 12 displaces the anionic ligand on Pd generating a reactive Pd-O-Si complex 
13, which can undergo intramolecular transmetallation (see 3 in Scheme 3) without 
additional activation (Scheme 5).91 
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Scheme 5. Proposed mechanism for silanol activation by TMSOK.91
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Development of new organogermanium (Ge) reagents for Pd-catalyzed cross-coupling 
reaction: 
The development of organogermanes as valuable reagents for the Pd-catalyzed 
cross-coupling has been less explored due to the higher cost and the diminished reactivity 
of germanium precursors compared to their silicon counterparts. The carbagermatranes 
14 (Figure 10) were the first examples of labile tetracoordinated germanes to undergo 
cross-coupling with aryl bromides in the presence of palladium catalyst.92 Subsequently, 
the oxagermatranes 15 were reported to be more efficient than the similar 
carbagermatranes 14 and triethoxygermanes 16.93 Internal coordination by the 
transannular nitrogen was attributed to the reactivity of both germatrane precursors. On 
the other hand, aryltri(2-furyl)germanes 17,94 arylgermanium trichlorides 18,95 and their 
hydrolyzed stable sesquioxides 1996 were coupled after treatment with either fluoride ions 
or NaOH, respectively. Interestingly, fluoride anion failed to promote the coupling of 
aryltrichlorogermanes 18.95 
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Figure 10. Organogermanes employed in Pd-catalyzed cross-coupling 
reactions.
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The vinyl tris(trimethylsilyl)germanes 20 were also described as efficient 
precursors in “ligand- and fluoride-free” coupling with halides upon oxidative (H2O2) 
activation.97 Moreover, the use of their (-fluoro)vinyl analogues 21 afforded the 
corresponding fluoroalkenes and fluorodienes.98 Coupling of vinyltributylgermanes 22 
with aryl halides gave preferential access to Z-alkenes, although the Heck mechanism 
was proposed as the major operative pathway.99 
1.2.1.1. Safety-catch precursors 
The application of the above-mentioned methodologies is often limited by the 
apparent lability of the heteroatom-substituted organometals and/or the harsh conditions 
needed for their in situ generation. However, continuous efforts are undertaken to 
develop novel “safety-catch” silicon and germanium precursors. Silyl hydrides,100 2-
pyridylsilanes,101 2-thienylsilanes,102 dimethylphenylsilanes,103 and dimethylbenzyl-
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silanes104 are successful examples of safety-catch substrates for Hiyama-Denmark 
coupling. On the other hand, the development of similar germanium precursors has been 
much less explored. Two of the most recent examples are described below. 
Hiyama’s allyl(phenyl)silanes:  
In 2004 Hiyama and co-workers reported the efficient coupling of aryl halides and 
the all carbon-substituted triallyl(phenyl)silane 23 (Scheme 6).105 The design was based 
on the polarization of the C-Si bond as a result of the in situ generation of pentavalent 
fluorosilicates. Optimization of the reaction conditions revealed that 4 equivalents of 
tetrabutylammonium fluoride trihydrate (TBAF3H2O) were necessary to efficiently 
promote the coupling reaction of silane 23 with several aryl halides. Supposedly, three 
equivalents of TBAF cleaved the three allyl substituents to afford trifluorophenylsilane, 
while the remaining equivalent of fluoride might generate the active pentavalent silicate 
suspected to undergo transmetallation. Furthermore, the couplings of 
diallyl(diphenyl)silanes 24, and allyl(triphenyl)silanes 25 were also performed under 
similar conditions to afford various biaryls. 
The experimental results suggested a clear dependence of the reactivity of the 
allyl(phenyl)silanes on the number of allyl substituents; PhSi(allyl)3 23 > Ph2Si(allyl)2 24 
> Ph3Si(allyl) 25. The identity of the active pentacoordinated silicate responsible for 
transmetallation is not yet well understood. The safety-catch triallyl(phenyl)silane 23 
may be seen as a promising alternative to be used in industrial and academic research, 
even though couplings using 23 and 24 required higher loadings of reagent to be 
efficient. Attempts to transfer more than one aryl group from 24 and 25 were ineffective 
supposedly due to the formation of inactive hexacoordinate silicate species. 
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Scheme 6. Coupling of safety-catch allyl(phenyl)silanes.105
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Spivey’s Bis(2-naphthylmethyl)arylgermanes: 
 In 2007 Spivey et al. developed novel bis(2-naphthylmethyl)arylgermane 28, 
highly stable towards bases and nucleophiles and that could be activated photochemically 
to assist cross-coupling with aryl halides affording biaryls.106 Also, the possibility for 
attachment of a phase-tag was successfully explored. On the basis of the assumed 
necessity for the presence of an electronegative heteroatom on the metallic center in order 
for it to render hypervalency and be active towards transmetallation, exploratory 
experiments using arylchlorogermanes and NaOH or KF were performed. They 
demonstrated that two chlorine ligands were necessary for efficient cross-coupling with 
aryl bromides. In the search for the most suitable safety-catch germane precursor, 
extensive and cautious screening established aryldibenzylgermanes as a promising 
candidate for photochemical activation. However, since the necessary short wavelength 
(275 nm) employed gave complex mixture of debenzylated products, an alterative group 
able to absorb light of lower energy was investigated. The replacement of the benzyl 
group for 2-naphthylmethyl (346 nm) proved to be an excellent choice since irradiation 
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of (2-naphthylmethyl)germane 26 with a high-pressure Hg lamp (125 W) in the presence 
of Cu(BF4)2nH2O afforded the corresponding {2-[4-(2-ethoxyethoxy)phenyl]ethyl}-
dimethylfluorogermane 27 [19F NMR  -196 ppm (“septet”, 3JF-H 7 Hz)] (Scheme 7).  
Ge
TAG
H3C CH3
2-Nap
O
OEt
TAG=
h, Cu(BF4)2
MeOH/MeCN
3:1
Ge
TAG
H3C CH3
F 2-Nap
OMe
2-Nap=
Scheme 7. Photooxidative cleavage of (2-naphthylmethyl)germane.106
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Analogously, treatment of the tagged (4-methoxyphenyl)-bis(naphthalene-2-
ylmethyl)germane 28 under the same conditions gave the expected difluorinated 
intermediate 29 ( -165 ppm). Subsequent fluoride-promoted Pd-catalyzed coupling of 29 
with 3,5-bis(trifluoromethyl)bromobenzene afforded the corresponding biaryl product 30 
in 86% yield (Scheme 8). 
The same group also reported the scope and limitations of the novel safety-catch 
bis(2-naphthylmethyl)germane containing a light-fluorous tag. Photooxidation of the 
bis(2-naphthylmethyl)arylgermanes and subsequent coupling with various arylbromides 
in the presence of PdCl2(MeCN)2/Pd(2-Tol)3, TBAF3H2O and CuI afforded the desired 
products in moderate to good yields.107 
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Scheme 8. Coupling of safety-catch bis(2-naphthylmethyl)germanes.106
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1.2.1.2. Hypervalent species as key reactives intermediates 
In the Stille-Migita-Kosugi reaction: 
Among all of the features of the Stille-Migita-Kosugi reaction, one of the most 
important is the ability to efficiently transfer an aryl or a vinyl group from an all-carbon 
substituted tin center without the need of previous activation. There are, however, a 
number of reports that show the increased tendency of highly coordinated tin compounds 
to transfer an alkyl group under mild conditions. As a consequence, many studies have 
been carried out employing transferable groups on a tin center coordinated to heteroatoms 
(deactivating group).108 
a) Hypervalency by internal coordination: 
Farina et al. reported the exclusive transfer of alkyl ligands from the highly-
constrained 1-(dimethylamino)-8-(tributylstannyl)naphthalene 31 (Figure 11).109 Similar 
alkyl transfer was promoted by internal coordination of the transannular nitrogen to the 
  28
tin center in the reaction of methyl-carbastannatranes 32 with aryl bromides in the 
presence of Pd catalysts.110 Noteworthy, the formation of a permanent pentacoordinate tin 
center failed to accelerate the transfer of the aryl substituent from 31.  
SnBu3Me2N
H3C Sn N
31 32
Figure 11. Hypervalent organostannates by internal coordination 
employed in Pd-catalyzed cross-coupling reactions.  
b) Hypervalency by nucleophilic activation: 
The Pd-catalyzed cross-coupling of highly deactivated organotin trichlorides upon 
alkaline aqueous activation was proven to be efficient as well. A pentavalent anionic 
hydroxotin complex 33 (Figure 12) generated by the basic hydrolysis of the trichlorotin 
precursor was assumed to be the reactive intermediate.111,112 
It is well documented that, similar to silicon,84 tin is fluorophilic. As a 
consequence, the generation of hypervalent tin species by fluoride activation has also 
been studied as a plausible way to increase its reactivity towards transmetallation. 
Fouquet and Rodriguez have described the Pd-catalyzed cross-coupling of the in situ 
generated hypervalent monoorganotin 34 with alkenyl/aryl triflates.113 The reaction of 
organic halides with Lappert’s stannylene afforded the monoorganotin precursors, which 
upon TBAF activation produced the reactive complex 34. The addition of fluoride 
activated haloorganotin (ArSnBu2Cl) reagents achieved efficient coupling with 
haloanisole. These results promoted further studies with (aryl)nSn(alkyl)n-4 precursors 
  29
from which more than one group was efficiently transferred in the presence of TBAF (see 
section 1.2.1.3).80  
Figure 12. Hypervalent organostannates by nucleophilic activation employed 
in Pd-catalyzed cross-coupling reactions.
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The stable and non-hygroscopic tetrabutylammonium difluorotriphenylstannate 
35 was reported as a convenient fluorinating agent in various organic transformations.114 
Moreover, Garcia Martinez et al. reported the use of 35 in the Pd-catalyzed cross-
coupling with alkenyl and aryl triflates.81 It was also assumed that the coupling of 
trimethylphenyltin with arylchlorides in the presence of TBAF occurred via a hypervalent 
fluorotin intermediate 36.115 
In the Hiyama-Denmark reaction: 
Since the original reports of Tamao-Kumada116 and Hiyama,83 development of Pd-
catalyzed cross-coupling reactions employing organosilanes have been driven by the 
assumed necessity to generate a pentavalent siliconate species. Although there is no 
irrefutable evidence for the participation of such hypervalent species in the 
transmetallation step, many reports have accounted for the critical effect of nucleophilic 
activation of tetracoordinated silanes in coupling reactions.117,118 
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Indirect indication of an activation step is found in the ability of stable, pentavalent 
siliconates to easily undergo cross-coupling. Hosomi has shown that pentacoordinate 
cathecolsiliconates 37 (Figure 13) are efficient agents for transferring alkenyl groups to 
aryl halides and triflates.119 The unsymmetrical biaryls were formed when aryl 
triethylammonium bis(cathechol)silicates 38 reacted with aryl and heteroaryl 
halides/triflates in the presence of TBAF and a suitable Pd/ligand combination.120 The 
stable tetrabutylammonium triphenyldifluorosilicate (TBAT) 39121,122 has been shown to 
be a versatile nucleophilic reagent for the transfer of phenyl groups through Pd-catalyzed 
cross-coupling with aryl halides and allylic alcohol derivatives.123,124 
Figure 13. Hypervalent siliconates in Pd-catalyzed 
cross-coupling reactions.
For compound 39: 19F NMR (DMSO-d6)  -96.0 ppm, 1J19F-29Si= 252 Hz.121
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 Despite all the progress made on the identification of the possible reactive 
intermediates involved in the Pd-catalyzed cross-coupling of organosilanes, a clear 
representation of the reaction mechanism is still lacking. Recent investigations by 
Denmark’s laboratory on the feasible mechanistic pathways and the reaction kinetics 
have been of extraordinary assistance.125 Initial efforts were dedicated to establish the 
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identity of the reactive intermediate(s) involved in the coupling of silanols, disiloxanes, 
and related fluorosilanes upon fluoride activation. Thus, independent synthesis and 
testing of all three precursors were performed affording coupling products with very 
similar yields after only 10 minutes. Spectroscopic analysis of the mixtures generated by 
treatment of representative silanol 40, disiloxane 41, or fluorosilane 42 with TBAF 
(Scheme 9) showed new species assigned to a silanol with a hydrogen-bonded fluorine 43 
and the corresponding disiloxane 41.  
Scheme 9. NMR analysis of alkenylsilane/TBAF mixtures.125
For compound 41: 29Si NMR (THF-d8)  -3.95 ppm 
                              
For compound 43: 29Si NMR (THF-d8)  -8.39 ppm
                                      19F NMR (THF-d8, rt)  -117.7 ppm
                                      (THF-d8, -95oC)  -150.8 ppm
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These results suggest that the fluoride-promoted coupling of silanol 40, disiloxane 
41, and fluorosilane 42 is likely to occur via a common mechanism. Furthermore, a 
meticulous kinetic investigation of the fluoride-promoted coupling of a silanol (e.g., 40) 
and 2-iodothiophene suggested that the predominant species exhibited a clear dependence 
on the concentration of TBAF. Hence, at low concentration of TBAF the corresponding 
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disiloxane 41 was predominant. In contrast, the hydrogen-bonded complex 43 became 
major at higher loadings of TBAF. 
The positive effect of fluoride on the Hiyama-Denmark coupling has also been 
illustrated in the formation of an aryl-Pd(II)-fluoride complex of type 44 (Scheme 10), 
expected to be more electrophilic at palladium and hence more reactive towards 
transmetallation. Nevertheless, aryl-Pd(II)-fluorides have been described to be less 
reactive than the corresponding iodides, bromides and chlorides.126  
Scheme 10. Formation of aryl-palladium-fluoride complex.
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In the coupling of organogermanes: 
 With the exception of carbagermatranes 1492 (Figure 10, section 1.2.1) and 
oxagermatranes 15,93 in which internal coordination was able to render the Ge center 
hypervalent, all the other Ge precursors needed activation before the transmetallation 
step. In general, cleavage/displacement of the existing substituents and formation of 
hypervalent germanium species by the action of fluoride or hydroxide ions have been 
assumed to take part in the coupling of tris(2-furyl)germanes 17,94 trichlorogermanes 
18,95 germanium sesquioxides 19,96 and tris(trimethylsilyl)germanes 20 and 21.97 On the 
other hand, the addition of fluoride ion to the heteroatom-substituted trialkoxygermanes 
1693 and difluorogermanes 29106 (Scheme 8, section 1.2.1.1) was suggested to produce 
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active pentavalent germanium derivatives. Moreover, the treatment of 
triphenylgermanium fluoride 45127 with KF and tetrabutylammonium hydrogensulphate 
in DMF resulted in the first synthesis of the pentavalent tetrabutylammonium 
difluorotriphenylgermanate 46 (Scheme 11).128 Despite the similarities to its tin and 
silicon analogues (35114 and 39121), the application of 46 to the Pd-catalyzed cross-
coupling reactions has not yet been explored.  
Scheme 11. Synthesis of tetrabutylammonium difluorotriphenylgermanate.128
KF, Bu4N+HSO4-
DMF, 60oC, 24 h
45
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F
F
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Ph
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For compound 45: 19F NMR (CDCl3)  -202.2 ppm127
For compound 46: 19F NMR (C6D6)  -118.9 ppm.128
 
Although hypervalent germanium species appear to play a critical role in all the 
above mentioned Pd-catalyzed cross-coupling approaches, clear evidences to prove their 
presence as reactive intermediates is still lacking.  
1.2.1.3. The multi-transfer paradigm 
While organostannanes, organosilanes, and organogermanes may carry four 
carbon substituents on the metallic center, only one group is usually transferred in the Pd-
catalyzed cross-coupling reactions due to the deactivating nature of halogen ligands in the 
haloorganometallic intermediates of type 47 (Scheme 12).62  
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Scheme 12. Pd-catalyzed cross-coupling of tetrasubstituted 
organometals from Group 14.
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Consequently, activation of the residual species derived from each 
transmetallation step would be required in order to promote multiple transfers from the 
organometallic precursors. Kosugi and co-workers reported the ability of TBAF to 
activate tetra(p-tolyl)tin 48 for the efficient transfer of all four aryl ligands (Scheme 13).80 
Obvious advantages were derived from this work since less toxic halotin by-products are 
generated from a sub-stoichiometric amount of organotin precursor employed. Recently, 
the atom-efficient Pd-catalyzed cross-coupling of tetraphenyltin (Ph4Sn) with several aryl 
bromides in the presence of NaOAc in polyethylene glycol (PEG-400) has been 
developed.129 
Scheme 13. Coupling of tetra(p-tolyl)tin with 4-bromoanisole.80
TBAF (6 eq.)
Pd(dba)2/4 PPh3
dioxane, reflux
Br
OCH3
4 4
48
Sn
4
OCH3
 
Attempts to promote similar multiple transfers using organosilicon reagents have 
also been undertaken. However, coupling of diallyl(diphenyl)silane 24 (Scheme 6, 
section 1.2.1.1) with excess of 4-chloroanisole was shown to occur by transfer of only 
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one phenyl substituent.105 The formation of inert hexacoordinate silicate species (after the 
transmetallation of the first phenyl group) was assumed to be impeding a second group 
transfer. Moreover, coupling of the pre-synthesized tetrabutylammonium 
triphenyldifluorosilicate 39 (Figure 13, section 1.2.1.2) (1 equiv.) with 4-iodoanisole (1 
equiv.) in the presence of TBAF (3 equiv.) indicated that TBAT delivered around 1.25 
phenyl groups.123 However, more convincing evidence for multiple phenyl transfer might 
be obtained by employing an excess of the aryl halide, but such experiments were 
lacking. Denmark et al. reported the transfer of each vinyl group from the inexpensive 
hexavinyldisiloxane 49 during the Pd-catalyzed cross-coupling with 4-iodoacetophenone 
in the presence of TBAF (Scheme 14).130 The remarkable low cost of the silicon reagents 
and the non-toxic nature of the corresponding by-products place this methodology in 
good standing for large scale preparations. 
Scheme 14. Coupling of hexavinyldisiloxane with 4-iodoacetophenone.130
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1.3. Pd-catalyzed coupling approaches for the synthesis of 5-modified pyrimidine 
nucleosides 
Although different approaches have been used for the synthesis of base-modified 
nucleosides, Pd-catalyzed cross-coupling strategies have offered a very convenient 
alternative.56 The easy access to 5 and 6 halo-modified pyrimidine nucleosides and 2- and 
8-halo purine nucleosides have facilitated their application as substrates for the synthesis 
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of more complex nucleoside/nucleotide scaffolds. Moreover, several 5-halo pyrimidine 
nucleosides have displayed important biological activity. Among them, 5-iodo-2'-
deoxyuridine shows antiviral activity, while 5-fluorouracil43 and 5-fluoro-2'-
deoxyuridine46 (see FUra and capecitabine in 1.1.1.1) are known for their potent 
antitumor properties. Several examples describing the application of the Pd-catalyzed 
cross-coupling to the synthesis of 5-modified pyrimidine nucleosides are presented as 
follows.  
1.3.1. Bergstrom’s approach using mercury (Hg) salts by Heck reaction 
Bergstrom was first to report the coupling between an alkene and a heterocyclic 
base131-133 and comprehensively reviewed the chemistry of the C-5-substituted pyrimidine 
nucleosides in 1982.134 The initial application of the Heck reaction in the synthesis of 5-
modified nucleoside analogues comprised the application of organopalladium 
intermediates generated in situ from unprotected 5-chloromercuriuridine 50 (Scheme 15). 
The coupling with ethylene afforded the desired 5-vinyl analogue 51 along with 5-(1-
methoxyethyl)-uridine 52 as a minor byproduct. 
Later, Bergstrom and others have extended the use of this methodology to prepare 
C-5 thioether pyrimidine nucleosides,135 to generate biotin-labeled DNA probes,136 and to 
connect iron-EDTA to an oligonucleotide.137 Other applications of this Pd-coupling 
approach include the formation of oligomers containing Ru complexes,138 and the 
synthesis of nucleoside-peptide conjugates,139 and the preparation of 
oligodeoxyribonucleotide methyl thioether probes.140 
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Scheme 15.  Coupling of 5-mercuri uridine and ethylene.131-133
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Whale et al. applied the Heck reaction between 5-iodo-2'-deoxyuridine 53 and 
acrylates to obtain (E)-5-(2-carboxyvinyl)uridine 54 (Scheme 16) in poor to moderate 
yields.141 Wybotusine, the first tricyclic fluorescent nucleoside isolated from 
phenylalanine-transfer ribonucleic acids142,143 was successfully synthesized utilizing the 
Heck approach.144 
1.3.2. Robins’ approach using Sonogashira reaction 
Several 5-alkynyl pyrimidine nucleosides 56 have been synthesized employing 
Pd-catalyzed cross-coupling reactions of the protected 5-iodonucleosides 55 with several 
terminal alkynes (Scheme 17).145 Noteworthy, an interesting bicyclic furanopyrimidine 
byproduct 57 (see BCNAs in 1.1.1.2.) was also reported. Formation of this type of 
bicyclic furanopyrimidine from (E)-5-bromovinyluracil upon base-catalysis was reported 
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by Blackey et al. in 1976.146 Robins and Barr145,147 described the exclusive synthesis of 
57 by treatment of 5-alkynyl uridine analogues 56 with CuI in Et3N/MeOH at reflux. 
Scheme 16. Coupling of 5-iodo-2'deoxyuridine with various acrylic esters.141
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Scheme 17. Sonogashira coupling of 5-iodouridine analogues with different 
        terminal acetylenes. Synthesis of furanopyrimidine analogues.145,147
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Coupling of various protected uridine 5-triflates 58 with alkynes also produced 
uridine 5-alkynes 59 in high yields (Scheme 18).148 Higher reaction temperature resulted 
in an increase of the rate of coupling, while the formation of minor bicyclic byproducts of 
type 57 (Scheme 17) was considerably inhibited employing DMF. An alternative 
approach was described employing tandem Sonogashira couplings. Thus, coupling with 
trimethylsilyl acetylene was followed by a straightforward desilylation and the resulting 
terminal alkynyl nucleoside analogue was further coupled with various aryl bromides.148 
Scheme 18. Sonogashira coupling of 5-triflate uridine analogues with 
                  terminal acetylenes.148
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Recently McGuigan et al.53,54 illustrated that furanopyrimidine byproducts 
displayed significant potency and selectivity against Varicella zoster virus (VZV) (see 
1.1.1.2). Meanwhile, imidazo[1,2-c]pyrimidin-5(6H)-one heterosubstituted analogues 
were reported to have anti-hepatatis B virus (HBV) activity.149 
Besides their interesting biological importance, the 5-alkynyl pyrimidine 
nucleosides have been used as linker arms for the attachment of fluorophores on chain-
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terminating 2',3'-dideoxynucleotides for DNA sequencing experiments.136,150 Analogues 
of the anti-HIV drug 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymidine (HEPT) 
bearing different alkynyl groups of C5 were also prepared employing the Sonogashira 
coupling reaction.151 
1.3.3. Approaches using Stille-Migita-Kosugi (Sn) coupling reaction 
The high efficiency and mild reaction conditions of the Pd-catalyzed cross-
coupling reaction using organotins makes it a very likely alternative for the 
functionalization of nucleoside analogues. Unfortunately, the high toxicity of tin 
byproducts has limited its application in their synthesis. The work of Farina and Hauck152 
is a good example in which protected 5-iodouracil/uridine 60 was successfully treated 
with various vinyl stannanes for the synthesis of 5-substituted uracil/uridine analogues 61 
in moderate to excellent yields (Scheme 19). Interestingly, the reaction showed a strong 
dependence to the type and amount of Pd catalyst used. For example, (MeCN)2PdCl2 (2 
mol %) led to a fast decomposition and 14% yield of product. In contrast, reaction under 
the same conditions but with Pd(PPh3)4 gave around 50% conversion. The combination 
of Pd2(dba)3/P(2-furyl)3 led to 89% conversion. Presence or absence of protecting groups 
on the sugar moiety did not affect the reaction outcome. 
Herdewijn et al.153 reported the coupling of 5-iodo-2'-deoxyuridines with 
symmetric tetraorganotin compounds under similar conditions. Later on, Rahim et al.154 
described couplings with tetra-vinyltins for the synthesis of analogues of the anti-herpes 
agent 2'-deoxy-4'-thio-5-vinyluridine. A year later, Wiebe and co-workers155 successfully 
synthesized (E)-5-(2-(trimethylsilyl)vinyl) uridine analogues employing (E)-2-
(tributylstannyl)-1-(trimethylsilyl)ethene in the presence of catalytic (PPh3)2PdCl2 in dry 
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acetonitrile.  Uridine analogues were further transformed into the radioactive (E)-5-(2-
[125I]iodovinyl derivatives for their evaluation as probes for monitoring gene therapy.155 
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Scheme 19. Coupling of 5-iodouracil, uridine, and 2'-deoxyuridine   
          analogues with different unsaturated organotins.152
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1.3.4. Approach using Hiyama-Denmark (Si) coupling reaction 
In 1996, Matsuhashi et al.156 reported the Pd-catalyzed cross-coupling of 5-iodo-
2'-deoxyuridine 62 with various vinylfluorosilanes activated by TBAF (Scheme 20). 
Although, a mixture of isomers 63 and 64 was obtained, the method offers a reliable and 
less toxic alternative to the organotin approach (see 1.2.1.3) for the preparation of 5-
substituted pyrimidine nucleosides.  
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Scheme 20. Hiyama-Denmark coupling of 5-iodo-2'-deoxyuridine with 
vinylfluorosilanes.156
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1.4. Biological activity of Germanium-containing compounds 
1.4.1. Non-nucleoside derived compounds 
Among Group 14 elements, the chemistry and biology of germanium remained 
unexplored until it was found as a decay product of some nuclear disintegration. In 1962 
van der Kerk and co-workers157 discovered the antifungal properties of 
triorganogermanium acetates. Later on, the water-soluble carboxyethylgermanium 
sesquioxide Ge-132 65 (Figure 14) was synthesized by Asai.158 In 1994 the first 
organogermanium pharmaceutical called propagermanium was released in Japan 
(Serocion®), which displays protection against viruses, immunostimulation, 
hepatoprotection, and low toxicity. Presently, various organogermanes exhibiting 
interferon-inducing, hypotensive, neurotropic, antitumor, radioprotective, and 
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immunomodulating properties have been prepared.159 The most studied 
organogermanium compounds are germanium sesquioxanes 65 (e.g., 2-
carboxyethylgermanium sesquioxide Ge-132; antiviral, immunomodulator, anticancer, 
hepatoprotective), spirogermanium 66 (2-(3-dimethylaminopropyl)-8,8-diethyl-2-aza-8-
germaspiro[4,5]decane; antitumor, antimalarial, antiarthritic), germatranes 67 (antitumor, 
neurotropic), and germylporphyrines 68 (antitumor). Studies on the biological properties 
of several organogermane derivatives have been reviewed.160 
R
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Figure 14. Organogermanes with interesting biological activity.
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1.4.2. Nucleoside derived compounds 
Several heterocyclic derivatives that contain germanium moieties have exhibited 
interesting biological properties. For example, organogermanium sesquioxanes 
containing uracil or 5-fluorouracil (5-FUra, see section 1.1.1.1) moieties showed 
antitumor activity against invasive microcapillary carcinoma (IMC) in mice.161 Similarly, 
some germanyl indolyl and furyl amino acid derivatives presented antitumor activity 
analogous to the potent 5-fluorouracil in sarcoma S-180.162 
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Figure 15. Nucleoside analogues containing germanium.
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Other modified uracil analogues have also displayed promising pharmaceutical 
profiles. For example, 5-trimethylgermyluracil 69 and 1-(2-tetrahydrofuryl)-5-
trimethylgermyluracil 70 exhibited cytotoxicity to melanoma B16 cells (EC50 32 g/mL) 
(Figure 15).163 Likewise, 1-(2-tetrahydrofuryl)-5-fluoro-6-trimethyl(ethyl)germyluracils 
71a-b have caused inhibition of DNA and RNA biosynthesis in Frhk cells by 1.5-2 times 
more than the renowned antitumor drug Ftorafur.164 The 5-trimethylgermyl derivatives of 
2'-deoxyuridine 72 also showed interesting properties. The -anomer presented weak 
biological action, however, the corresponding -anomer restrained the replication of 
herpes simplex virus HSV-1.165 The -anomer of 72 repressed the incorporation of 2'-
deoxyuridine into DNA of hepatoma 22A cells and of thymidine into DNA of cancer 
ovarian cells as well. 
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2. RESEARCH OBJECTIVES 
The objective of this dissertation was to develop novel Group 14 (Si, Ge) 
organometallic substrates for the Pd-catalyzed cross-coupling reaction and evaluate their 
possible application for the synthesis of 5-modified pyrimidine nucleoside analogues. 
The rational selection of such targets was based on an extensive review of the methods 
available in the current literature and the analysis of their advantages, limitations, and 
possible improvements. 
The first targets were novel 5-[(tris(trimethylsilyl)germyl)ethenyl]uridine 
analogues A bearing acyl protections at sugar hydroxyls (Scheme 21). The vinylgermane 
uridine analogues A were designed, in order to explore their application to the synthesis 
of the highly conjugated pyrimidine nucleosides modified at C5 (B) via Pd-catalyzed 
cross-coupling reactions. The synthesis of E- and Z-isomers of A was envisioned via the 
stereoselective hydrogermylation of the readily available 5-acetylenic uridine analogues 
with (TMS)3GeH in the presence of different radical promoters. The hydrogermylation 
with other organogermanium hydrides, such as Ph3GeH or Me3GeH, was expected to 
afford novel 5-vinylgermane uridine analogues with interesting biological properties (see 
section 1.4.2). 
  In order to optimize the synthesis of 5-modified nucleoside analogues of type B 
through a Pd-catalyzed cross-coupling approach, we initially planned to investigate the 
less expensive vinyl tris(trimethylsilyl)silane model substrates of type C as possible 
nucleophilic precursors for the cross-coupling with several organic halides (Figure 16). 
We were especially interested to monitor the progress of the coupling of vinyl 
  46
tris(trimethylsilyl)silanes C using 29Si NMR to acquire additional information about the 
structure of the possible reactive intermediates.  
Scheme 21. Designed Pd-catalyzed cross-coupling of 5-[2-(tris(trimethylsilyl)germyl)-
ethenyl]uridine analogues.
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The next objective was to develop novel organogermanium substrates capable of 
transferring the aryl groups from the Ge atom via Pd-catalyzed cross-coupling. We 
designed allyl(phenyl)germanes D (Figure 16), as a bench friendly and stable precursor 
readily available from inexpensive starting materials, as a possible source of phenyl 
groups in the cross-coupling reaction with aryl halides in the presence of Pd catalysts.  
We envisioned that the activation/cleavage of the allyl groups with fluoride or bases 
would generate in situ reactive germanol/germanoxanes and/or their corresponding 
hypervalent intermediates, which may undergo efficient cross-coupling reactions.  
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Figure 16.  Possible novel Group 14 organometallic substrates for the Pd-
catalyzed cross-coupling reaction.
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We also designed 2-(dimethyl(aryl)germyloxy)pyridine E (Figure 16) as a 
possible transmetallating partner for the Pd-catalyzed cross-coupling. The rationale 
behind the design of germanoxanes E was the possibility to engage the lone electron pair 
at nitrogen in the pyridine moiety into an intramolecular coordination that would render 
the Ge atom hypervalent. Moreover, coordination of the pyridyl group to the Pd-halide 
complex was envisioned to bring the germanium center into the proximity of the Pd 
catalyst and promote an efficient intramolecular transmetallation. 
The design, synthesis and study of the Pd-catalyzed cross-coupling of 
organometals D and E under different reaction conditions (temperature, solvent, catalyst, 
additives) was expected to provide valuable information about the reactivity of 
organogermanium species, constructing a platform for valuable comparison with the 
more established organostannanes and organosilanes. 
 
 
 
 
 
 
  48
3. RESULTS AND DISCUSSION 
The major interest of the current work was to develop novel Pd-catalyzed cross-
coupling methodologies utilizing Group 14 metal (Si, Ge) organometallic precursors and 
to study their possible application for the synthesis of 5-modified pyrimidine nucleoside 
analogues. For this reason we started our search encouraged by the results reported by 
Wang and Wnuk97,98 on the Pd-catalyzed cross-coupling of vinyl and -fluorovinyl 
tris(trimethylsilyl)germanes 20 and 21 with several aryl and alkenyl halides (Figure 10). 
Consequently, our initial efforts were focused on the efficient synthesis of 5-[2-
(tris(trimethylsilyl)germyl)ethenyl]uridine analogues 73 as potential organometallic 
precursors for the coupling with different aryl halides (Scheme 22). 
Scheme 22. A possible application of tris(trimethylsilyl)germanes towards the 
synthesis of 5-modified uridine analogues.
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3.1. Synthesis of protected 5-[2-(germyl)ethenyl)]uridine analogues  
The increasing interest in vinylmetals as efficient substrates for the Pd-catalyzed 
cross-coupling reactions have promoted the development of several efficient protocols for 
the hydrometalation of simple alkyl and aryl acetylenic substrates.166-169 However, their 
application to nucleic acid derivatives is often jeopardized by the poor stability of the 
latter under the commonly employed reaction conditions.  
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In order to obtain the desired vinyl germanes of type 73 in good yields and with 
good regio- and stereoselectivity, we screened the available methods using the 
moderately reactive and inexpensive Ph3GeH ($24/g) instead of (TMS)3GeH ($90/g). 
Thus, treatment of 5-ethynyl uridine analogue 74 with Ph3GeH in the presence of 1,1'-
azobis(cyclohexanecarbonitrile) (ACCN) in degassed toluene at 90 oC (Method A)166 
produced a mixture of Z- and E-isomers of vinyl germane 75 in 36% yield (E/Z 5:95, 
Scheme 23). Nuclear Magnetic Resonance (NMR) spectra were diagnostic in establishing 
the configuration of E-75 (J=18.8 Hz) and Z-75 (J=13.5 Hz). The formation of the Z 
major isomer is in agreement with expected166 radical anti-addition to alkynes. Careful 
column chromatography led also to the separation of a third compound for which we 
tentatively assigned the structure of 76 (12%), based on a downfield signal ( -194.03 
ppm) typical for ketones in the corresponding 13C NMR analysis. 
Lewis-acid catalyzed hydrogermylation employing B(C6F5)3168 in CH2Cl2 at room 
temperature proved to be unsuccessful to give the desired product 75 after 24 hours of 
stirring. Heating, increasing the concentration of B(C6F5)3 and prolonged time (48 h, 
reflux) had minimal effect on the formation of more product.  The presence of large 
quantities of non-consumed starting material as a major spot even after prolonged 
treatment made this method unlikely to be employed for the synthesis of our target 
molecules. The Pd(PPh3)4-catalyzed hydrogermylation167 of 74 with Ph3GeH afforded an 
isomeric mixture of vinylic product 75 (E/Z 70:30) with the expected preference for the 
E-isomer (based on mechanistic considerations). Also, compound 76 was detected in the 
reaction mixture.  
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Scheme 23. Thermal radical hydrogermylation of acetyl-protected 5-
ethynylarabinouridine with Ph3GeH.
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3.1.1. Et3B-induced hydrogermylation of 5-ethynyluridine analogues  
Since our previous attempts to obtain 5-(triphenylgermyl)ethenyl uridine analogue 
75 resulted in complex mixtures of products, we started the search for a milder and 
selective hydrogermylation protocol. Thus, the Et3B promoted radical addition169 of 
Ph3GeH to the terminal acetylenic substrate 74 in THF at -78 oC (Method B) exclusively 
gave protected (Z)-5-(triphenylgermyl)ethenyl uridine 75 in 47% yield (Scheme 24). The 
Z-stereoselectivity of the product under the applied non-equilibrating conditions (-78 oC) 
was in perfect agreement with the reported results for simpler substrates.169 Noteworthy, 
analogous treatment at 0 oC gave 75 along with 76 in a 59:41 ratio (based on 1H NMR of 
the purified mixture). 
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Scheme 24. Et3B-promoted radical hydrogermylation of 5-alkynylarabinouridine 
analogues with Ph3GeH.
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Because of the interesting biological properties exhibited by some compounds 
containing germanium (see section 1.4), we also examined the hydrogermylation of 74 
with alkyl germanium hydrides. Thus, treatment of 74 with the commercially available 
trialkyl-substituted germanium hydrides Me3GeH and Bu3GeH in the presence of Et3B 
failed to form the desired products after 3 hours at -78 oC. However, increasing the 
temperature to 0 oC with progressive warming to room temperature resulted in the 
formation of the corresponding 5-germanovinylic nucleosides 77 and 78 but in lower 
yields and with lower stereoselectivity (Scheme 25). The requirement for higher 
temperatures may be accounted for the lower reactivity of the alkyl-substituted germyl 
radicals compared to their aryl-substituted counterparts.169 Since only small amounts 
(approx. 10-15%) of 74 were recovered, it seems that the reaction temperature may have 
an impact on the stability of the protected 5-ethynyl nucleoside 74 and/or products 77 and 
78 during the radical forming processes. 
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Scheme 25. Et3B-promoted radical hydrogermylation of 5-ethynylarabinouridine 
analogues with Me3GeH and n-Bu3GeH.
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Next, we explored the applicability of the Et3B promoted hydrogermylation to 
other pyrimidine nucleoside scaffolds, such as of 2',3',5'-O-triacetyl-5-ethynyluridine 79a 
and 1-(3,5-O-diacetyl-2-deoxy--D-erythro-pentofuranosyl)-5-ethynyluracil 79b (Table 
2). Thus, treatment of 79a with Ph3GeH and Et3B in anhydrous THF at -78 oC gave Z-
80a selectively as a trans-addition product in 50% yield (Table 2, entry 1). Analogous 
treatment of 79a with Me3GeH afforded the corresponding vinylic product 81a as a 
mixture of geometric isomers (E/Z 12:88) but in lower yield (entry 2). Later on, we 
turned our attention to the preparation of the corresponding 2'-deoxyuridine analogues 
due to their similarity to the potent antiviral drug BVDU (see section 1.1.1.2). Thus, 
Et3B-promoted hydrogermylation of the 3',5'-O-diacetyl-2'-deoxy-5-ethynyluridine 79b  
with Ph3GeH (Method B) afforded exclusively Z-80b in 62% yield (entry 3). In a similar 
fashion, the treatment of 79b with Me3GeH or Et3B in THF with progressive warming 
from 0 oC to ambient temperature produced product E/Z-81b with a moderate preference 
for the kinetic Z-isomer (E/Z, 23:77) in 46% yield (entry 4). 
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Table 2. Et3B-promoted radical hydrogermylation of acetyl-protected 2'-deoxy and 5-
ethynyluridine with Ph3GeH or Me3GeH. 
Et3B (1.2 equiv.)
THF, -78 oC
O
AcO
AcO
HN
N
O
O
79 80  R=Ph  
81  R=Me
H
O
AcO
AcO
HN
N
O
O
GeR3
R3GeH
X
Series   a  X=OAc
             b  X=H
X
 
Entry Substrate Product Conversion (%)a Yield (%)b E/Z ratioc 
1 79a 80a 90 50 0:100 
2 79a 81a 90 13 d 12:88 
3 79b 80b 95 62 0:100 
4 79b 81b 90 46 d 23:77 
a Based on recover starting material. b Isolated yield. c Determined using coupling 
constants for E- and Z-isomer on 1H NMR. d From 0 oC to r.t. 
Effect of protecting group: O-acetyl vs O-toluoyl: 
Even though the hydrogermylation of O-acetyl protected uridine analogues 74, 
79a, and 79b gave the corresponding vinyl germanes in moderate yields; we were 
interested in exploring the effect of other protecting groups on the outcome of the 
reaction. Hence, the triethylborane (Et3B) promoted hydrogermylation of 5-ethynyl-1-
(2,3,5-tri-O-p-toluoyl--D-ribofuranosyl)uracil 82a with Ph3GeH at -78 oC (Method B) 
showed slow conversion to the desired product. However, progressive warming of the 
reaction mixture to 0 oC afforded para-toluoyl protected Z-83a in 40% yield (Table 3, 
entry 1) together with product 85 (13%) (see Figure 17).  Similar treatment of 82a with 
Me3GeH gave E/Z-84a (E/Z 45:55) in 37% yield (entry 2). Analogous treatment of the 
corresponding 2'-deoxy derivative 82b with Ph3GeH and Me3GeH gave products 83b and 
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84b in 61% and 30%, respectively (entries 3 and 4). Interestingly, the synthesis of 83b 
also required a significant increase of the reaction temperature (from -78 oC to 0 oC) and 
resulted in the concomitant formation of byproduct 86 (12%) (see Figure 17). 
Table 3. Et3B-promoted radical hydrogermylation of p-toluoyl-protected 2'-deoxy and 5-
ethynyluridine with Ph3GeH or Me3GeH. 
Et3B, THF
-78oC       0 oC
O
p - TolO
p - To lO
HN
N
O
O
82 83  R=Ph  
84  R=Me
H
O
p - TolO
p - TolO
HN
N
O
O
GeR3
R3GeH
X
Series   a  X=OTol-p
             b  X=H
X
 
Entry Substrate Product Conversion (%)a Yield (%)b E/Z ratioc 
1 82a 83a 90 40 0:100 
2 82a 84a 90 37 d 45:55 
3 82b 83b 95 61 0:100 
4 82b 84b 85 30 d 41:59 
a Based on recover starting material. b Isolated yield. c Determined using coupling 
constants for E- and Z-isomer on 1H NMR. d From 0 oC to r.t. 
Our results suggested that changing from the base-labile acetyl-protecting group to 
a more robust p-toluoyl group did not result in an appreciable enhancement in the yields 
or the stereoselectivity. However, the higher reaction temperatures necessary to promote 
the hydrogermylation of the para-toluoyl-protected substrates 82a-b resulted in the 
formation of 5-(2-triphenylgermyl)acyl byproducts 85 and 86, respectively (Figure 17). 
The tentative structure for the unexpected byproducts 85 and 86 was assigned based on 
1H and 13C NMR analyses. The 1H NMR spectrum of 85 showed two doublets (J=9.0 Hz) 
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part of an isolated spin-coupling system at  3.76 and 3.87 ppm, while the corresponding 
13C spectrum displayed a new peak at  193.3 ppm characteristic of ketones. The HMBC 
correlations (Figure 17) and NOE interactions (Figure 18) supported the proposed 
structures. In addition, ultraviolet spectroscopic analysis of compound 85 revealed a 
maximum absorption (max) at 282 nm, in agreement with the reported values for similar 
5-acylated uridine derivatives.170 Moreover, it was evident that the steric hindrance 
and/or electronic effects conferred by the phenyl/alkyl germanium hydrides reagents 
played a decisive role in the yields and stereochemical outcome of the radical additions 
across the acetylenic moiety (Ph3GeH vs Me3GeH). 
Figure 17. Structure of p-toluyl-protected 5-[(2-triphenylgermyl)acetyl]uridine 
analogues.
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Figure 18. Important NOE interactions observed for 5-[2-(triphenyl-
germyl)acetyl]-2',3',5'-tri-O-p-toluyluridine.  
To correlate the reactivity of the used organometallic hydride (e.g., Ph3GeH) and 
the outcome of the hydrometallation reaction, hydrostannylation and hydrosilylation of 
82a with Ph3SnH and Ph3SiH in the presence of Et3B was performed at -78 oC and 0 oC. 
Interestingly, fast formation of the vinyl stannane Z-87 was achieved at low temperature, 
while a mixture of geometric isomers was obtained at 0 oC (E/Z, 51:49) (Scheme 26). In 
a sharp contrast, the Et3B promoted hydrosilylation of 82a with Ph3SiH did not proceed 
at either -78 oC or 0 oC. It seems likely that the generation of the 5-acylated byproducts 
(e.g. 76, 85 and 86) is selective for the use of moderately reactive Ph3GeH, since no 
byproduct of this type was detected when more reactive tin analogues, such as Ph3SnH, 
were employed. 
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Scheme 26. Et3B-promoted radical hydrostannylation of p-toluyl-
protected 5-ethynyluridine analogues.
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The removal of the acetyl and para-toluoyl protecting groups was successfully 
achieved under the typically used basic conditions. Thus, treatment of 75 with a saturated 
solution of NH3 in MeOH afforded the deprotected arabino uracil nucleoside 88 in 86% 
yield (Scheme 27). Analogous treatment of p-toluoyl-protected 2'-deoxyuridine analogue 
83b gave deprotected 89 in moderate yield (65%), although, the reaction required longer 
time to be completed. Treatment of the trimethylgermyl derivative E/Z-84a (E/Z 45:55) 
with 0.1N NaOMe in MeOH afforded E/Z-90 (E/Z 42:58) in 71% yield. As described in 
previous reports,171 the C(sp2)-Ge(alkyl)3 and C(sp2)-Ge(aryl)3 bond seems to be stable 
under the basic conditions required for the removal of both acetyl and para-toluoyl 
protecting groups. Moreover, the stereochemistry of the protected derivatives remained 
intact even after prolonged treatment with strongly nucleophilic sodium methoxide. 
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Scheme 27. Deprotection of acetyl and p-toluyl-protected 5-[2-(germyl)ethenyl] 
uridine analogues.
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3.1.2. Investigation on the possible origin of 5-[2-(triphenylgermyl)acetyl]uridine 
analogues 
As described above, the Et3B promoted hydrogermylation of 74 in the presence of 
Ph3GeH at 0 oC produced the desired germanovinylic nucleoside 75 together with the 
hydrated byproduct 76. Also, the higher temperature (0 oC vs -78 oC) required for the 
efficient hydrogermylation of substrates 82a-b resulted in the formation of small amounts 
of the unexpected 85 and 86 (Figure 17). Intrigued by this interesting effect of the 
reaction temperature and the lack of reports on the formation of similar 5-keto products 
during the hydrogermylation of simpler acetylenes,169 we have undertaken efforts to 
examine the origin of 76, 85 and 86 (Scheme 28). 
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Scheme 28. A working hypothesis for the formation of 5-[2-(triphenylgermyl)acetyl]-
uridine derivatives.
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 In our working hypothesis, an initial attack from the relatively stable 
triphenylgermyl radical at the acetylenic moiety of 91 would generate a vinylic radical at 
the carbon  to the uracil base (92). Subsequent intramolecular interaction of the newly 
formed radical with the carbonyl oxygen attached to carbon C4 of the base would result 
in the formation of an unstable oxy radical intermediate 93. The rigid planar 
configuration of the uracil ring facilitates the formation of the bicyclic structure 93. Rapid 
re-aromatization caused by the abstraction of the hydrogen at N-3 should lead to a 
“metastable” intermediate 94 with increased electrophilicity at carbon C4. Consequently, 
the attack from a water molecule to C4 would lead to a considerable release of strain 
energy forming the germyl-enol intermediate 95. A final keto-enolic tautomerization 
would generate the more stable conjugated -germylketone 96. The experiments with 
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18O-labeled uracil precursor at C4 (91) were designed to investigate the formation of the 
byproduct of type 96 by analysis of the fragments from its mass spectrometry analyses.   
3.1.2.1. Synthesis of model compound 1-N-benzyl-5-ethynyluracil and its 4-[18O]-
labeled analogue 
In an attempt to support our proposed pathway for the formation of the keto 
byproducts 76, 85, and 86 (Scheme 28) a model compound 1-N-benzyl-5-ethynyluracil 
105 and its 4-[18O]-labeled analogue 106 were synthesized. Our strategy was comprised 
of the synthesis of 1-N-benzyluracil 97 by alkylation of freshly prepared 2,4-
bis(trimethylsilyloxy)pyrimidine172 with benzylbromide (Scheme 29).173 Treatment of 97 
with Lawesson’s reagent in THF at 56 oC for 1 h gave the corresponding 1-N-benzyl-4-
thiouracil 98 in 65% yield. S-methylation174 of the purified 98 by treatment with MeI in 
the presence Et3N in CH2Cl2 led to thioether 99 (93%). The acid-catalyzed hydrolysis175 
of 99 with commercially available H2[18O] in anhydrous ethanol produced the desired 
18O-labeled 1-N-benzyluracil analogue 100 in 90% yield. Iodination of 97, as well as 100, 
with a solution of iodine monochloride176 (1 M in CH2Cl2) in dry CH2Cl2 afforded 5-
iodouracils 101 and 102 in excellent yields (93% avg.). Sonogashira couplings of the 5-
iodouracils with (trimethyl)silylethyne in Et3N resulted in the formation of 103 (80%) 
and 104 (62%) respectively.  
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Scheme 29. Synthesis of 1-N-benzyl-5-ethynyluracil and its 4-[18O]-labeled 
analogue.  
The fluoride-promoted desilylation with tetrabutylammonium fluoride (TBAF) 
conveniently furnished products 105 and 106 with moderate to good yields (60% and 
58%, respectively). Although the traditional desilylation using TBAF also gave the 
product 105 (60%) effectively, the treatment with the partially soluble NH4F/MeOH177 
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system offered similar results (57%) and substantially eased the purification from TBAF-
derived residues. 
3.1.2.2. Hydrogermylation of 1-N-benzyl-5-ethynyluracil and its 4-[18O]-labeled 
analogue 
Having synthesized the 5-acetylenic precursors 105 and 106, the next step was to 
investigate their hydrogermylation in attempts to obtain 1-N-benzyl-5-[2-
(triphenylgermyl)acetyl]uracil 108 and its 18O-labeled analogue 110 (Scheme 30). Initial 
treatment of compound 105 by Method B (Ph3GeH, Et3B) at 0 oC resulted only in the 
isolation of the trans-addition product Z-107.  
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Scheme 30. Hydrogermylation of 1-N-benzyl-5-ethynyluracil and its 4-1[8O]-labeled 
analogue.  
In contrast, upon thermal radical-generation with ACCN (Method A) a mixture of 
Z-107 and byproduct 108 was obtained. Careful column chromatography of the mixture 
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yielded a small fraction of 108 with high purity. A similar treatment of the 18O-labeled 
acetylenic precursor 106 conveniently afforded a small amount of pure 110 after cautious 
purification from a mixture with Z-109. 
In order to support the pathway proposed for the formation of compounds 76, 85, 
and 86 (see Scheme 28), the isolated uracil compounds 108 and 110 were analyzed by 
mass spectrometry employing various ionization techniques. Thus, ESI+ analysis of 
compound 108 showed a peak at m/z 605 corresponding to the molecular ion [M+58]+. A 
similar experiment performed on 110 exhibited a signal for m/z 607 also assigned to 
[M+58]+. These results indicated the difference of two mass units expected for the 
analogue containing a heavier isotope of oxygen [18O] in the C5 side chain (see Scheme 
28). However, experiments employing electron-impact ionization exhibited the same 
molecular ion (m/z 547 for M+) for both 108 and 110. Although the fragmentation 
patterns differed, MS analyses did not lead to any conclusive assignment.   
3.1.3. Synthesis of protected 5-[2-(tris(trimethylsilyl)germyl)ethenyl] uridine 
analogues 
Once the conditions for the hydrogermylation of 5-ethynyluridine analogues with 
several organogermanium hydrides (Ph3GeH and Me3GeH) were optimized, 
hydrogermylation with the more reactive (Me3Si)3GeH was also explored in order to 
develop a convenient synthesis of vinylgermanes 111/112; possible substrates for the Pd-
catalyzed cross-coupling reactions. Therefore, treatment of the protected 5-
ethynylarabinouridine analogue 74 with (Me3Si)3GeH and ACCN in degassed toluene at 
95 oC (Method A) efficiently produced the hydrogermylated product 111 (E/Z 4:96) in 
68% yield after 20 minutes (Scheme 31). The increased reactivity of the corresponding 
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hydride and a shorter reaction time may be attributed for the better yield and a higher 
stereoselectivity of the product with respect to the hydrogermylation with Ph3GeH under 
similar conditions (see Scheme 24).  
Scheme 31. Synthesis of 5-[2-(tris(trimethylsilyl)germyl)ethenyl]uridine analogues.
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H
AcO
O
AcO
AcO
HN
N
O
O
111
AcO
Ge(TMS)3
(TMS)3GeH
ACCN
Toluene, 95 oC
20 min
(68%)
E/Z 4:96
(61%)
 
Interestingly, treatment of 2',3',5'-tri-O-p-toluoyl protected 82a with (Me3Si)3GeH 
in the presence of Et3B in THF at -78 oC (Method B) for 14 hours also afforded TTMS-
germyl vinyl product Z-112 in 61% as a single isomer (1H NMR). Although the 
vinylgermane product E/Z-111 was obtained in much shorter time and slightly higher 
yield employing thermal conditions (Method A), formation of 112 by Et3B-induced 
hydrogermylation (Method B, -78 oC to r.t.) offered a comparable yield and higher 
stereoselectivity. 
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3.1.4. Pd-catalyzed cross-coupling of 5-[2-(tris(trimethylsilyl)germyl)ethenyl] 
uridine analogues 
 The efficient Pd-catalyzed cross-coupling of vinyl tris(trimethylsilyl)germanes 20 
and their (-fluoro)vinyl analogues 21 (see Figure 10, section 1.2.1) proved to be an 
excellent methodology for the synthesis of substituted alkenes, fluoroalkenes, dienes, and 
fluorodienes.97,98 Therefore, we explored the application of this methodology to the 
synthesis of 5-alkenyluridine analogues. Thus, the Pd-catalyzed coupling [Pd(PPh3)4] of 
protected 5-[2-(tris(trimethylsilyl)germyl)ethenyl] uridine analogue E/Z-111 (E/Z, 4:96) 
with iodobenzene under oxidative conditions (H2O2/NaOH/H2O/TBAF) yielded the 
highly conjugated product E/Z-113a in low yields (15%) as a mixture of geometric 
isomers (E/Z, 89:11) (Scheme 32). Unfortunately, The observed inversion of the 
stereochemistry (ZE) was previously described for the coupling of Z-vinyl 
tris(trimethylsilyl)germanes.97 As expected, the alkaline conditions required for the 
coupling effected the removal of the acetyl protecting groups during the reaction. The 
degermylated 5-vinyl byproduct 114 was also detected in the crude reaction mixture. 
Moreover, analogous treatment of E/Z-111 with 4-iodoanisole resulted in the formation 
of a complex mixture of E/Z-113b and 114 (113b/114, 34:66) in an overall low yield. 
 It seems that the application of the oxidative conditions necessary for the efficient 
coupling of vinyl tris(trimethylsilyl)germanes (e.g. 20 and 21, Figure 10), which also 
requires a base (NaOH) for the synthesis of more complex nucleoside analogues is 
hampered by the instability of the acetyl-groups in the ribose of 111. An alternative 
approach would require the use of 5-[2-(tris(trimethylsilyl)germyl]uridine analogues 
bearing base-resistant protecting groups. In addition, the use of a different Pd 
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catalyst/ligand might modulate the reactivity of the corresponding aryl halide leading to a 
more efficient transmetallation. 
Scheme 32. Pd-catalyzed cross-coupling of 5-[2-(tris(trimethylsilyl)germyl)ethenyl]-
uridine analogues.
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3.2. Novel organosilanes and organogermanes as organometallic substrates for the  
Pd-catalyzed cross-coupling reaction 
3.2.1 Vinyl tris(trimethylsilyl)silanes: substrates for Hiyama coupling  
 Encouraged by the reports on the Pd-catalyzed cross-coupling of vinyl 
tris(trimethylsilyl)germanes 20 and their corresponding (-fluoro)vinyl analogues 21 
(Figure 10), an analogous methodology employing the less expensive vinyl 
tris(trimethylsilyl)silanes was explored. 
3.2.1.1. Synthesis of vinyl tris(trimethylsilyl)silane substrates 
The (Z)-vinyl tris(trimethylsilyl)silanes (TTMS-silanes) 116a-d were synthesized in 
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80-92% yield by the radical-mediated hydrosilylation178 of the corresponding alkynes 115 
with (TMS)3SiH (Scheme 33). Attempted hydrosilylation of terminal alkynes 115a-c 
with (TMS)3SiH in the presence of Rh(COD)2BF4/PPh3/NaI or RhCl(PPh3)3/NaI catalyst 
systems179 produced E isomers 117a-c in high yields, however, complete stereoselectivity 
was not achieved since Z isomers 116a-c were also formed (~5-20%).  
R R
Si(SiMe 3)3
R
Si(SiMe 3)3
115 116
117
(Me3Si)3SiH, AIBN
toluene or benzene
85oC
(Me3Si)3SiH
RhCl(PPh3)3, NaI
75 oC
Series: a R=H
            b R=CH3
            c R=OCH3
            d R=CF3
(Me3Si)3SiH, 
Rh(COD)2BF4, PPh3
NaI, neat, 
Scheme 33. Stereoselective synthesis of (E)- and (Z)-vinyl tris(trimethylsilyl)silanes.  
For example, hydrosilylation of 115b gave a 117b/116b (E/Z, ~9:1) mixture, 
which was purified to afford 117b (82%). Alternative treatment of the (Z)-silanes 116a 
and 116c with 0.5 equivalent of (TMS)3SiH in the presence of Wilkinson’s catalyst179 
efficiently effected the isomerization to give the corresponding (E)-silanes 117a (78%) 
and 117c (89%). Extended heating (54 h) of 116b in the presence of 
(TMS)3SiH/RhCl(PPh3)3/NaI resulted in the quantitative conversion of 116b into 117b. 
3.2.1.2. Pd-catalyzed cross-coupling of Z- and E-vinyl tris(trimethylsilyl)silanes 
As found previously in the Wnuk laboratory, the presence of peroxide and base are 
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critical for the competent coupling of vinyl tris(trimethylsilanes) 116b, while fluoride 
ions seems to only facilitate this conversion (see section 3.2.1.3). See Table 4 for details. 
Table 4. Effect of reaction parameters on the cross-coupling of vinyl TTMS-silanes. 
H3C
Si(SiMe3)3
116b
I
Pd(PPh3)4 (10 mol%)
THF, 55oC, 10 h
H3C
118b  
Entry Peroxide Base Fluoride Yielda (%) E/Zb 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
none 
H2O2 
H2O2 
H2O2 
H2O2 
H2O2 
none 
H2O2 
H2O2 
t-BuOOH 
None 
NaOH 
KOSiMe3 
NaOH 
KOSiMe3 
none 
KOSiMe3g 
NaOH 
NaOH 
KH 
TBAF 
none 
none 
TBAF 
TBAF 
TBAF 
TBAF 
NaF 
CsF 
noneh 
<5c 
61d,e,f 
60 
90 
81 
18c 
<2c 
60 
12c 
15c 
5/95 
15/85 
25/75 
3/97 
2/98 
67/33 
n/a 
40/60 
60/40 
75/25 
a Isolated yields (combined for both isomers of 118b). Couplings were 
performed on 0.1 mmol scale of silane (0.03 mM). b Determined by GC-
MS [with internal standard of (E)- and (Z)-stilbenes] and/or 1H NMR of 
the crude reaction mixture.  c Based on GC-MS. d Pd2(dba)3 also gave 
118b (52%; E/Z, 25:75). e Attempted couplings with H2O2 (without 
NaOH ) or with NaOH (without  H2O2) failed to give 118b. f Coupling 
with bromobenzene instead of iodobenzene gave 118b (40%; E/Z, 
20:80). g Reaction with NaOH instead of KOSiMe3 was also 
unsuccessful. h Coupling in the presence of TBAF gavec 118b in ~2% 
yield. 
The conditions described above (Table 4, entries 2-5) are general for the coupling of 
various vinyl TTMS-silanes with several aryl iodides and bromides. Thus, treatment of 
the conjugated silane (Z)-116a with H2O2/H2O (30%, 3 equiv.) and NaOH (3 equiv.)/H2O 
in THF followed by addition of bromobenzene, Pd(PPh3)4 and TBAF gave stilbene 118a 
(82%; Table 5, entry 1). Similarly, silane (Z)-116b coupled with iodobenzene and 
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bromobenzene to give p-methylstilbene 118b in 90% and 86% yield, respectively (entries 
2 and 3). Less reactive electrophiles such as chlorobenzene and aryl triflate180 failed to 
give the desired coupling products (entries 4 and 5). Coupling of (Z)-116b with 4-butyl-
1-iodobenzene and 1-iodonaphthalene efficiently afforded products 119b and 120b in 
moderately good yields (entries 6 and 7). Interestingly, it seems that the substituent on the 
phenyl ring in (Z)-silanes 116a-d (p-MeO, p-Me, H, p-CF3) has an effect on the coupling 
reactions with bromobenzene, since both higher yields (from 70% to 97%) and better 
steroselectivity (E/Z from 55:45 to 9:91) were obtained as the substituent changed from 
an electron-withdrawing group to an electron-donating group (entries 1, 3, 8 and 9). The 
observed higher coupling efficiency of (Z)-116c with bromobenzene may be attributed to 
the increased nucleophilicity of the vinylic carbon attached to the Si atom, resulting in 
faster transmetallation and subsequently better yields and less isomerization. 
The (E)-TTMS-silanes 117a-c underwent coupling with aryl halides under the same 
conditions (H2O/NaOH/H2O/TBAF), although with retention of the existing 
stereochemistry. Thus, coupling of conjugated silanes 117a-c with aryl iodides and 
bromides (H2O2/NaOH/Pd(0)/TBAF) provided the corresponding products 
stereoselectively in good to excellent yields (48-90%; Table 6, entries 1-9). The electron-
deficient aryl iodides gave to some extent higher yields than the electron rich aryl iodides 
in the reactions with silane 117a (entries 1, 3 and 4). 
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Table 5. Coupling of vinyl (Z)-TTMS-silanes. 
R
Si(SiMe3)3
116
Pd(PPh3)4 (10 mol%)
THF, 55oC, 10 h
R
Ar
H2O2, NaOH(aq)
Ar-X, TBAF
Series: a R=H
            b R=CH3
            c R=OCH3
            d R=CF3
118 Ar=Ph
119 Ar=(4)-BuPh
120 Ar=
 
Entry Silane Ar-X Product Yielda (%) E/Zb 
1 
2 
3 
4 
5 
6 
7 
8 
9 
116a 
116b 
116b 
116b 
116b 
116b 
116b 
116c 
116d 
PhBr 
PhI 
PhBr 
PhCl 
PhOTf 
(4)BuPhI 
1-iodonaphthalened 
PhBr 
PhBr 
118a 
118b 
118b 
118b 
118b 
119b 
120b 
118c 
118d 
82 
90 
86 
<5c 
<5c 
61 
73 
97 
70 
40/60 
3/97 
30/70 
n/a 
n/a 
24/76 
15/85 
9/91 
55/45 
a Isolated yields (combined for the E/Z isomers). Couplings were performed 
on 0.1-1.0 mmol scale of silanes (0.03 mM). Pd(PPh3)4 (10% mol). b 
Determined by GC-MS and/or 1H NMR of the crude reaction mixture.  c GC-
MS. d Coupling with 1-bromonaphthalene gave 120b (51%, E/Z = 27:73). 
3.2.1.3. Coupling experiments without fluoride participation 
Even though TBAF promotes couplings of vinyl TTMS-silanes in the presence of 
H2O2/base, it was found that fluoride activation of vinyl TTMS-silanes was not required 
for the cross-coupling to occur. Hence, oxidative treatment (H2O2/NaOH or KOSiMe3) of 
the conjugated silane (E)-117a with bromo- and iodobenzene also produced (E)-stilbene 
(Table 7, entries 1 and 2).  Other conjugated (E)- and (Z)-silanes also coupled with the 
substituted aryl halides (entries 3-7). Again coupling of (Z)-silanes occurred with lower 
stereoselectivity to produce an E/Z mixture (entries 4-7). It is noteworthy that TBAF 
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promoted reactions generally gave higher yields and are more stereoselective than the 
fluoride-free reactions. 
Table 6. Coupling of vinyl (E)-TTMS-silanes. 
118 Ar=Ph
119 Ar=(4)-BuPh
120 Ar=
R
117
Pd(PPh3)4 (10 mol%)
THF, 55oC, 10 h
R
H2O2, NaOH(aq)
Ar-X, TBAF
Series: a R=H
            b R=CH3
            c R=OCH3
Si(SiMe3)3 Ar
 
Entry Silane Ar-X Producta (E) Yieldb (%) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
117a 
117a 
117a 
117a 
117b 
117b 
117b 
117b 
117c 
PhI 
PhBr 
(4)CH3OPhI 
(4)CF3PhI 
PhI 
(4)BuPhI 
1-bromonaphthalene 
1-iodonaphthalene 
PhBr 
118a 
118a 
118c 
118d 
118b 
119b 
120b 
120b 
118c 
83 
67 
79 
90 
72 
59 
48 
70 
63 
a Only E-isomers were detected (1H NMR, GC-MS). Couplings were 
performed on 0.1-0.5 mmol scale of silanes (0.03 mM). Pd(PPh3)4 (10% mol). 
b Isolated yields. 
 It is also noteworthy that under the oxidative conditions required for the coupling of 
vinyl TTMS-silanes, the reductive self-coupling of the aryl halides has not been observed 
for the fluoride promoted reactions (Table 5 and 6) and was only sporadically observed 
for the fluoride-free reactions (Table 7, entries 2 and 4; 1-3%, GC-MS). Moreover, 
byproducts resulting from the oxidative homocoupling18 of the vinyl silanes 116 and 117 
have not been observed. Also, although the oxidative conditions employed for generation 
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of the active organosilane species are similar to the ones used in Tamao-Kumada and 
Fleming oxidation of silanes to alcohols (including vinyl silanes to aldehydes and 
ketones), which involve cleavage of the C-Si bond,181 we did not observe conversion of 
the vinyl silanes 116 and 117 to the corresponding aldehydes. Apparently, Si-Si bond 
cleavage takes place chemoselectively with the C-Si bond tolerating the relatively mild 
oxidative conditions required for the cleavage of Si-Si bonds.182 
Table 7. Fluoride-free coupling of the vinyl TTMS-silanes. 
118 Ar=Ph
120 Ar=
R
116(Z) or 117(E)
Pd(PPh3)4 (10 mol%)
THF, 55oC, 10 h
R
H2O2, NaOH(aq)
Ar-X
Series: a R=H
            b R=CH3
Si(SiMe3)3 Ar
 
Entry Silane Ar-X Product Yield a (%) E/Z
b 
1 
2 
3 
4 
5 
6 
7 
117a 
117a 
117b 
116a 
116b 
116b 
116b 
PhI 
PhBr 
1-iodonaphthalene    
PhBr 
PhI 
PhBr 
1-bromonaphthalene 
118a 
118a 
120b 
118a 
118b 
118b 
120b 
75c 
50 
46 
55 
61d 
40e 
30 
100/0 
100/0 
100/0 
25/75 
15/85 
20/80 
17/83 
a Isolated yields. Couplings were performed on 0.1 mmol scale of silanes (0.03 
mM). Pd(PPh3)4 (10% mol). b Determined by 1H NMR and/or GC-MS of the 
crude reaction mixture.  c With KOSiMe3 instead of NaOH yield was 60% (E/Z, 
100:0).  d With KOSiMe3 instead of NaOH yield was 60% (E/Z, 25:75). e With 
KOSiMe3 instead of NaOH yield was 48% (E/Z, 10:90). 
3.2.1.4. Stereochemistry of the coupling with Z-vinyl tris(trimethylsilyl)silanes 
The lack of stereoselectivity for the coupling of (Z)-silanes probably results from the 
isomerization of silane/Pd intermediate complexes derived from (Z)-TTMS-silanes under 
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the coupling conditions. Isomerization183,184 of the products was excluded based on the 
following experiments (Scheme 34): (i) no isomerization of the (Z)-stilbene 118a was 
observed when (Z)-118a was refluxed in THF in the presence of H2O2/NaOH or TMSOK 
with or without Pd(0) and/or TBAF, (ii) coupling of the 4-methyl-phenyl (Z)-silane 116b 
under typical conditions [H2O2/NaOH/Pd(0)/THF/with or without TBAF] with phenyl 
iodide or bromide in the presence of 0.25 or 1.0 equiv. of the (Z)-stilbene 118a produced 
4-methylstilbene 118b as the E/Z mixture [see Table 5 (entries 2 and 3) and Table 7 
(entries 5 and 6)], while isomerization of the (Z)-stilbene 118a into E isomer was not 
observed (GC/MS). 
Moreover, a "side-by-side" comparison of the coupling of (Z)-116b with 1-
iodonaphthalene [1 h (30%, E/Z 0:100); 3 h (58%, E/Z 3:97)] and 1-bromonaphthalene [1 
h (22%, E/Z 5:95); 3 h (35%, E/Z 13:87)] showed that product 120b is formed at different 
pace (Table 5, entry 7).  It appears that coupling with the aryl iodides is faster and occurs 
with a higher degree of stereoretention than with the corresponding aryl bromides (see 
also Table 5, entry 2 vs. 3; Table 7, entry 5 vs. 6). Longer stirring of the silanes 116 and 
117 with H2O2/NaOH (45 min. vs. 15 min.) prior to the addition of the aryl halide and the 
catalyst resulted in no improvement of yield or stereoselectivity. 
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H3C
Si(SiMe 3)3
116b
THF, 
with or without
Pd and/or TBAF
H3C
H2O2, NaOH(aq)
or TMSOK
Ph Ph
Pd(0), THF
H2O2, NaOH(aq)
Ar-X, (TBAF)
(Z)-118a
(Z)-118a
Ph Ph
(Z)-118a
E/Z-118b
Ph Ph
(Z)-118a
Scheme 34. Study of the inversion of stereochemistry in the coupling of (Z)-
tris(trimethylsilyl)silanes.
X=I, Br
"No isomerization"
 
3.2.1.5.  Vinyl tris(trimethylsilyl)silanes as “masked silanols”. Selective in situ 
generation of reactive intermediates by H2O2/NaOH 
Denmark and Tymonko have recently utilized substrates bearing two distinct silyl 
subunits [RSiMe2OH vs. RSiMe2Bn], which required complementary activations 
(TMSOK vs. TBAF) for the construction of unsymmetrical disubstituted 1,4-
butadienes.185 Tris(trimethylsilyl)silanes can also serve as alternative organosilane 
substrates in Pd-catalyzed couplings. For example, TTMS-silane 117a remained intact 
under typical conditions employed in the coupling of dimethylsilanols185,186 [TMSOK(2 
equiv.)/Pd2(dba)3/dioxane/r.t./4 h] with more than 95% of 117a being recovered after 4 h 
and ~85% after 24 h (Scheme 35). This experiment demonstrated that TTMS-silanes 
could act as masked silanols, which require hydrogen peroxide for activation towards 
coupling. 
  75
117a
Pd(PPh3)4 (10 mol%)
THF, 55oC
H2O2, NaOH(aq)
Ar-X
Scheme 35. Possible application of vinyl tris(trimethylsilyl)silanes as "masked 
silanols".
Si(SiMe 3)3 TMSOK (2 equiv.)
Ar-X
Pd2(dba)3, dioxane
r.t., 4 h
117a
95% recovered after 4 h
85% recovered after 24 h
118a
Ar
X=I, Br
 
3.2.1.6. Mechanistic implications 
We have not yet had the opportunity to systematically investigate the mechanism(s) 
of the vinyl TTMS-silanes Pd-catalyzed coupling but it appears that hydrogen peroxide 
might chemoselectively cleave187 the SiSi bond(s) to generate silanol species 
RSi(OH)n(SiMe3)3-n (n = 1, 2, or 3). Subsequently, the silanol(s) are converted by the 
base to a silanolate anion 121a, which might further follow the coupling mechanism 
suggested by Denmark et al. for the organosilanols which involves the formation of an 
oxy-palladium intermediate of type 121b91  (Scheme 36, see also section 1.2.1). 
Alternatively, vinyl TTMS-silanes can be converted by hydrogen peroxide to 
siloxane species RSi(OSiMe3)n(SiMe3)3-n of type 122 (n = 1, 2, or 3), that can be further 
transformed to the reactive pentacoordinate species of type 123 (hypervalent silicate 
anion) by fluoride or base, as suggested by Denmark125 and DeShong 187 (Scheme 37).  
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Scheme 36. A plausible mechanism for the coupling of vinyl tris(trimethyl-
silyl)silanes via formation of silanolate anion by H2O2/base.
Ar'PdLnX
M+ X-
Ar
Si
TMS TMS
O
Pd
Ar'
L L
121a
L
Pd
L
Ar'
Ar
Transmetalation
Ar
Si
TMS TMS
TMS Ar
Si
TMS TMS
O- +M
(Isomerization ??)
Reductive
Elimination
Ar' Ar
116(Z) or 117(E)
H2O2/NaOH
THF/H2O
121b
 
Ar
Si
TMS TMS
TMS
116(Z) or 117(E)
H2O2/NaOH
THF/H2O
Si
Ar
(O)TMS
OTMS
(O)TMS
Si
Ar
(O)TMS
OTMS
(O)TMS
Nu
Nu
122
"Cross-coupling"
Ar'PdLnX
Ar' Ar
Scheme 37. A plausibe mechanism for the coupling of vinyl tris(trimethylsilyl)-
silanes via formation of pentavalent silicate anion by fluoride or base.
123
 
In order to obtain additional mechanistic insights, we examined the coupling 
reaction of 117a with iodobenzene by 29Si NMR. Thus, treatment of 117a with hydrogen 
peroxide (THF-d8/NaOH/H2O) resulted in the appearance of new peaks at 9.82, 7.20 and 
5.59 ppm (Figure 19), which are characteristic of the species having oxygen attached to 
silicon,87,125,182,187 with progressive disappearance of the two distinctive peaks at -85.31 
ppm (Si atom attached to sp2 carbon) and -14.37 pm (SiMe3) for the silicon atoms present 
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in substrate 117a. Addition of Pd catalyst and phenyl iodide to the resulting mixture 
resulted in the formation of stilbene (E)-118a.  
 
Figure 19. 29Si NMR analysis of the reaction of (E)-2-phenyl-1-[tris(trimethylsilyl)-
silyl]ethene with H2O2/NaOH(aq.) in THF-d8.  
Moreover, when coupling of 116b with 1-iodonaphthalene under fluoride-free 
conditions was quenched after 2 h (Scheme 38), the corresponding 
tris(trimethylsiloxy)silyl compound 124 [(4)CH3C6H4CH=CHSi(OSiMe3)3] was isolated 
in 7% yield in addition to product 120b (12%).   
  78
H3C
Si(SiMe3)3
116b Pd(PPh3)4 (10 mol%)THF, 55oC
"2 h"
H3C
Si(OSiMe 3)3
H2O2, NaOH(aq)
Ar-I 124
H3C
Ar
120
Ar=
Scheme 38. The Formation of (Z)-2-(4-methylphenyl)-1-[tris(trimethylsiloxy)silyl]-
ethene during the coupling with (Z)-tris(trimethylsilyl)silanes.
(7%)
(12%)
 
 
Figure 20. 29Si NMR spectra of (Z)-2-(4-Methylphenyl)-1-
[tris(trimethylsiloxy)silyl]ethane. 
The structure of 124 was assigned based on the HRMS and NMR spectra. The 
corresponding 29Si NMR spectrum of 124 showed one distinctive peak at  7.94 ppm 
attributable to the three OSiMe3 groups from the siloxane moieties (Figure 20), in 
agreement with values reported for analogous siloxanes188 (-5 to 20 ppm). The peak for 
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the Si atom attached to the C(sp2) is hardly detectable at  -66 ppm. Moreover, subjection 
of 124 to TBAF promoted coupling with 1-iodonaphthalene (Scheme 39) afforded 
product 120b but in low yield (8%; GC/MS). 
Ar=
H3C
Si(OSiMe3)3
124
H3C
Ar
120
H2O2, NaOH(aq)
Ar-I, TBAF
Pd(PPh3)4 (10 mol%)
THF, 55oC, 10 h
Scheme 39. Pd-catalyzed cross-coupling of  (Z)-2-(4-methylphenyl)-1-
[tris(trimethylsiloxy)silyl]ethene with 1-iodonaphthalene.
(8%)
 
3.2.2. Allyl(phenyl)germanes as substrates for the Pd-catalyzed cross-coupling 
reaction 
In an attempt to develop all-carbon substituted germane substrates as possible 
safety-catch precursors for the Pd-catalyzed cross-coupling, we synthesized 
allyl(phenyl)germanes (125-127) and investigated their ability to transfer the phenyl 
group from the Ge center. The design of the germanes 125-127 was made based on the 
reported transfer of the phenyl/aryl group from the moderately reactive 
allyl(phenyl)silanes 23105 and aryl(2-naphthylmethyl)germanes 28106 (see section 
1.2.1.1).  
3.2.2.1. Synthesis of allyl(phenyl)germanes 
Treatment of the commercially available trichloro(phenyl)germane with 3 equiv. 
of allylmagnesium bromide yielded triallyl(phenyl)germane 125 in 85% yield as a 
"bench" stable compound (Scheme 40). Analogous reaction of the 
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dichloro(diphenyl)germane with allylmagnesium bromide gave diallyl(diphenyl)germane 
126 (94%). Treatment of the allyl(trichloro)germane with phenylmagnesium bromide 
produced allyl(triphenyl)germane 127 (44%). Alternatively, treatment of 
chloro(triphenyl)germane with allylmagnesium bromide at ambient temperature also 
afforded germane 127 in 92% yield. 
GeCln Ge
Scheme 40. Synthesis of allyl(phenyl)germanes.
n
4-n 4-n
MgBr (n equiv.)
Et2O
0oC or r.t.
125  n=3 (85%)
126  n=2 (94%)
127  n=1 (92%)
GeCl3
PhMgBr (5 equiv.)
Et2O, 
127  (44%)
 
3.2.2.2. Pd-catalyzed cross-coupling of allyl(phenyl)germanes 
 Allylgermanes have been studied to probe their participation in - C-M 
hyperconjugation and p-d bonding.189 These type of interactions are associated with 
their enhanced reactivity towards electrophilic reagents.190 Umpolung reactivity has also 
been induced and employed for the direct allylation of aromatic substrates (e.g. 
alternative Friedel-Crafts methodology).191 Allylgermanes also efficiently participate in 
addition chemistry and a range of cycloaddition reactions.192,193 However, the application 
of allylorganogermanes as substrates for the Pd-catalyzed cross-coupling remained 
scarcely developed. Consequently, reactions of triallyl(phenyl)germanes 125 under 
typically employed coupling conditions were explored. 
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We have attempted to engage triallyl(phenyl)germane 125 in the Pd-catalyzed 
cross-coupling reactions with aryl iodides employing PdCl2/TBAF/PCy3/DMSO/H2O 
[used for triallyl(phenyl)silanes 23];105 or NaOH/H2O/H2O2/Pd(PPh3)4/THF [utilized for 
vinyl tris(trimethylsilyl) germanes 20]97. However, the transfer of the phenyl group from 
the germane precursor to yield the corresponding biaryl was not observed. Nevertheless, 
treatment of 125 with 1-butyl-4-iodobenzene under the conditions employed for the 
coupling of trichloro(phenyl)germanes 18 [NaOH (8 equiv.)/H2O/dioxane/Pd(OAc)2]95 
afforded 1-allylbenzene product 128a in 55% yield resulting from the unexpected transfer 
of the allyl group (Table 8, entry 1). A small amount of the structural isomer 129a was 
also detected by GC-MS (128a/129a, 87:13). Based on these results, we turned our 
attention to examine the effect of NaOH and other reaction parameters (Table 8) on the 
transfer of the allyl group(s) from triallyl(phenyl)germane 125. 
Thus, treatment of 125 with 1-butyl-4-iodobenzene in the presence of various 
amounts of NaOH (10 and 12 equiv.) and Pd(OAc)2 in 1,4-dioxane at 95 oC afforded a 
mixture of regioisomers 128a and 129a in up to 78% yield (entries 2 and 3). The 
combination of NaOH and Pd catalyst proved to be critical for the transfer of allyl groups 
from 125, since reactions with only NaOH or Pd(OAc)2 afforded products 128a and 129a 
in much lower yields (entries 4 and 5). Moreover, use of different Pd catalysts also gave 
the corresponding products with similar yields and regioselectivity (entries 6 and 7). 
Similar treatment employing Et3N and TBAF also afforded 128a/129a in moderate yields 
(entries 8 and 9). Alternative addition of Lewis acid BF3Et2O resulted in the formation of 
128a in poor yield (6%, entry 10). The observed results suggested the idea of a Heck type 
mechanism in which the base plays a crucial role66 (entry 3 vs. 4) and demonstrated that 
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the ratio of isomers 128a/129a seems to be independent of the conditions employed 
(entries 3, 4, 5, 8, and 9). It is possible that an easier approach to a less hindered  
position of the allyl substituent on 125 could be accountable for the observed selectivity. 
Table 8. Effect of the reaction parameters in the reaction of triallyl-
(phenyl)germanes with 1-butyl-4-iodobenzene. 
Ge 3
I
Bu Bu Bu
base, Pd
1,4-dioxane
95 oC
125 128a 129a  
Entry NaOH (equiv.) Pd Others Yield (%)a 128a/129a Ratiob 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
8 
10 
12 
- 
12 
12 
12 
- 
- 
- 
Pd(OAc)2 
Pd(OAc)2 
Pd(OAc)2 
Pd(OAc)2 
- 
Pd(PPh3)4
Pd2(dba)3 
Pd(OAc)2 
Pd(PPh3)4 
Pd(OAc)2 
- 
- 
- 
- 
- 
- 
-  
Et3N 
TBAF 
BF3Et2O 
55 
60 
78 
15 
16 
78 
80 
32 
42 
6 
87:13 
89:11 
82:18 
94:6 
82:18 
84:16 
86:14 
83:17 
82:18 
100:0 
               a Determined by GC-MS of the crude reaction mixture using 4-allylanisole as internal 
standard. b Determined based on GC-MS of the crude reaction mixture. 
In order to investigate the effect of the temperature on the regioselectivity of the 
reaction of allylgermane 125 with 1-butyl-4-iodobenzene and Pd2(dba)3 in 1,4-dioxane 
(Table 8, entry 7), “side by side” experiments at 50 oC, 70 oC and 95 oC were performed 
and their outcome monitored by GC-MS (Table 9). 
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Table 9. Effect of the temperature on the regioselectivity of the reaction of 
triallyl(phenyl)germane with 1-butyl-4-iodobenzene. 
Ge 3
I
Bu Bu Bu
1,4-dioxane
50oC or 70oC 
or 95oC
NaOH (12 eq.)
Pd2(dba)3
125 128a 129a  
 4/5 ratioa 
  50oC 70oC 95oC 
1 h 
3 h 
6 h 
90:10 
91:9 
91:9 
90:10 
91:9 
91:9 
87:13 
87:13 
87:13 
a Determined by GC-MS of the crude 
reaction mixture. 
The presence of both isomeric products 128a and 129a after only 1 h heating at 
50 oC, 70 oC, or 95 oC implied the lack of correlation between the selectivity and the 
reaction temperatures. Although faster conversion to products 128a and 129a was 
observed at higher temperatures, the 128a/129a ratios remained constant (90:10) after 
prolonged heating. 
Since the structure of triallylgermane 125 offers the possibility of transfer of three 
allyl substituents in the reaction with aryl halides, experiments with 3 equivalents of 1-
iodonaphthalene were attempted. Thus, treatment of 125 under the optimized conditions 
[NaOH(12 equiv.)/dioxane/Pd(OAc)2/95 oC] afforded a mixture of products 128b and 
129b in 92% yield (128b/129b, 87:13, Scheme 41). Similar reactions employing 
diallyl(diphenyl)germane 126 or allyl(triphenyl)germane 127 with 1-iodonaphthalene (3 
equiv.) gave regiosomers 128b and 129b in 78% and 38%, respectively. A considerable 
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amount of unchanged aryl halide remained in the reaction mixture.  
Ge
Scheme 41. Transfer equivalency of allyl(phenyl)germanes.
n
4-n
125  n=3
126  n=2
127  n=1
I
(3 equiv.)
NaOH (12 equiv.), Pd(OAc)2
1,4-dioxane, 95 oC, 18 h
128b 129b
from 125 (92%-128b/129b, 87:13)
from 126 (78%-128b/129b, 89:11)
from 127 (38%-128b/129b, 92:8)
 
Since the overall yield for the couplings was less than 100% (based on 
allylgermanes 125-127 as limiting reagents), it seems likely that only one allyl group 
from each of the germanes (125-127) participates in the reaction. However, the increase 
in the number of available allyl moieties affects the yields in a proportional fashion [from 
germane 125(92%), 126(78%), and 127(38%)]. Also, the increased steric 
hindrance conferred by replacing allyl groups with bulkier phenyl substituents 
(125126127) promoted a slight enhancement in the corresponding isomeric ratios. 
Moreover, the reactions of allylgermanes 125, 126, or 127 with only 1 equivalent of 1-
butyl-4-iodobenzene and 1-iodonaphthalene showed a similar proportional decrease of 
the yields of isomeric products 128a-b and 129a-b from triallyl(phenyl)germane (125) to 
allyl(triphenyl)germane (127) (Table 10, entries 1-3 and 7-9). Alternative use of 
Pd2(dba)3 afforded the products 128a-b and 129a-b in higher yields, albeit the 
regioselectivity was not improved (entry 1 vs 4, 2 vs 5, 3 vs 6). 
Interestingly, the reactions with the bulkier 1-iodonaphthalene showed a 
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significant enhancement in the regioselectivity compared with similar reactions with 1-
butyl-4-iodobenzene (entry 1 vs 7, 4 vs 10). 
It seems feasible that the formation of products 128 and 129 from 
allyl(phenyl)germanes 125-127 in the presence of NaOH and Pd catalyst might follow a 
Heck arylation mechanism (Scheme 42). Allylgermatranes93 and allyltrimethylsilanes194 
have been reported to undergo Heck reaction with aryl halides under similar conditions. 
In our proposed mechanism (Scheme 42), addition of the aryl-Pd complex 130a to 
the double bond on the allylgermane (125-127) would lead to the formation of the -
bound complex 130b. Addition of the aryl group to the double bond might take place 
either on the terminal (131a) or on the internal (131b) carbon (pathways A and B) 
leading to the formation of isomeric products 128 and 129. In pathway A, the 
intermediate 131a would undergo an iodide-promoted intramolecular degermylation 
yielding 1-allylbenzene product 128. In pathway B, a -hydrogen elimination would 
occur on 131b, producing an internally arylated allylgermane -bound to Pd(H)(I) (132). 
Insertion of this alkene into the Pd-H bond would afford the complex 133, which will 
eleminate R3GeI and Pd(0) to give product 129. 
Although the described Heck arylation of allylgermanes (125-127) in the presence 
of NaOH displayed less efficiency than other available methodologies,195 a careful 
investigation of the proposed mechanism would advance the usually limited knowledge 
about the reactivity of organogermanium species. However, the development of a 
convenient strategy for the selective cleavage of the Ge-allyl bond in germanes 125-127 
was still our main objective. 
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 Table 10. Reaction of allyl(phenyl)germanes with 1-butyl-4-iodobenzene and 1-
iodonaphthalene. 
Ge n
4-n
125  n=3
126  n=2
127  n=1
Ar Ar
Ar-I (1.1 equiv.)
NaOH (12 equiv.), Pd
1,4-dioxane, 95oC, 18 h
128 129


Series a Ar=
           
          b Ar=
Bu
 
Entry Germane Pd Products Yield (%)a 128/129 Ratiosb 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
125 
126 
127 
125 
126 
127 
125 
126 
127 
125 
126 
127 
Pd(OAc)2 
Pd(OAc)2 
Pd(OAc)2
Pd2(dba)3 
Pd2(dba)3 
Pd2(dba)3 
Pd(OAc)2 
Pd(OAc)2 
Pd(OAc)2
Pd2(dba)3 
Pd2(dba)3 
Pd2(dba)3 
128a/129a
128a/129a
128a/129a
128a/129a
128a/129a
128a/129a
128b/129b
128b/129b
128b/129b
128b/129b
128b/129b
128b/129b
78 
47 
32 
80 
55 
33 
73 
51 
29 
88 
69 
40 
82:18 
82:18 
86:14 
86:14 
85:15 
85:15 
91:9 
90:10 
91:9 
91:9 
92:8 
93:7 
a Determined by GC-MS of the crude reaction mixture using 4-allylanisole as 
internal standard. b Determined GC-MS of the crude reaction mixture. 
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Scheme 42. A plausible mechanism for the Heck arylation of allyl(phenyl)germanes.
Ar I
[Pd]
Ar Pd I Ar Pd
I
GeR3
GeR3
Ar
Pd
GeR3
IPd
Ar
Ar
- IGeR3
128
"Heck Reaction"
-[Pd]
GeR3
Ar
HPd I
Ar
129
I
130a
131a
H
GeR3
H
Pd
Ar
- IGeR3
-[Pd]
131b
133
GeR3
125-127
Pathway B
Pathway A
I
130b
132
 
3.2.2.3. Treatment of allyl(triphenyl)germane with TCNE. Possible transfer of the 
phenyl group 
 During our study of the Pd-catalyzed cross-coupling of allyl(phenyl)germanes 
125-127, the coupling of photochemically activated (2-naphthylmethyl)germanes 28 (see 
Scheme 8) with different aryl halides was reported.106 The photooxidation of 28 in the 
presence of Cu(BF4)2 resulted in the selective cleavage of  Ge-C(2-naphthylmethyl) 
bonds and formation of reactive arylfluorogermanes 29 which subsequently underwent 
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transmetallation.  
On this basis, the reaction of allyl(triphenyl)germane 3 with the strong oxidizing 
agent tetracyanoethylene196 (TCNE) was envisioned as a possible route to reactive halo- 
or hydroxogermanes known to be active in the Pd-catalyzed cross-coupling reactions.93-97 
Thus, treatment of triallyl(phenyl)germane 125 with TCNE in refluxing acetonitrile for 7 
h resulted in the complete consumption of starting allylgermanes, as shown by TLC 
analysis of the crude reaction mixture. Presumably, the Ge-C(allyl) bond of 125 was 
cleaved following a similar pathway to that proposed for the reaction of 
allyltrimethylsilanes with TCNE (Scheme 43).196 In a first step, the electron-accepting 
TCNE would promote the interaction with the -system of 125, generating zwitterionic 
complex 134, stabilized by - hyperconjugation with the Ge-C bond. Subsequent 
solvation of the Ge center would promote the formation of the R3Ge+solvent adduct 136 
and an anionic cyano-contaning compound 135.  
Scheme 43. A tentative mechanism for the reaction of allylgermanes with 
tetracyanoethylene.
NC
NC CN
CN
GeR3
NC CN CN
CN
GeR3
NC CN CN
CNSolvent
CN
CN
NC CN
H2O
R3Ge solven t
125
(134)
135
136
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 Based on the pathway described above (Scheme 43), we explored the synthesis of 
reactive fluorogermanes by quenching in situ the generated solvated R3Ge+ ion 136 [from 
the reaction of allylgermane 125 and TCNE (1 equiv.)] with fluoride ions (e.g. NaF). The 
19F NMR spectrum of the crude reaction mixture displayed two peaks at  -204.1 and  -
163.3 ppm (Scheme 44), characteristic for organogermanes bearing 1 and 2 fluorine 
atoms.106 In agreement with the observed results, 1H NMR confirmed the presence of the 
residual Ge-C(allyl) bonds. The attempted separation of the resulting fluorogermanes 
from an intense colored reaction mixture was not successful due to their instability on 
silica gel. Experiments employing excess of TCNE followed by addition of the more 
soluble TBAF, as a fluoride source, did not produce an analogous signal in the 
corresponding 19F NMR spectrum.  
Ge
Scheme 44. Reaction of triallyl(phenyl)germane with TCNE and NaF.
125
NC
NC CN
CN
(1 equiv.)
ACN, 82 oC, 5 h
then
NaF, 3 h
3 Ge 3-n
Fn
n=1 19F NMR ( -204.1)
n=2 19F NMR ( -163.3)
 
In an attempt to promote the cleavage of all the Ge-C(allyl) bonds in the 
organogermanium precursor (to avoid competition between allyl and aryl group 
transfers), analogous experiments were initially performed employing 
allyl(triphenyl)germane 127. Thus, treatment of 127 with TCNE (1.5 equiv.) in refluxing 
acetonitrile for 4 h (total disappearance of 127 on TLC) followed by addition of TBAF 
(1.5 equiv.) afforded a green-colored reaction mixture. However, 19F NMR of the 
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decolorized (charcoal) crude reaction exhibited only a small signal for the 
monofluorinated germane Ph3GeF ( -201.9 ppm). It seems likely that solvation of the 
fluoride ions by the polar acetonitrile precluded the efficient fluorination of the 
R3Ge+solvent adduct.  
Analogous reaction of 127 employing excess of the inexpensive NH4F (10 equiv.) 
as the fluoride source failed to generate the desired Ph3GeF (Scheme 45). However, 
analysis of the crude reaction mixture by 1H NMR and GC-MS suggested the presence of 
an oxy germane of type Ph3GeOR (137, R=H or 138, R=GePh3). Subsequent treatment of 
the non-purified crude with TBAF (7 equiv.), 1-iodonaphthalene, and Pd2(dba)3 in 
toluene at 100 oC (see section 3.2.3.1) afforded an equal mixture of the desired biaryl 
product 139a, 1-cyanonaphthalene 140, and unreacted aryl halide. Since the reaction of 
TCNE with 1-iodonaphthalene in the presence of Pd2(dba)3 failed to produce 1-
cyanonaphthalene,  the cyano-containing byproducts generated from the treatment of 127 
with TCNE (see Scheme 43) might be accounted forby the formation of unexpected 140. 
The 1-cyanonaphthalene could be formed via Pd-catalyzed transfer of the cyano group or 
via nucleophilic aromatic substitution.  
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Ge
Scheme 45. Reaction of allyl(triphenyl)germane with TCNE and NH4F 
followed by coupling with 1-iodonaphthalene.
3
127
NC
NC CN
CN
(1.5 equiv.)
ACN, 82 oC, 5 h
then
NH4F (10 equiv.), 3 h
Ge OR
137 R=H or 
138 R=GePh3
I
TBAF, Pd2(dba)3
toluene, 100 oC
CN
139a 140
3
 
 On the basis of the results described above, the synthesis of oxo-germanium 
species of type 137/138 was attempted by replacing the fluoride sources with NaOH. The 
strong alkaline conditions were anticipated to perform a dual role: i) hydrolyze the 
corresponding Ph3Ge+solvent adduct (see Scheme 43) to produce oxo-germanes 
137/138; and ii) hydrolyze the residual cyano-byproducts to the water-soluble 
carboxylate salts. As predicted, treatment of allylgermane 127 with TCNE in refluxing 
acetonitrile for 7 h, followed by addition of a 2 M NaOH solution afforded 
hexaphenyldigermoxane 138 as a crystalline solid (Scheme 46). The identity of 138 was 
confirmed by comparison of the spectroscopic data and meting point (179-181 oC, 
uncorrected) with commercially available (Ph3Ge)2O (m.p. 181 oC). 
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Ge
Scheme 46. Reaction of allyl(triphenyl)germane with TCNE and NaOH. 
Formation of hexaphenyldigermoxane.
3
127
NC
NC CN
CN
(1.5 equiv.)
ACN, 82 oC, 5 h
then
NaOH (2 M), 3 h
Ge
3
O Ge
3
138
 
Next, we explored the ability of digermoxane 138 to participate in the Pd-
catalyzed cross-coupling reactions under the conditions applied for the coupling of 
analogous diaryl(dimethyl)disiloxanes [Ag2O/Pd(PPh3)4/TBAF/THF]197. Thus, treatment 
of 138 with 1-iodonaphthalene (3 equiv.), Ag2O, Pd2(dba)3, and TBAF in 1,4-dioxane at 
100 oC afforded  1-phenylnaphthalene 139a (54%) along with the reductive 
homocoupling byproduct 141a (139a/141a, 59:41) (Scheme 47). The yield was 
determined by GC-MS using 2-ethylnaphthalene as internal standard [internal response 
factor (IRF=0.703)], while the 139a/141a ratio was calculated based on GC-MS of the 
crude reaction mixture. Moreover, treatment of 138 with 1-iodonaphthalene in toluene as 
solvent afforded 139a in better yields (95%, organogermane as limiting reagent) and 
better 139a/141a ratio (61:39). 
Scheme 47. Coupling of hexaphenyldigermoxane and 1-iodonaphthalene.
(1.5 equiv.)
Ag2O, TBAF, Pd2(dba)3
1,4-dioxane, 100 oC
Ge
3
O
138
I
139a 141a
2
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Although digermoxane 138 bears 6 phenyl groups among its two Ge centers, the 
obtained results suggested that presumably only one phenyl group is transferred from 138 
in the Pd-catalyzed coupling with 1-iodonaphthalene. It seems that the development of 
the first methodology able to promote multi-transfers from an organogermanium 
precursor is still a very ambitious challenge. Additional implications regarding the 
participation of 138 in the Pd-catalyzed cross-coupling reaction will be discussed later. 
Further efforts to efficiently engage digermoxane 138 in the coupling with aryl 
halides were undertaken employing the conditions described for the reaction of 
arylgermanium sesquioxides 1996 (see Figure 10 in section 1.2.1) with various aryl 
halides in the presence of base. However, treatment of 138 with 1-iodonaphthalene (3 
equiv.) in the presence of aqueous NaOH and Pd2(dba)3 in 1,4-dioxane (100 oC) failed to 
efficiently produce biaryl 139a (<5%).  
3.2.3. Arylchlorogermanes/TBAF/”moist” toluene. A promising combination for Pd-
catalyzed germyl-Stille cross coupling 
 Given our interest in developing new organogermanium substrates for the Pd-
catalyzed cross-coupling reaction, the synthesis of novel 2-
(dimethyl(phenyl)germyloxy)pyridine 142 (Figure 21) was undertaken. Thus, treatment 
of the commercially available chloro(dimethyl)phenylgermane 143 with 2-
(hydroxymethyl)pyridine in the presence of Et3N (or other bases) in ethanol/reflux or 
toluene at 95 oC failed to afford the desired product 142, but instead gave unchanged 2-
(hydroxymethyl)pyridine and some unidentified byproducts. Nevertheless, treatment of 
143 with 2-(hydroxymethyl)pyridine followed by the addition of TBAF (1.5 equiv.), 1-
iodonaphthalene, and Pd2(dba)3 to the reaction mixture and stirring at 95 oC overnight 
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afforded coupling product 139a (detected by GC-MS) (Scheme 48). A subsequent 
reaction of germane 143 with 1-iodonaphthalene under similar conditions 
[TBAF/Pd2(dba)3/toluene/95 oC] without 2-(hydroxymethyl)-pyridine and Et3N also 
afforded biaryl product 139a, suggesting that the coupling was likely to happen through a 
reactive organogermane derived from chlorogermane 143. 
Ge
O
Me
Me
N
142
Figure 21. Structure of 2-(dimethyl(phenyl)germyloxy)pyridine.  
143
139a
2) TBAF, Pd2(dba)3
1-idonaphthalene
toluene, 100 oC
12 h
Ge
Cl
Me
Me
N
HO
1) Et3N, toluene
95 oC
Scheme 48. Tandem alkoxylation/Pd-catalyzed coupling of 
chloro(dimethyl)phenylgermane and 1-iodonaphthalene.  
3.2.3.1. Pd-catalyzed cross-coupling of chlorophenylgermanes 
Motivated by the results with chloro(dimethyl)phenylgermane (143), optimization 
of the reaction parameters was performed. Thus, treatment of PhGeMe2Cl 143 with 1-
iodonaphthalene in the presence of TBAF and tris(dibenzylideneacetone)dipalladium(0) 
[Pd2(dba)3] in toluene gave cross-coupling product 139a in addition to the binaphthyl 
homocoupling byproduct 141a (Table 11). The amount of TBAF was found to be crucial 
for the successful coupling (entries 1-5). At least 4 equiv. of TBAF were required to 
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produce 139a in maximum yield. Other Pd catalysts afforded 139a in lower yields and a 
decreased ratio of 139a to 141a (entries 6-7). Replacing 1M TBAF/THF solution with 
neat TBAF3H2O also gave product 139a (entry 8). Coupling in the presence of Me4NF, 
CsF or NH4F instead of TBAF failed to produce 139a. The reaction also proceeded 
successfully at 80 oC (80%; 10:1) and 110 oC (93%; 10:1) as well as at reflux in benzene 
(90%; 10:1), requiring 12 h for the best results (entry 4). 
Table 11. Effect of various reaction parameters on the efficiency of cross-coupling of 
chloro(dimethyl)phenylgermane with 1-iodonaphthalene.a 
143
139a 141a
I
TBAF
Pd, toluene
100 oC, 12 h
Ge
Cl
Me
Me
 
Entry Pd TBAFb 139a [yield(%)]c 139a/141a ratioc 
1 Pd2(dba)3 1.0 19 1:1 
2 Pd2(dba)3 2.0 61 9:1 
3 Pd2(dba)3 3.0 79 17:1 
4 Pd2(dba)3 4.0 93d,e 20:1 
5 Pd2(dba)3 5.0 94 12:1 
6 Pd(OAc)2 4.0 58 5:2 
7 Pd(PPh3)4 4.0 5 2:1 
8 Pd2(dba)3 4.0f 70 6:1 
a Couplings were performed on 0.14 mmol scale of 143 (0.04 M) with 1.1 
equiv of iodonaphthalene and 0.09 equiv of Pd catalyst. b Commercial 1M 
THF solution containing 5% of water, unless otherwise noted. c Determined 
by GC-MS of the crude reaction mixture. d Isolated yield. e After 4 h, 49% 
(8:1); 8 h, 78% (15:1). f With TBAF3H2O. 
Toluene was the obvious solvent choice since attempts in DMSO (5%, 110 oC) or 
THF at reflux (0%) or dioxane at reflux (59%; 3:1) failed or afforded 139a in lower 
yields. Higher yield for the coupling in dioxane than in THF may be attributable to the 
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increased temperature of the reaction as well the difference in dielectric constant  [7.58 
for THF as compared to dioxane (2.21) and toluene  (2.15)].120  Bases such as NaOH 
[Pd(OAc)2; dioxane/H2O, 2:1] or KOSiMe3 [Pd2(dba)3, toluene)], instead of TBAF, failed 
or were less efficient in promoting couplings. 
3.2.3.2. Effect of added water on the coupling of chloro(phenyl)germanes with 1-
iodonaphthalene 
In order to examine the effect of additional chloro ligands on the Ge center, 
couplings of dichloro(diphenyl)germane 144 or chloro(triphenyl)germane 145 with 
iodonaphthalene were performed. Thus, treatment of 144 with 1.1 equiv. of iodide and 
TBAF (7 equiv.) gave 139a (Table 12, entry 1). Coupling of 144 with 2.2 equiv of 
iodonaphthalene also resulted in total consumption of iodide to afford 139a and 141a 
(entry 2). Interestingly, couplings in toluene with addition of the measured amount of 
water (1 M TBAF/THF//H2O; ~1:5 M/M) gave a higher yield of 139a with a superior 
ratio of 139a/141a (entries 3 vs 1 and 4 vs 2). An investigation of the coupling reactions 
with different amounts of water, revealed that addition of 100 μL of H2O (~40 equiv.) 
gave optimal yields (entry 10). Two phenyl groups were efficiently transferred in the 
presence of excess iodide with the average efficiency of 89% (entry 4; yield is based 
upon two phenyl groups transferring from the chlorogermane reagent 144). It is worth 
noting that halides are often used in couplings as limiting reagents to reduce formation of 
homocoupling byproducts and the yields are based on the halide components unlike 
herein. 
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Table 12. Cross-coupling of dichloro(diphenyl)germane and chloro(triphenyl)germane 
with 1-iodonaphthalene promoted by TBAF and TBAF/H2O. 
Ge
144 Y=Cl
145 Y=Ph 139a 141a
I
TBAF (H2O)
Pd, toluene
100 oC, 12 hY
Cl
n
n=2 (for 144)
n=3 (for 145)
n
 
Entry germane R-X (equiv.) methoda 139a [yield(%)]b 139a/141a ratio 
1 144 1.1 A 32c (30) 2.7:1 
2 144 2.2 A 58 (55) 2.2:1 
3 144 1.1 B 45 (42) 23:1 
4 144 2.2 B 91 (89) 10:1 
5 145 1.1 A 13d (12) 1:1.4 
6 145 2.2 A 37 (35) 2:1 
7 145 3.3 A 40 (39) 1.2:1 
8 145 1.1 B 18 (17) 2.5:1 
9 145 2.2 B 60 (60) 9:1 
10 145 3.3 B 95e (88) 13:1 
a Method A: Couplings were performed on 0.14 mmol scale of germane (0.04 M) with 
Pd2(dba)3 (0.09 equiv) and 7 equiv of TBAF (1M/THF). Method B: as in Method A with 
addition of H2O (100 μL). b Based upon transferring two phenyl groups from 144 or three 
phenyl groups from 145. Determined by GC-MS of the crude reaction mixture (isolated 
yields in parenthesis). c 26% and 31% with 6 and 8 equiv. of TBAF. d 11% and 14% with 6 
and 8 equiv of TBAF. e 57% (3.8:1) with 50 μL H2O; 82% (7:1) with 150 μL H2O. 
We were very fortunate to find that the couplings of chloro(triphenyl)germane 
145 with 1.1, 2.2 or 3.3 equiv of iodonaphthalene proceeded with efficient transfer of up 
to three phenyl groups to give 139a (entries 5-10). Again, yields and 139a/141a ratios 
increased when wet toluene was used. Atom-efficient Stille cross-couplings of Ar4Sn 
with aryl halides (48, Scheme 13, section 1.2.1.3), where all four substituents on tin 
participate in the carbon-carbon bond formation, are known.80,129 Also, 
vinylpolysiloxanes (49, Scheme 14, section 1.2.1.3) were shown to transfer each of their 
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vinyl groups during Pd-catalyzed couplings with aryl and alkenyl iodides in the presence 
of TBAF.130 However, attempts to induce multiple transfer of the phenyl group during 
fluoride-promoted couplings of (allyl)XPh4-XSi (x = 1 or 2) with aryl halides failed (23 
and 24, Scheme 6, section 1.2.1.1).105 
It is viable that the germanium species with extra halogen ligands formed after 
each transmetallation cycle is rendered more reactive to efficiently transfer a second or 
third phenyl group from the Ge atom. Water might play multiple roles in enhancing the 
efficiency of the couplings as was found with organosilanes, including the formation of 
the reactive hydroxypalladium intermediates.91,125,198  For example, the hydration level of 
Cs2CO3 and CsOH were found to be a decisive factor during the coupling of the 
aryl(dimethyl)silanols with aryl halides.199 Also, Denmark and Sweis showed that water 
was a critical additive in the fluoride promoted reaction of alkenylsilanols with phenyl 
nonaflate.200 In addition,  the fluorination of the bulky chlorogermanes may be 
accelerated by the addition of water as was reported for hindered chlorosilanes.201 
Couplings of 144 or 145 with other aryl, alkenyl, and heterocyclic iodides and 
bromides (using 2.2 or 3.3 equiv of halides, respectively) promoted by TBAF/H2O are 
presented in Table 13 (entries 1-14). Reactions of germanes 144 or 145 with reactive 4-
iodoacetophenone produced 139d in low yields in addition to large quantities of the 
reductive homocoupling byproduct  141d. However, coupling of the less reactive 4-
bromoacetophenone at higher temperature (115 oC) resulted in better yields and improved 
139d/141d ratios (entries 5 vs 4 and 12 vs 11). Treatment of PhGeCl3 146 with halides 
and TBAF/toluene or wet toluene also afforded coupling products 7 (entry 15-22), 
although it has been reported that fluoride ion did not promote the couplings of PhGeCl3 
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with aryl halides.95 It appears that reactivity of the chlorogermanes increases with the 
number of halogen ligands on the Ge center (145 < 144 < 146). As expected,94 coupling 
attempts with Ph4Ge failed, and thus emphasize the need for at least one labile 
heteroatom ligand at the Ge center. The necessity of two halogen ligands had been 
proposed for nucleophilic activation by F- or OH- ions.106 
Table 13. Cross-coupling of chloro(phenyl)germanes with halides.a 
Ge
144 Y=Cl, Z=Ph
145 Y=Z=Ph
146 Y=Z=Cl
139a-f 141a-f
TBAF (H2O)
Pd2(dba)3, toluene
100 oC, 12 h
Z
Y
Cl
n=2 (for 144)
n=3 (for 145)
n=1 (for 146)
n  R X
R
R Rn
 
Entry germane R-X Product yield (%)b 139/141 ratio 
1 144 1-Bromonaphthalenec 139a 54 (48) 7.2:1 
2 144 (4)CH3OPhI 139b 86d (85) 9.8:1 
3 144 (3)CF3PhI 139c 70 (68) 3.4:1 
4 144 (4)CH3COPhI 139d 12 (10) 3:2 
5 144 (4)CH3COPhBr 139d 26d (21) 99:1 
6 144 PhCH=CHBr 139e 8e,g (5) 1:3 
7 144 2-Iodo-5-Me-thiophene 139f 13e (6) 2:3 
8 145 1-Bromonaphthalene 139a 24 1.4:1 
9 145 (4)CH3OPhI 139b 48f (40) 4:1 
10 145 (3)CF3PhI 139c 48 3:2 
11 145 (4)CH3COPhI 139d 3 1:20 
12 145 (4)CH3COPhBr 139d 24d 1:1 
13 145 PhCH=CHBr 139e 3g 1:8 
14 145 2-Iodo-5-Me-thiophene 139f 3g 2:3 
15 146 1-Iodonaphthalene 139a 99h (96) 35:1 
16 146 1-Bromonaphthalene 139a 90g (82) 99:1 
17 146 (4)CH3OPhI 139b 88g (80) 10:1 
18 146 (3)CF3PhI 139c 93 (87) 9:1 
19 146 (4)CH3COPhI 139d 99 (88) 99:1 
20 146 (4)CH3COPhBr 139d 91 99:1 
21 146 PhCH=CHBr 139e 30e,g (28) 3:1 
22 146 2-Iodo-5-Me-thiophene 139f 48e,g (35) 3:2 
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a  Couplings were performed on 0.14 mmol scale of germanes (0.04 M) with 0.09 equiv 
of Pd catalyst,  1.1 (146), 2.2 (144) or 3.3 (145) equiv of halides and TBAF/(1 M/THF, 
7 equiv)/water (100 μL). b Based upon transferring of one, two or three phenyl groups 
from 146, 144 or 145,  respectively. Determined by GC-MS of the crude reaction 
mixture (isolated yields in parenthesis). c Coupling with 1-chloronaphthalene failed. d 
115 oC. e Biphenyl was also produced (~25-50%).  f 28 h. g Without H2O. h 88% (81%, 
19:1) without H2O.  
3.2.3.3. Comparison with chloro(phenyl)stannanes and chloro(phenyl)silanes 
 Since organostannanes and organosilanes have been known to display much 
higher reactivity towards the Pd-catalyzed cross-coupling and reports in literature on the 
ability of chlorosilanes to undergo coupling were inconsistent,  we performed a 
comparative study of the coupling efficiency of chloro(phenyl)-germanes, -silanes, and –
stannanes under our conditions [TBAF/ “moist” toluene]. In order to establish reaction 
protocols, couplings of dichloro(diphenyl)germane 144, -silane 147, and -stannane 148 
with 1-iodonaphthalene (2 equiv.) in the presence of Pd2(dba)3 were attempted under 
different conditions and the results summarized in Table 14. 
We found that coupling with dichloro(diphenyl)germane 144 required heating at 
100 oC for 15 h to afford biaryl 139a in good yields (86%; based on the transfer of two 
phenyl groups, 172% total yield of 1-phenylnaphthalene). Analogous reaction conditions 
promoted the coupling of dichloro(diphenyl)silane 147 (93%) and 
dichloro(diphenyl)stannane 148 (99%) after only 5 h and 2 h respectively (Table 14, 
entry 4). The reaction of 144, 147, and 148 at lower temperature (60 oC and 80 oC) 
indicated a higher reactivity of organostannane 147 with respect to its silicon and 
germanium counterparts (entry 4, footnotes). Moreover, the smaller amounts of TBAF 
required for the efficient coupling of 148 or 147 with 1-iodonaphthalene in toluene also 
indicated a faster activation of stannanes or silanes towards transmetallation. Additional 
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experiments utilizing an alternative fluoride source (entry 5) and different solvents 
(entries 6 and 7) supported the described observations. Noteworthy, the coupling of silane 
147 under our optimized conditions constitutes the first example of the cross-coupling of 
halosilanes from which every phenyl groups has been transferred. 
Table 14. Comparison of the couplings of dichloro(diphenyl)-germane, -silane, and -
stannane with 1-iodonaphthalene. 
M
144 M=Ge
147 M=Si
148 M=Sn
139a 141a
I
TBAF (H2O)
Pd, toluene
100 oC, 12 h
2
Cl
Cl
2
 
From 144 (15 h) From 147 (5 h) From 148 (2h) 
Entry TBAF b 139a Yield 
(%)c 
139a/141a 
ratiod 
139a 
Yield 
(%)c 
139a/141a
ratio d 
139a 
Yield 
(%)c 
139a/141a 
ratio d 
1 1.0 -- -- -- -- 14 99:1 
2 3.0 7 20:1 3 1:0 63 99:1 
3 5.0 34 17:1 72 20:1 93 99:1 
4 7.0 86 e 10:1 93 f 10:1 99 g 99:1 
5 7.0 h 80 4:1 95 33:1 96 99:1 
6 7.0 i 48 6:1 56 2:1 95 Pure 
7 7.0 j 94 20:1 81 19:1 97 Pure 
a Couplings were performed on 0.14 mmol scale of organometallics (0.04 M) with 
2.0 equiv. of 1-iodonaphthalene and 0.05 equiv. of Pd catalyst. b Commercial 1M 
THF solution containing 5% H2O, unless otherwise noted. c Based upon transferring 
two phenyl groups from 144, 147-148. Determined by GC-MS of the crude reaction 
mixture. d Molar ratio. e At 60 oC (19%, 10:1) and at 80 oC (43%, 4:1). f At 60 oC 
(43%, 30:1) and at 80 oC (91%, 15:1). g At 60 oC (87%, pure) and at 80 oC (94%, 
pure). h TBAF3H2O. i THF (60 oC). j Dioxane (80 oC). 
3.2.3.4. Mechanistic implications 
During the optimization of the cross-coupling reactions between 143 
(PhMe2GeCl) and 1-iodonaphthalene (Table 11) it became obvious that the coupling 
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outcome strongly depended on TBAF/organogermane ratios. TBAF most likely facilitates 
the coupling by generating the more reactive hypervalent fluorogermanium species and 
the reactivity of these hypervalent Ge species could be superior in toluene due to weak 
solvation. Hypervalent (fluoro pentacoordinated) tin81,114,115 and silicon121-123,202 species 
has been established as active intermediates in Pd-catalyzed coupling reactions (see 
section 1.2.1.2).  
In order to get insight about the role hypervalent germanium species play in the 
coupling of chlorogermanes 143-146, we have studied their interaction with TBAF. 
Initial experiments were conducted using chloro(dimethyl)phenylgermane 143. Thus, 
mixing of 143 (32.2 mg, 0.15 mmol) and TBAF (1.5 equiv. 1 M solution in THF) in 
benzene-d6 at room temperature resulted in the substitution of the chlorine ligand by the 
fluoride ion and formation of PhMe2GeF. The observed septet centered at -194.6 ppm 
(19F NMR) with the coupling to six equivalent protons of the two methyl groups (3JF-H  
6.0 Hz, spectrum a, Figure 22) had a chemical shift in agreement with the literature value 
(-196.0) for the analogous fluorodimethylgermane.106,127 Heating the sample at 50 oC for 
3 h resulted in broadening of the signal at -194.6 ppm and appearance of a major broad 
peak centered at -150.8 ppm suggesting an equilibrium between PhMe2GeF and 
PhMe2GeF(X)- (X=Cl or OH) species (spectrum b). The pentavalent difluorogermanate 
Ph(Me)2GeF2- appeared as a minor peak at -126.4 (septet, 3JF-H 5.8 Hz) is agreement 
with reported chemical shift for the analogous hypervalent difluorotriphenylgermana 
46128 (see Scheme 11, section 1.2.1.2). Overnight heating resulted both in the additional 
broadening of the peaks at -150.8 ppm and -194.3 ppm and in increasing intensity of 
signal(s) at -126.4 ppm (spectrum c). Washing the sample with D2O resulted in the 
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reappearance of the septet at -194.3 ppm [PhMe2GeF] as the sole signal (spectrum d). 
 
Figure 22. 19F NMR analyses of the reaction of chloro(dimethyl)phenylgermane with              
TBAF in benzene-d6. 
A similar treatment of chlorotriphenylgermane 145 (68 mg, 0.20 mmol) with 
TBAF in benzene-d6 gave comparable pattern of peaks as that of 143. As expected, 
reactions of di- and trichlorogermanes 144 and 146 with TBAF led to more complex 
mixtures. Nevertheless, treatment of dichlorogermane 144 produced difluorinated 
tetravalent germane Ph2GeF2 showing a signal -163.88 ppm in agreement with the value 
reported by Spivey for analogous difluoride.106  
To correlate ease of formation, spectroscopic characteristics, and reactivities in 
the fluoride-promoted couplings of the hypervalent germanium species with those of the 
corresponding silanes and stannanes, reactions of the fluoride ion with 
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chloro(triphenyl)silane 149 and chloro(triphenyl)stannane 150 in benzene-d6 were also 
explored. Thus, heating of chlorostannane 150 (71.1 mg, 0.18 mmol) with TBAF (1.5 
equiv.) resulted in the appearance on 19F NMR spectra of two singlets at -158.6 and -
159.5 ppm accompanied by F-Sn satellite signals (spectrum a, Figure 23). Further 
addition of TBAF (1.5 equiv.) resulted in the formation of difluorotriphenylstannate 35 
which resonated as a sharp singlet at -160.5 ppm with satellite peaks (1J19F-119Sn=2034.2 
Hz, 1J19F-117Sn=1940.2 Hz) in close agreement with the reported values for the isolated 
35114 (spectrum b).  Treatment of chlorosilane 149 with TBAF (1.5 equiv.) produced a 
broad peak for Ph3SiF Although only slow equilibration between Ph3Si-F201 at -168.39 
ppm which exists in equilibrium with Ph3SiF2- 39 (-94.5 ppm) (spectrum c). The 
characteristic signal121 for the pentavalent complex 39 was, however, clearly observed 
with 3 equiv. of TBAF after additional heating [ -94.6 ppm (1J19F-29Si=255.1 Hz) and -
95.3 ppm (1J19F-29Si=255.1 Hz)] (spectrum d). In contrast, chlorogermane 145, under 
similar conditions, produced only a small amount of the pentavalent intermediate 151 (-
154.7 ppm) in equilibrium with the monofluorinated tetravalent compound 45 (-201.6 
ppm, spectrum e, see section 1.2.1.2). An additional portion of TBAF and prolonged 
heating resulted in further broadening of the signal(s) but also in dissapearance of the 
signal from 45 (spectrum f). It appears that Ph3SnCl is more susceptible than its silicon 
and germanium counterparts to form the reactive pentavalent complex 35, even at low 
concentrations of fluoride ions. On the other hand, the silicon analogue 149, although it 
requires higher concentration of TBAF to afford the corresponding pentavalent complex 
39 than the tin counterpart, is more prone to form hypervalent species than the analogous 
organogermane precursor. Since substrates 144, 147, and 148 undergo coupling under 
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similar conditions (sovent/TBAF; Table 14) but require divergent reaction conditions 
(time/temperature), these results might suggest that differences in their coupling 
efficiencies might be related to their ability to generate reactive hypervalent intermediates 
upon fluoride activation. 
 
Figure 23. 19F NMR analysis of the reaction of chloro(triphenyl)germane, silane, and 
stannane with TBAF in benzene-d6. 
To investigate the effect of the addition of water on the coupling of 
chlorotriphenylgermane 145 (68 mg, 0.20 mmol) with TBAF (1.5 equiv) in benzene-d6 (2 
mL) in the presence of various amounts of water (25, 50, and 100 L) were analyzed by 
19F NMR (Scheme 49). It seems that increasing the amount of water resulted in the faster 
formation of sharper and higher peak at -202.5 ppm for Ph3GeF (45; r.t. and 1.5 equiv. 
TBAF). Interestingly, fluorination of the bulky chlorosilanes has been reported to be 
  106
accelerated by the addition of water.201 Heating of the reaction mixture at 50 oC produced 
also the hypervalent germanium compound 151 (-154.8 ppm) matching the results from 
the analogous experiments without additional water added (Figure 23, spectrum e). 
Overnight stirring with 4.5 equiv. of TBAF and extraction of the benzene slution with 
D2O, resulted in the disappearance of the 19F signals. It is likely that the putative 
hypervalent germanium species 151, generated during the study, were hydrolyzed and/or 
transformed into triphenylgermanol 137 or hexaphenyldigermoxane 138 derivatives. 
Ge
145
TBAF (1.5      4.5 equiv.)
benzene-d6
H2O (50, 70 or 100 L)
r.t.          50 oC
Ph
Ph
Ph
Cl GePh
Ph
Ph
F "Unknown" 151
45
D2O - extraction
No 19F NMR signal 45   
19F NMR:  -201.6 ppm
151  19F NMR:  -150.6 ppm
Scheme 49. 19F NMR study of the effect of added water in the reaction of 
chloro(triphenyl)germane with TBAF.  
To establish the role of digermoxane 138 in the coupling of chlorogermane 145 in 
toluene, the reaction of 138 with 1-iodonaphthalene was attempted under our optimized 
conditions (Table 11). Thus, treatment of 138 with 1-iodonaphthalene (3 equiv.) in the 
presence of TBAF (7 equiv.) and Pd2(dba)3 in toluene afforded biaryl product 139a in 
68% yield (Scheme 50; the yield was determined by GC-MS using 2-ethylnaphthalene as 
internal standard and 138 as limiting reagent) in addition to homocoupling byproduct. 
Analogous coupling of 138 with 3 or 6 equiv. of 1-iodonaphthalene also afforded 139a 
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(with total yields not exceeding the theoretical 100% yield which would indicate multiple 
transfer of phenyl group from 138). All attempts of changing the reaction conditions 
between 138 and 1-iodonaphthalene (e.g. wet toluene, THF or 1,4-dioxane at reflux as 
solvents, and Ag2O/TBAF and NaOH as base) failed or give 139a in lower yield. It 
seems that 138 although might be formed during the coupling of chlorogermane 145, and 
can contribute to the overall yield of the cross-coupling, it is not formed on a major 
reaction pathway but rather on a deactivation pathway. 
 Scheme 50. Coupling of hexaphenyldigermoxane and 1-iodonaphthalene.
(3 equiv.)
TBAF (7 equiv.) Pd2(dba)3
toluene, 100 oC
Ge
3
O
138
I
139a 141a
2
 
To confirm the structure of the postulated intermediates generated during the 
reaction of chloro(triphenyl)germane 145 with TBAF, and to study their role in the 
fluoride-promoted coupling with halide in “moist” toluene, the independent synthesis of 
fluoro(triphenyl)germane 45 was undertaken. Thus, treatment of 145 with 
tetramethylammonium fluoride127 (Me4NF) in dry CH2Cl2 at reflux afforded 45 (-201.9 
ppm; see Scheme 11, section 1.2.1.2) along with the unknown compound 151 (-
145.8ppm, Scheme 51). Moreover, slow conversion of 45 to 151 was observed when the 
stability of 45 was monitored by 19F NMR during different periods of time. Nevertheless, 
treatment of the isolated sample of 45/151 (3:1, 19F NMR) with TBAF (1.5 equiv.) in 
benzene-d6 at room temperature resulted in the complete dissapearance of the signal at -
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201.9 ppm (45), broadening of the signal at -145.8 ppm (151) and appearance of a new 
broad signal around -117.0 ppm. These results might suggest that the unknown species 
151 are in equilibrium with the corresponding hypervalent difluorogermanate species 46 
(  -117 ppm; see Scheme 11, section 1.2.1.2).128    
Ge
45
TBAF (1.5 equiv.)
benzene-d6 
r.t.
Ph
Ph
Ph
F "Unknown" 151
46
 45   19F NMR:  -201.6 ppm
 46   19F NMR: around  -117 ppm
151  19F NMR:  -150.6 ppm
Scheme 51. 19F NMR study of the effect TBAF to a mixture of 
fluoro(triphenyl)germane and unknown compound 151.
Ph Ge
F
F
Ph
Ph
NBu4
"Unknown" 151
 
 Based on our results, we propose that the coupling of chloro(triphenyl)germane 
145 occurs via the formation of fluoro(triphenyl)germane 46 which generates unknown 
compound 151 upon hydrolysis. The hydrolysis of compound 46 could be accelerated by 
the presence of water either from TBAF (5% in 1 M/THF solution) or from the 
measured amount added (Table 12). If the aryl-Pd complex(es) is not present in the 
reaction mixture in sufficient amount (e.g. with less reactive aryl bromides or chlorides), 
two molecules of the unknown 151 could condense eliminating fluoride and water to 
afford less reactive hexaphenyldigermoxane 138. Therefore, the structure of the unknown 
intermediate 151 has been proposed as a reactive pentavalent 
  109
fluoro(hydroxo)triphenylgermanate which would be in equilibrium with a hydrogen-
bonded germanol 152 (Scheme 52). It is worth pointing out that similar reactive 
intermediates have been proposed by Denmark as reactive intermediates during the 
coupling of vinyl silanols promoted by fluoride ions.125  
Ge
145
Ph
Ph
Ph
Cl
151
Scheme 52. Proposed pathway for the activation of chloro(triphenyl)germane 
with TBAF.
Ph Ge
OH
F
Ph
Ph
Ge
45
Ph
Ph
Ph
F
F H2O
Ge
152
Ph
Ph
Ph
O
H
F
- H2O
- F
Ge
138
Ph
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O Ge
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4. EXPERIMENTAL SECTION 
4.1. General procedures 
 The 1H (Me4Si, 400 MHz), 13C (Me4Si, 100.6 MHz), and 19F (CCl3F, 376.4 MHz) 
NMR spectra were determined in CDCl3 unless otherwise stated. Mass spectra (MS) were 
obtained by atmospheric pressure chemical ionization (APCI) or electro-spray ionization 
(ESI) techniques. Reagent grade chemicals were used and solvents were dried using a 
solvent purification system. TLC was performed on Merck kieselgel 60-F254 and products 
were detected with 254 nm light or by development of color with I2. Merck kieselgel 60 
(130-400 mesh) was used for column chromatography. Elemental analyses were 
performed by Galbraith Laboratories, Knoxville, TN. Purity and identity of the products 
(crude and/or purified) were also established using a Hewlett-Packard (HP) GC/MS (EI) 
system with a HP 5973 mass selective detector [capillary column HP-5MS (30 m x 0.25 
mm)] or a reverse phase (RP)-HPLC/MS (APCI) system (C18 column). 
4.2 Synthesis 
1-(2,3,5-Tri-O-acetyl--D-arabinofuranosyl)-5-[(Z)-2-(triphenylgermyl)ethenyl]-
uracil (Z-75).  
Method A. Thermally-induced radical hydrogermylation of the protected 5-
ethynyluridine analogues. In a round-bottomed flask, the starting material 74 (50 mg, 
0.13 mmol) was added to freshly distilled toluene (6 mL) and the suspension was stirred 
and degassed with N2 for 40 min. The mixture was then pre-heated at 80 oC and Ph3GeH 
(50 mg, 0.16 mmol) was added followed by 1,1'-azobis(cyclohexanecarbonitrile) (4 mg, 
0.02 mmol). The temperature was increased to 90 oC and the solution was stirred until 74 
was completely consumed (TLC). The volatiles were removed in vacuo and the oily 
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residue was chromatographed (hexanes/EtOAc, 2:3) to give a separable mixture of Z-75 
(31.5 mg, 36%) and 76 (10.5 mg, 12%). 1H NMR  1.99 (s, 3H, Ac-Me), 2.09 (s, 3H, Ac-
Me), 2.11 (s, 3H, Ac-Me), 3.70 (dd, 2JH5''-H5'=13.7 Hz, 3JH5''-H4'=7.7 Hz, 1H, H5''), 3.91-
3.98 (m, 2H, H4' and H5'), 4.97 (dd, 3JH3'-H4'=3.2 Hz, 3JH3'-H2'=2.0 Hz, 1H, H3'), 5.27 (dd, 
3JH2'-H1'=4.1 Hz, 3JH2'-H3'=1.9 Hz, 1H, H2'), 5.71 (d, 3JH1'-H2'=4.1 Hz, 1H, H1'), 6.56 (d, 
3JV1-V2=13.5 Hz, 1H, vinyl 1), 7.08 (d, 4JH6-V2=1.0 Hz, 1H, H6), 7.36 (m, 10H, GePh3 + 
vinyl 2), 7.52 (m, 6H, GePh3), 8.30 (br. s, 1H, NH). 13C NMR  20.38, 20.65, 20.72 (Ac-
Me), 62.31 (C5'), 74.57 (C2'), 76.10 (C3'), 79.82 (C4'), 84.37 (C1'), 113.39 (C5), 128.35 
(GePh3 x 6), 129.11 (GePh3 x 3), 131.67 (vinyl 1), 134.80 (GePh3 x 6), 136.39 (C6), 
136.44 (GePh3 Q x 3), 138.20 (vinyl 2), 148.57 (C2), 161.28 (C4), 168.45, 169.36, 
170.24 (Ac-C=O). MS (APCI+) m/z 700.9 [MH]+ based on 74Ge. 
Method B. Et3B-induced radical hydrogermylation of 5-ethynyl protected 
uridine analogues. Placed in a screw-capped glass tube, a 1M solution of Et3B in THF 
(140 L, 0.14 mmol) was added to a solution of 74 (50.0 mg, 0.127 mmol) and Ph3GeH 
(43.0 mg, 0.14 mmol) in dry THF (5 mL) at -78 oC. The resulting solution was stirred for 
3 hours at -78 oC and TLC analysis showed appearance of a less polar spot and remaining 
74. The reaction mixture was slowly warmed up to -60 oC and was stirred for another 1.5 
h. The volatiles were removed under vacuum and the resulting crude was 
chromatographed (hexanes/EtOAc, 2:3) to give Z-75 (42.0 mg, 47%), with identical data 
to the reported above. 
Treatment of 74 (49.0 mg, 0.12 mmol) with Ph3GeH (42.0 mg, 0.14 mmol) by 
Method B at 0 oC for 6 h gave an unseparable mixture of 75 and 76 (39.0 mg; 75/76 
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59:41 based on 1H NMR of the mixture). Recrystallyzation from a hexane/Et2O mixture 
gave 75 as a white powder (23.0 mg, 26%).  
1-(2,3,5-Tri-O-acetyl--D-arabinofuranosyl)-5-[2-(triphenylgermyl)acetyl]uracil 
(76). 1H NMR  1.92 (s, 3H, Ac-Me), 2.150 (s, 3H, Ac-Me), 2.154 (s, 3H, Ac-Me), 3.48 
(d, 3JH8a-H8b=9.3 Hz, 1H, H8a), 4.19 (d, 3JH8b-H8a=9.3 Hz, 1H, H8b), 4.16-4.21 (m, 1H, 
H4'), 4.36 (dd, 2JH5''-H5'=12.1 Hz, 3JH5''-H4'=4.7 Hz, 1H, H5''), 4.46 (dd, 2JH5'-H5''=12.1 Hz, 
3JH5'-H4'=4.9 Hz, 1H, H5'), 5.14 (dd, 3JH3'-H4'=3.4 Hz, 3JH3'-H2'=1.6 Hz, 1H, H3'), 5.35 (dd, 
3JH2'-H4'=4.1 Hz, 3JH2'-H3'=1.6 Hz, 1H, H2'), 6.24 (d, 3JH1'-H2'=4.1 Hz, 1H, H1'), 7.32-7.42 
(m, 2.25H, GePh3), 7.50-7.57 (m, 1.5H, GePh3), 8.10 (s, 1H, H6), 8.49 (bs, 1H, NH). 13C 
NMR  20.26, 20.60, 20.62 (Ac-Me), 32.84 (C8), 62.26 (C5'), 74.43 (C2'), 76.42 (C3'), 
80.64 (C4'), 83.77 (C1'), 113.20 (C5), 128.23 (GePh3 x6), 129.35 (GePh3 x 3), 135.00 
(GePh3 x 6), 135.11 (GePh3 Q x 3), 146.07 (C2), 148.33 (C6), 159.92 (C4), 168.64, 
169.46, 170.66 (Ac-Me), 194.03 (C7-ketone). MS (APCI+) m/z 716.9 (MH+ for 76, 33%) 
based on 74Ge.  
1-(2,3,5-Tri-O-acetyl--D-arabinofuranosyl)-5-[(E/Z)-2-(trimethylgermyl)ethenyl]-
uracil (E/Z-77). A solution of 74 (49.6 mg, 0.126 mmol) and Me3GeH (29.9 mg, 29.6 
L, 0.252 mmol) in dry THF (5 mL) was treated according to Method B (with injection 
of Me3GeH into the reaction mixture via syringe and progressive warming from 0 oC to 
25 oC) for 8 h. The volatiles were removed under reduced pressure and the residue was 
chromatographed (hexanes/EtOAc, 2:3) to give E/Z-77 (22.0 mg, 33%, E/Z 39:61). 1H 
NMR  0.26 (s, 5.5H, GeMe3-Z), 0.28 (s, 3.5H, GeMe3-E), 2.02 (s, 3H, Ac-Me E+Z), 2.12 
(s, 1.83H, Ac-Me-Z), 2.15 (s, 1.17H, Ac-Me-E), 2.16 (s, 1.83H, Ac-Me-Z), 2.17 (s, 
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1.17H, Ac-Me-E), 4.19-4.25 (m, 1H, H4'-E+Z), 4.34 (dd, 2JH5''-H5'=11.9 Hz, 3JH5''-H4'=6.2 
Hz, 0.61H, H5''-Z), 4.37-4.45 (m, 0.39H, H5''-E), 4.44 (dd, 2JH5'-H5''=11.9 Hz, 3JH5'-H4'=4.2 
Hz, 0.61H, H-5'Z), 4.52 (dd, 2JH5'-H5''=11.9 Hz, 3JH5'-H4'=6.2 Hz, 0.39H, H5'-E), 5.11 (dd, 
3JH3'-H4'=3.8 Hz, 3JH3'-H2'=1.4 Hz, 0.61H, H3'-Z), 5.15 (dd, 3JH3'-H4'=3.4 Hz, 3JH3'-H2'=1.6 
Hz, 0.39H, H3'-E),  5.44-5.48 (m, 1H, H2'-E+Z), 6.10 (d, 3JV1-V2=13.8 Hz, 0.61H, vinyl 
1-Z), 6.24 (d, 3JH1'-H2'=3.8 Hz, 0.61H, H1'-Z), 6.33 (d, 3JH1'-H2'=4.0 Hz, 0.39H, H1'-E), 
6.60 (d, 3JV1-V2=18.9 Hz, 0.39H, vinyl 1-E), 6.80 (d, 3JV2-V1=19.0 Hz, 0.39H, vinyl 2-E), 
6.98 (dd, 3JV2-V1=13.8 Hz, 4JV2-H6=0.9 Hz, 0.61H, vinyl 2-Z), 7.45 (d, 4JH6-V2=0.8 Hz, 
0.61H, H6-Z), 7.59 (s, 0.39H, H6-E), 8.97 (br. s, 0.39H, NH-E), 9.09 (br. s, 0.61H, NH-
Z). 13C NMR  -1.70 (GeMe3-E), -0.23 (GeMe3-Z), 20.53, 20.59, 20.79, 20.87, 20.92 (Ac-
Me), 62.67 (C5'-E), 63.16 (C5'-Z), 74.69 (C2'-E), 74.76 (C2'-Z), 76.44 (C3'-E), 76.49 
(C3'-Z), 80.43 (C4'-Z), 80.76 (C4'-E), 84.55 (C1'-E+Z), 112.90 (C5-E), 114.19 (C5-Z), 
132.14 (vinyl 1-E), 133.62 (vinyl 2-E), 134.30 (vinyl 2-Z), 136.10 (C6-Z), 136.36 (C6-E), 
137.55 (vinyl 1-Z), 149.18 (C2-E), 149.56 (C2-Z), 161.81 (C4-E), 162.17 (C4-Z), 168.63, 
168.73, 169.69, 169.78, 170.50 (Ac-C=O). MS (APCI+) m/z 514.9 [MH]+ based on 74Ge. 
1-(2,3,5-Tri-O-acetyl--D-arabinofuranosyl)-5-Z-[2-(tributyl-germyl)ethenyl]uracil 
(E/Z-78). A solution of 74 (50.0 mg, 0.13 mmol) and Bu3GeH (63.7 mg, 69.5 L, 0.26 
mmol) in dry THF (5 mL) was treated according to Method B (with stirring at 0 oC and 
progressively warming to ambient temperature) for 18 h (TLC showed approximately 
85% consumption of 74, based on comparison with new spots).  The volatiles were 
removed under vacuum and the oily residue was chromatographed (hexanes/EtOAc, 2:3) 
to give a mixture of E/Z-78 (11.0 mg, E/Z6:94). 1H NMR  0.88-1.00 (m, 15H, GeBu3), 
1.25-1.40 (m, 12H, GeBu3), 2.02 (s, 3H, Ac-Me-Z), 2.12 (s, 3H, Ac-Me-Z), 2.16 (s, 3H, 
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Ac-Me-Z), 4.19-4.25 (m, 1H, H4'-Z), 4.34 (dd, 2JH5''-H5'=11.8 Hz, 3JH5'-H4'=6.0 Hz, 1H, 
H5''-Z), 4.44 (dd, 2JH5'-H5''=11.8 Hz, 3JH5'-H4'=5.0 Hz, 1H, H5'-Z), 5.12 (dd, 3JH3'-H4'=3.8 Hz, 
3JH3'-H2'=1.5 Hz, 1H, H3'-Z), 5.46 (dd, 3JH2'-H1'=3.8 Hz, 3JH2'-H3'=1.6 Hz, 1H, H2'-Z), 6.07 
(d, 3JV1-V2=14.0 Hz, 1H, vinyl 1-Z), 6.24 (d, 3JH1'-H2'=3.8 Hz, 1H, H1'-Z), 6.59 (d, 3JV1-
V2=19.1 Hz, 0.05H, vinyl 1-E), 6.76 (d, 3JV2-V1=19.1 Hz, 0.06H, vinyl 2-E), 7.02 (dd, 3JV2-
V1=14.0 Hz, 4JV2-H6=1.0 Hz, 1H, vinyl 2-Z), 7.42 (d, 4JH6-V2=0.9 Hz, 1H, H6-Z), 8.54 (br. 
s, 1H, NH-Z). 13C NMR  13.72 (GeBu3), 14.15 (GeBu3), 20.40 (Ac-Me), 20.65 (Ac-Me), 
20.68 (Ac-Me), 26.41 (GeBu3), 27.39 (GeBu3), 62.92 (C5'), 74.68 (C2'), 76.39 (C3'), 
80.22 (C4'), 84.50 (C1'), 114.44 (C5), 134.70 (vinyl 2), 135.27 (vinyl 1), 135.50 (C6), 
149.28 (C2), 161.72 (C4), 168.56, 169.46, 170.27 (Ac-C=O). MS (APCI+) m/z 641.0 
[MH]+ based on 74Ge. 
2',3',5'-Tri-O-acetyl-5-[(Z)-2-(triphenylgermyl)ethenyl]uridine (Z-80a). A solution of 
79a (89.7 mg, 0.228 mmol), Ph3GeH (76.3 mg, 0.25 mmol) in dry THF (8 mL) was 
treated according to Method B for 6 h. The volatiles were removed under vacuum and the 
residue was chromatographed (hexanes/EtOAc, 3:7) to give Z-80a (64.2 mg, 50%). 1H 
NMR  2.055 (s, 3H, Ac-Me), 2.060 (s, 3H, Ac-Me), 2.09 (s, 3H, Ac-Me), 3.95 (“d”, 
J=4.3 Hz, 2H, H5'/5''), 4.05-4.10 (m, 1H, H4'), 4.98 (“t”, 3JAvg=6.1 Hz, 1H, H3'), 5.02 
(dd, 3JH2'-H3'=6.1 Hz, 3JH2'-H1'=3.9 Hz, 1H, H2'), 5.26 (d, 3JH1'-H2'=3.8 Hz, 1H, H1'), 6.56 (d, 
3JV1-V2=13.6 Hz, 1H, vinyl 1), 7.01 (d, 4JH6-V2=0.9 Hz, 1H, H6), 7.31 (dd, 3JV2-V1=13.6 
Hz, 4JV2-H6=0.8 Hz, 1H, vinyl 2), 7.32-7.39 (m, 9H, GePh3), 7.48-7.54 (m, 6H, GePh3), 
8.00 (br. s, 1H, NH). 13C NMR  20.37, 20.38, 20.75 (Ac-Me), 62.75 (C5'), 69.39 (C3'), 
72.85 (C2'), 79.23 (C4'), 89.29 (C1'), 114.92 (C5), 128.49 (GePh3 x 6), 129.17 (GePh3 x 
3), 131.45 (vinyl 1), 134.72 (GePh3 x 6), 136.44 (C6), 136.53 (GePh3 Q x 3), 138.60 
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(vinyl 2), 149.08 (C2), 161.71 (C4), 169.12, 169.21, 170.14 (Ac-C=O). MS (ESI+) m/z 
701.0 [MH]+ based on 74Ge. 
1-(2-Deoxy-3,5-di-O-acetyl--D-erythro-pentofuranosyl)-5-[(Z)-2-(triphenylgermyl)-
ethenyl]uracil (Z-80b). A solution of 79b (43.5 mg, 0.129 mmol) and Ph3GeH (43.4 mg, 
0.142 mmol) in dry THF (5 mL) was treated according to Method B for 6 h. The volatiles 
were removed under vacuum and the residue was chromatographed (hexanes/EtOAc, 3:7) 
to give Z-80b (24.3 mg, 46%). 1H NMR  1.40 (“dt”, 2JH2''-H2'=15.0 Hz, 3JAvg=7.5 Hz, 1H, 
H2''), 2.02 (ddd, 2JH2'-H2''=14.2 Hz, 3JH2'-H1'=5.8 Hz, 3JH2'-H3'=2.0 Hz, 1H, H2'), 2.05 (s, 3H, 
Ac-Me), 2.06 (s, 3H, Ac-Me), 3.84 (dd, 2JH5''-H5'=11.8 Hz, 3JH5''-H4'=5.9 Hz, 1H, H5''), 3.89 
(dd, 2JH5'-H5''=11.9 Hz, 3JH5'-H4'=4.5 Hz, 1H, H5'), 3.93-3.97 (m, 1H, H4'), 4.75 (“dt”, 
3J=7.1 Hz, 3J=2.6 Hz, 1H, H3'), 5.72 (dd, 3JH1'-H2''=8.3 Hz, 3JH1'-H2'=5.8 Hz, 1H, H1'), 6.53 
(d, 3JV1-V2=13.5 Hz, 1H, vinyl 1), 7.00 (s, 1H, H6), 7.33-7.40 (m, 10H, GePh3 + vinyl 2), 
7.50-7.56 (m, 6H, GePh3), 8.90 (br. s, 1H, NH). 13C NMR  20.76, 20.85 (Ac-Me), 36.53 
(C2'), 63.48 (C5'), 73.76 (C3'), 81.76 (C4'), 85.12 (C1'), 114.82 (C5), 128.52 (GePh3 x 6), 
129.25 (GePh3 x 3), 130.84 (vinyl 1), 134.71 (GePh3 x 6), 135.55 (GePh3 Q x 3), 136.54 
(C6), 138.97 (vinyl 2), 149.39 (C2), 161.81 (C4), 170.11, 170.22 (Ac-C=O). MS (ESI+) 
m/z 643.0 [MH]+ based on 74Ge. 
2',3',5'-Tri-O-acetyl-5-[(E/Z)-2-(trimethylgermyl)ethenyl]uridine (E/Z-81a). A 
solution of 79a (99.8 mg, 0.25 mmol) and Me3GeH (35.3 mg, 35.0 L, 0.30 mmol) in dry 
THF (8 mL) was treated according to Method B (with injection of Me3GeH into the 
reaction mixture via syringe at 0 oC) for 7 h. The volatiles were removed under vacuum 
and the oily residue was chromatographed (hexanes/EtOAc, 3:7) to give E/Z-81b (15.7 
mg, 13%, E/Z 12:88). 1H NMR  0.21 (s, 9H, GeMe3-Z), 0.25 (s, 1.17H, GeMe3-E), 2.09 
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(s, 3H, Ac-Me-Z), 2.10 (s, 3H, Ac-Me-Z), 2.13 (s, 3H, Ac-Me-Z), 4.30-4.41 (m, 3H, H4' 
and H5'/H5''), 5.29-5.36 (m, 2H, H2' and H3'), 6.06 (d, 3JH1'-H2'=3.8 Hz, 1H, H1'-Z), 6.12 
(d, 3JV1-V2=13.6 Hz, vinyl 1-Z), 6.55 (d, 3JV1-V2=19.0 Hz, 0.13H, vinyl 1-E), 6.75 (d, 3JV2-
V1=19.0 Hz, 0.13H, vinyl 2-E), 6.92 (dd, 3JV2-V1=13.7 Hz, 4JV2-H6=1.2 Hz, 1H, vinyl 2-Z), 
7.28 (d, 4JH6-V2=1.0 Hz, 1H, H6-Z), 7.44 (s, 0.13H, H6-E), 8.68 (br. s, 0.13H, NH-E), 
8.74 (br. s, 1H, NH-Z). 13C NMR  -1.70 (GeMe3-E), -0.05 (GeMe3-Z), 20.51, 20.63, 
20.96 (Ac-Me-Z), 63.16 (C5'-Z), 70.14, 72.87 (C2' and C3'-Z), 80.11 (C4'-Z), 87.55 (C1'-
Z), 116.14 (C5-Z), 134.80 (vinyl 2-Z), 135.39 (C6-Z), 138.88 (vinyl 1-Z), 149.99 (C2-Z), 
161.99 (C4-Z), 169.63, 169.71, 170.23 (Ac-C=O-Z).  
1-(2-Deoxy-3,5-di-O-acetyl--D-erythro-pentofuranosyl)-5-[(E/Z)-2-(trimethylger-
myl)ethenyl]uracil (E/Z-81b). A solution of 79b (43.5 mg, 0.13 mmol) and Me3GeH 
(30.9 mg, 30.6 L, 0.26 mmol) in dry THF (5 mL) was treated according to Method B 
(with injection of Me3GeH into the reaction mixture via syringe at 0 oC) for 7 h. The 
volatiles were removed in under vacuum and the oily residue was chromatographed 
(hexanes/EtOAc, 2:3) to give E/Z-81b (24.3 mg, 46%, E/Z 23:77). 1H NMR  0.22 (s, 
6.93H, GeMe3-Z), 0.25 (s, 2.07H, GeMe3-E), 2.04-2.24 (m, 10H, Ac-Me-E/Z + H2''-E/Z), 
2.49-2.57 (m, 1H, H2'-E/Z), 4.25-4.30 (m, 1H, H4'-E/Z), 4.28-4.44 (m, 1H, H5'/5''-E/Z), 
5.18-5.26 (m, 1H, H3'-E/Z), 6.12 (d, 3JV1-V2=13.6 Hz, 0.77H, vinyl 1-Z), 6.27 (dd, 3J=8.6 
Hz, 3J=5.7 Hz, 0.77H, H1'-Z), 6.30-6.35 (m, 0.23H, H1'-E), 6.56 (d, 3JV1-V2=18.8 Hz, 
0.23H, vinyl 1-E), 6.76 (d, 3JV2-V1=19.0 Hz, 0.23H, vinyl 2-E), 6.93 (dd, 3JV2-V1=13.7 Hz, 
4JV2-H6=1.0 Hz, 0.77H, vinyl 2-Z), 7.39 (d, 4JH6-V2=0.9 Hz, 0.77H, H6-Z), 7.56 (s, 0.23H, 
H6-E), 8.22 (br. s, 0.23H, NH-E), 8.26 (br. s, 0.77H, NH-Z). 13C NMR  -1.83 (GeMe3-
E), -0.18 (GeMe3-Z), 20.83 (Ac-Me-Z), 20.89 (Ac-Me-Z), 38.03 (C2'-Z), 63.75 (C5'-Z), 
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73.88 (C3'-Z), 82.23 (C4'-Z), 85.25 (C1'-Z), 115.47 (C5-Z), 134.66 (vinyl 2-Z), 134.95 
(C6-Z), 138.39 (vinyl 1-Z), 149.63 (C2-Z), 161.76 (C4-Z), 170.14 (Ac-C=O-Z), 170.33 
(Ac-C=O-Z).  
5-[(Z)-2-(Triphenylgermyl)ethenyl]-2',3',5'-tri-O-p-toluoyl-uridine (Z-83a). A 
solution of 82a (49.0 mg, 0.079 mmol) and Ph3GeH (26.0 mg, 0.085 mmol) in dry THF 
(5 mL) was treated according to Method B. After 6 h at -78 oC TLC analysis revealed 
slow progression towards product. Hence, the reaction mixture was slowly warmed to 0 
oC until TLC reveal approximately 95% consumption of the starting 82a relative to the 
possible product. The volatiles were removed under vacuum and the residue was 
chromatographed (hexanes/EtOAc, 1:1) to give a separable mixture of Z-83a (29.0 mg, 
40%) and 85 (10 mg, 13%). Compound Z-83a had: 1H NMR  2.40 (s, 6H, p-Tol-Me), 
2.42 (s, 3H, p-Tol-Me), 4.34 (dd, 2JH5''-H5'=12.2 Hz, 3JH5''-H4'=5.4 Hz, 1H, H5''), 4.40 (dd, 
2JH5'-H5''=12.2 Hz, 3JH5'-H4'=3.4 Hz, 1H, H5'), 4.47 (ddd, 3JH4'-H3'=5.8 Hz, 3JH4'-H5''=5.4 Hz, 
3JH4'-H5'=3.5 Hz, 1H, H4'), 5.38 (dd, 3JH2'-H3'=6.2 Hz, 3JH2'-H1''=4.5 Hz, 1H, H2'), 5.51 (“t”, 
3JAvg=6.0 Hz, 1H, H3'), 5.52 (d, 3JH1'-H2'=4.4 Hz, 1H, H1'), 6.50 (d, 3JV1-V2=13.6 Hz, 1H, 
vinyl 1), 7.11 (d, 4JH6-V2=0.8 Hz, 1H, H6), 7.16 (d, 3Jo-m=8.1 Hz, 2H, p-Tol-H), 7.19 (d, 
3Jo-m=8.0 Hz, 2H, p-Tol-H), 7.22 (dd, 3JV2-V1=13.5 Hz, 4JV2-H6=1.0 Hz, 1H, vinyl 2), 7.24 
(d, 3Jo-m=8.0 Hz, 2H, p-Tol-H), 7.31-7.36 (m, 9H, GePh3), 7.50-7.55 (m, 6H, GePh3), 
7.80 (d, 3Jo-m=8.2 Hz, 4H, p-Tol-H), 7.96 (d, 3Jo-m=8.2 Hz, 2H, p-Tol-H), 8.09 (br. s, 1H, 
NH). 13C NMR  21.67, 21.69, 21.73 (p-Tol-Me), 63.54 (C5'), 70.51 (C3'), 73.59 (C2'), 
79.91 (C4'), 89.76 (C1'), 114.99 (C5), 125.90 (p-Tol-Q), 125.98 (p-Tol-Q), 126.67 (p-
Tol-Q), 128.47 (GePh3 x 6), 129.13 (GePh3 x3 + p-Tol-CH), 129.21 (p-Tol-CH), 129.29 
(p-Tol-CH), 129.75 (p-Tol-CH), 129.82 (p-Tol-CH), 129.91 (p-Tol-CH), 131.42 (vinyl 
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1), 134.74 (GePh3 x 6), 136.61 (GePh3 Q x 3), 136.96 (C6), 138.23 (vinyl 2), 144.19 (p-
Tol-Q), 144.36 (p-Tol-Q), 144.52 (p-Tol-Q), 148.84 (C2), 161.38 (C4), 164.97, 165.07, 
166.08 (p-Tol-C=O). MS (ESI+) m/z 951.2 [M+Na]+ based on 74Ge.  
5-[2-(Triphenylgermyl)acetyl]-2',3',5'-tri-O-p-toluoyl-uridine (85). 1H NMR  2.35 (s, 
3H, p-Tol-Me), 2.40 (s, 3H, p-Tol-Me), 2.42 (s, 3H, p-Tol-Me), 3.76 (d, 2JH8a-H8b=9.0 Hz, 
1H, H8a), 3.87 (d, 2JH8b-H8a=9.0 Hz, 1H, H8b), 4.67-4.75 (m, 3H, H4' and H5'/5''), 5.66 
(dd, 3JH2'-H3'=5.9 Hz, 3JH2'-H1'=5.1 Hz, 1H, H2'), 5.83 (“t”, 3JAvg=5.7 Hz, 1H, H3'), 6.01 (d, 
3JH1'-H2'=5.0 Hz, 1H, H1'), 7.16-7.22 (m, 6H, p-Tol-H), 7.31-7.36 (m, 9H, GePh3), 7.50-
7.55 (m, 6H, GePh3), 7.83 (d, 3Jo-m= 8.2 Hz, 2H, p-Tol-H), 7.87 (d, 3Jo-m= 8.2 Hz, 2H, p-
Tol-H), 8.02 (d, 3Jo-m= 8.2 Hz, 2H, p-Tol-H), 8.05 (s, 1H, H6). 13C NMR  21.72 (p-Tol-
Me x3), 32.95 (C8), 63.50 (C5'), 70.95 (C3'), 73.89 (C2'), 80.89 (C4'), 90.35 (C1'), 
113.69 (C5), 125.66, 125.96, 126.58 (p-Tol-Q), 128.21 (GePh3 x 6), 129.21, 129.24, 
129.27 (p-Tol-CH), 129.36 (GePh3 x 3), 129.86 (p-Tol-CH), 129.92 (p-Tol-CH x2), 
135.04 (GePh3 x 6), 135.09 (GePh3 Q x 3), 144.06, 144.50, 144.69 (p-Tol-Q), 146.56 
(C6), 148.51 (C2), 160.17 (C4), 165.19, 165.21, 166.25 (p-Tol-C=O), 193.32 (C7-
ketone). Qualitative UV/Vis (MeOH) max=282 nm. MS (ESI+) m/z 945.0 [M+H]+ based 
on 74Ge.  
1-(2-Deoxy-3,5-di-O-p-toluoyl--D-erythro-pentofuranosyl)-5-[(Z)-2-(triphenylger-
myl)ethenyl]uracil (Z-83b). A solution of 82b (44.0 mg, 0.09 mmol) and Ph3GeH (30.0 
mg, 0.099 mmol) in dry THF (5 mL) was treated according to Method B. After 6 h at -78 
oC TLC analysis revealed slow progression towards product. Thus, the reaction mixture 
was slowly warmed to 0 oC until TLC reveal approximately 95% consumption of the 
starting 82b relative to the possible product. The volatiles were removed under vacuum 
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and the residue was chromatographed (hexanes/EtOAc, 3:2) to give a separable mixture 
of Z-83b (43.0 mg, 61%) and 86 (9 mg, 12%). Compound Z-83b had: 1H NMR  1.68 
(ddd, 2JH2''-H2'=14.9 Hz, 3JH2''-H1'=8.1 Hz, 3JH2''-H3'=7.0 Hz, 1H, H2''), 2.31 (ddd, 2JH2'-
H2''=14.5 Hz, 3JH2'-H1'=5.7 Hz, 3JH2'-H3'=1.8 Hz, 1H, H2'), 2.41 (s, 3H, p-Tol-Me), 2.45 (s, 
3H, p-Tol-Me), 4.16 (dd, 2JH5''-H5'=11.1 Hz, 3JH5''-H4'=3.5 Hz, 1H, H5''), 4.26-4.30 (m, 1H, 
H4'), 4.32 (dd, 2JH5'-H5''=11.1 Hz, 3JH5'-H4'=5.0 Hz, 1H, H5'), 5.20 (“dt”, 3JH3'-H2''=6.8 Hz, 
3JH3'-H2'=1.8 Hz, 3JH3'-H4'=1.8 Hz, 1H, H3'), 5.85 (dd, 3JH1'-H2''=8.3 Hz, 3JH1'-H2'=5.8 Hz, 1H, 
H1'), 6.51 (d, 3JV1-V2=13.5 Hz, 1H, vinyl 1), 7.11 (d, 4JH6-V2=0.9 Hz, 1H, H6), 7.21-7.27 
(m, 5H, p-Tol-H + vinyl 2), 7.36-7.40 (m, 9H, GePh3), 7.52-7.56 (m, 6H, GePh3), 7.88 
(d, 3Jo-m=8.2 Hz, 2H, p-Tol-H), 7.91 (d, 3Jo-m=8.2 Hz, 2H, p-Tol-H). 13C NMR  21.68 
(p-Tol-Me), 21.72 (p-Tol-Me), 37.27 (C2'), 63.87 (C5'), 74.47 (C3'), 82.32 (C4'), 85.49 
(C1'), 114.78 (C5), 126.35 (p-Tol-Q), 126.71 (p-Tol-Q), 128.50 (GePh3 x 6), 129.21 
(GePh3 x 3), 129.26, 129.28, 129.63, 129.80 (p-Tol-CH x 2), 130.96 (vinyl 1), 134.75 
(GePh3 x 6), 135.62 (C6), 136.62 (GePh3 Q x 3), 138.83 (vinyl 2), 144.24 (p-Tol-Q), 
144.46 (p-Tol-Q), 149.33 (C2), 161.73 (C4), 165.80 (p-Tol-C=O), 166.00 (p-Tol-C=O). 
MS (APCI+) m/z 794.9 [MH]+ based on 74Ge.  
1-(2-Deoxy-3,5-di-O-p-toluoyl--D-erythro-pentofuranosyl)-5-[2-(triphenylgermyl)-
acetyl]uracil (86). 1H NMR  2.18-2.27 (m, 1H, H-2''), 2.36 (s, 3H, p-Tol-Me), 2.45 (s, 
3H, p-Tol-Me), 2.64 (ddd, 2JH2'-H2''=14.3 Hz, 3JH2'-H1'=5.7 Hz, 3JH2'-H3'=1.8 Hz, 1H, H2'), 
3.81 (d, 2JH8a-H8b=9.1 Hz, 1H, H8a), 3.85 (d, 2JH8b-H8a=9.1 Hz, 1H, H8b), 4.53-4.60 (m, 
2H, H4' and H5''), 4.74-4.80 (m, 1H, H5'), 5.54 (“d”, 3J=6.6 Hz, 1H, H3'), 6.16 (dd, 3JH1'-
H2''=8.3 Hz, 3JH1'-H2'=5.7 Hz, 1H, H1'), 7.16 (d, 3Jo-m=8.0 Hz, 2H, p-Tol-H), 7.28 (d, 3Jo-m= 
8.1 Hz, p-Tol-H), 7.32-7.39 (m, 9H, GePh3), 7.53-7.57 (m, 6H, GePh3), 7.94 (d, 3Jo-m= 
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8.2 Hz, 2H, p-Tol-H), 7.95 (d, 3Jo-m= 8.2 Hz, 2H, p-Tol-H), 8.15 (br. s, 1H, C6). 13C 
NMR  21.71, 21.73 (p-Tol-Me), 32.80 (C8), 38.42 (C2'), 63.76 (C5'), 74.52 (C3'), 83.19 
(C4'), 86.15 (C1'), 113.58 (C5), 126.30, 126.58 (p-Tol-Q), 128.20 (GePh3 x 6), 129.25 (p-
Tol-CH), 129.28 (p-Tol-CH), 129.32 (GePh3 x 3), 129.82 (p-Tol-CH x2), 135.06 (GePh3 
x 6), 135.24 (GePh3 Q x 3), 144.12 (p-Tol-Q), 144.55 (p-Tol-Q), 145.17 (C6), 148.76 (C-
2), 160.26 (C-4), 165.82 (p-Tol-C=O), 166.19 (p-Tol-C=O), 193.48 (C7-ketone). MS 
(ESI+) m/z 810.9 [MH]+ based on 74Ge. 
5-[(E/Z)-2-(Trimethylgermyl)ethenyl]-2',3',5'-tri-O-p-toluoyl-uridine (E/Z-84a). A 
solution of 82a (50.0 mg, 0.08 mmol) and Me3GeH (19.0 mg, 18.8 L 0.16 mmol) in dry 
THF (5 mL) was treated according to Method B (with injection of Me3GeH into the 
reaction mixture via syringe and progressive warming from 0 oC to 25 oC) for 10 h. The 
volatiles were removed under reduced pressure and the oily residue was 
chromatographed (hexanes/EtOAc, 3:2) to give E/Z-84a (22.0 mg, 37%, E/Z 45:55). 1H 
NMR  0.12 (s, 4.05H, GeMe3-E), 0.20 (s, 4.95H, GeMe3-Z), 2.40, 2.43, 2.44 (singlets, 
9H, p-Tol-Me-E/Z), 4.68-4.82 (m, 3H, H4' and H5'/5''-E/Z), 5.72 (“t”, 3JAvg=6.0 Hz, 
0.55H, H2'-Z), 5.78 (“t”, 3JAvg=6.3 Hz, 0.45H, H2'-E), 5.82 (dd, 3J=6.1 Hz, 3J=3.9 Hz, 
0.55H, H3'-Z), 5.88 (dd, 3J=5.8 Hz, 3J=2.8 Hz, 0.45H, H3'-E), 5.98 (d, 3JV1-V2=13.7 Hz, 
0.55H, vinyl 1-Z), 6.34 (d, 3JH1'-H2'=5.9 Hz, 0.55H, H1'-Z), 6.37 (d, 3JV1-V2=19.0 Hz, 
0.45H, vinyl 1-E), 6.50 (d, 3JH1'-H2'= 6.8 Hz, 0.45H, H1'-E), 6.69 (d, 3JV2-V1=19.0 Hz, 
0.45H, vinyl 2-E), 6.72 (dd, 3JV2-V1=13.7 Hz, 4JV2-H6=1.0 Hz, 0.55H, vinyl 2-Z), 7.16-7.32 
(m, 6H, p-Tol-H, set of doublets collapsed), 7.34 (d, 4JH6-V2=1.0 Hz, 0.55H, H6-Z), 7.54 
(s, 0.45H, H6-E), 7.83, 7.86, 7.89, 7.91, 7.96, 8.04 (doublets, 3Jo-m=8.2 Hz, 6H, p-Tol-H), 
8.24 (br. s, 0.45H, NH-E), 8.27 (br. s, 0.55H, NH-Z). 13C NMR  -2.02 (GeMe3-E), -0.17 
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(GeMe3-Z), 21.71 (p-Tol-Me-E/Z), 63.72 (C5'-Z), 64.19 (C5'-E), 71.08 (C3'-Z), 71.47 
(C3'-E), 73.45 (C2'-E), 73.54 (C2'-Z), 80.73 (C4'-Z), 81.05 (C4'-E), 86.87 (C1'-E), 88.04 
(C1'-Z), 114.42 (C5-E), 115.95 (C5-Z), 125.65, 125.70, 125.96, 125.97, 126.27, 126.48 
(p-Tol-Q-E/Z), 129.23, 129.25, 129.29, 129.39, 129.63, 129.71, 129.73, 129.886, 129.89, 
129.95, 130.00 (p-Tol-CH-E/Z), 131.77 (vinyl 2-E), 134.06 (vinyl 2-Z), 134.43 (vinyl 1-
E), 135.14 (C6-E), 135.78 (C6-Z), 138.68 (vinyl 1-Z), 144.29, 144.54, 144.57, 144.62, 
144.64, 144.66 (p-Tol-Q-E/Z), 149.30, 149.66 (C2-E+Z), 161.34, 161.72 (C4-E+Z), 
165.28, 165.36, 165.39, 165.48, 166.11 (p-Tol-C=O). MS (ESI+) m/z 765.1 [M + Na]+ 
based on 74Ge.  
1-(2-Deoxy-3,5-di-O-p-toluoyl--D-erythro-pentofuranosyl)-5-[(E/Z)-2-(trimethylger-
myl)ethenyl]uracil (E/Z-84b). A solution of 82b (45.0 mg, 0.092 mmol) and Me3GeH 
(21.8 mg, 21.6 L, 0.18 mmol) in dry THF (5 mL) was treated according to Method B 
(with injection of Me3GeH into the reaction mixture via syringe and progressive warming 
from 0 oC to 25 oC) for 10 h. The volatiles were removed in under vacuum and the 
residue was chromatographed (hexanes/EtOAc, 1:1) to give E/Z-84b (14.2 mg, 30%, E/Z 
41:59). 1H NMR  0.14 (s, 3.69H, GeMe3-E), 0.21 (s, 5.31H, GeMe3-Z), 2.25-2.34 (m, 
1H, H2''-E/Z), 2.42, 2.43, 2.45 (singlets, 6H, p-Tol-Me-E/Z), 2.78 (ddd, 2JH2''-H2'=14.2 Hz, 
3JH2''-H1'=5.5 Hz, 3JH2''-H3'=1.6 Hz, 0.59H, H2'-Z), 2.80 (ddd, 2JH2'-H2''=14.3 Hz, 3JH2'-H1'=5.1 
Hz, 3JH2'-H3'=1.2 Hz, 0.41H, H2'-E), 4.56-4.61 (m, 1H, H4'-E/Z), 4.65 (dd, 2JH5''-H5'=12.2 
Hz, 3JH5''-H4'=3.2 Hz, 0.59H, H5''-Z), 4.73-4.77 (m, 0.82H, H5'/5''-E), 4.75 (dd, 2JH5'-
H5''=12.2 Hz, 3JH5'-H4'=3.8 Hz, 0.59H, H5'-Z), 4.59 (“dt”, 3J=4.9 Hz, 3J=1.9 Hz, 0.59H, 
H3'-Z), 4.63 (“d”, 3J=6.4 Hz, 0.41H, H3'-E), 6.00 (d, 3JV1-V2=13.7 Hz, 0.59H, vinyl 1-Z), 
6.40 (dd, 3JH1'-H2''=8.7 Hz, 3JH1'-H2'=5.4 Hz, 0.59H, H1'-Z), 6.41 (d, 3JV1-V2=19.2 Hz, 
  122
0.41H, vinyl 1-E), 6.46 (d, 3JH1'-H2''=8.9 Hz, 3JH1'-H2'=5.2 Hz, 0.41H, H1'-E), 6.72 (d, 3JV2-
V1=19.0 Hz, 0.41H, vinyl 2-E), 6.78 (dd, 3JV2-V1=13.7 Hz, 4JV2-H6=0.9 Hz, 0.59H, vinyl 2-
Z), 7.22-7.32 (m, 4H, p-Tol-H-E/Z), 7.48 (d, 4JH6-V2=1.0 Hz, 0.59H, H6-Z), 7.67 (s, 
0.41H, H6-E), 7.85-7.99 (m, 4H, p-Tol-H-E/Z), 8.51 (br. s, 0.41H, NH-E), 8.57 (br. s, 
0.59H, NH-Z). 13C NMR  -1.99 (GeMe3-E), -0.20 (GeMe3-Z), 21.70, 21.74 (p-Tol-Me-
E/Z), 38.51 (C2'-E/Z), 64.06 (C5'-Z), 64.39 (C5'-E), 74.65 (C3'-Z), 74.94 (C3'-E), 82.94 
(C4'-Z), 83.14 (C4'-E), 85.59 (C1'-E/Z), 113.85 (C5-E), 115.37 (C5-Z), 126.27, 126.39, 
126.50 (p-Tol-Q-E/Z), 129.30, 129.34, 129.50, 129.55, 129.61, 129.83 (p-Tol-H-E/Z), 
131.93 (vinyl 2-E), 133.93 (vinyl 1-E), 134.18 (vinyl 2-Z), 134.86 (C6-E), 135.08 (C6-Z), 
138.27 (vinyl 1-Z), 144.35, 144.53, 144.59 (p-Tol-Q-E/Z), 149.20 (C2-E), 149.66 (C2-Z), 
161.53 (C4-E), 161.88 (C4-Z), 165.97, 166.04 (p-Tol-C=O-E/Z). MS (ESI+) m/z 631.0 
[M + Na]+ based on 74Ge.  
5-[(Z)-2-(Triphenylstannyl)ethenyl]-2',3',5'-tri-O-p-toluoyl-uridine (Z-87). A solution 
of 82a (41.0 mg, 0.066 mmol) and Ph3SnH (26.0 mg, 0.074 mmol) in dry THF (4.5 mL) 
was treated according to Method B. After 6 h, the volatiles were removed under vacuum 
and the residue was chromatographed (hexanes/EtOAc, 1:1) to give Z-87 (20.0 mg, 31%). 
1H NMR  2.37 (s, 3H, p-Tol-Me), 2.42 (s, 6H, p-Tol-Me), 4.53 (dd, 2JH5''-H5'=12.2 Hz, 
3JH5''-H4'=4.0 Hz, 1H, H5''), 4.62 (“q”, 3JAvg=3.7 Hz, 1H, H4'), 4.71 (dd, 2JH5'-H5''=12.2 Hz, 
3JH5'-H4'=2.8 Hz, 1H, H5'), 5.62 (“t”, 3JAvg=5.8 Hz, 1H, H2'), 5.77 (dd, 3JH3'-H2'=5.9 Hz, 
3JH3'-H4'=4.7 Hz, 1H, H3'), 5.92 (d, 3JH1'-H2'=5.5 Hz, 1H, H1'), 6.43 (d, 3JV1-V2=13.9 Hz, 
1H, vinyl 1), 6.87 (dd, 3JV2-V1=14.1 Hz, 1H, vinyl 2), 7.20 (d, 3Jo-m=8.1 Hz, 4H, p-Tol-H), 
7.25-7.35 (m, 12H, p-Tol-H + SnPh3 + H6), 7.52-7.57 (m, 6H, SnPh3), 7.84 (d, 3Jo-m=8.4 
Hz, 2H, p-Tol-H), 7.86 (d, 3Jo-m=8.4 Hz, 2H, p-Tol-H), 8.01 (d, 3Jo-m=8.2 Hz, 2H, p-Tol-
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H). 13C NMR  21.64, 21.72, 21.74 (p-Tol-Me), 63.53 (C5'), 71.06 (C3'), 73.71 (C2'), 
80.68 (C4'), 88.52 (C1'), 115.17 (C5), 125.77 (p-Tol-Q), 125.97 (p-Tol-Q), 126.49 (p-
Tol-Q), 128.39 (SnPh3 x 6), 128.64 (SnPh3 x 3) 129.23, 129.26, 129.52, 129.74, 129.87, 
129.97 (p-Tol-CH), 133.90 (vinyl 1), 136.84 (SnPh3 x 6), 138.02 (C6), 139.45 (vinyl 2), 
140.42 (SnPh3 Q x 3), 144.55 (p-Tol-Q x2), 144.66 (p-Tol-Q), 148.52 (C2), 161.65 (C4), 
165.20, 165.31, 166.08 (p-Tol-C=O). MS (ESI+) m/z 896.7 [M-77]+ based on 120Sn.  
1-(-D-Arabinofuranosyl)-5-[(Z)-2-(triphenylgermyl)ethenyl]uracil (Z-88). A 
saturated solution of MeOH/NH3 was added to a suspension of Z-75 (40.0 mg, 0.057 
mmol) in MeOH (2 mL) was added and the reaction mixture stirred for 6 h at 0 oC. An 
additional portion of MeOH/NH3 solution (1 mL) was then added and the solution was 
stirred overnight at ambient temperature. The mixture was concentrated under vacuum 
and the residue was chromatographed (dry method; EtOAc/MeOH, 98:2) to give Z-88 
(28.2 mg, 86%). 1H NMR (MeOH-d4)  3.28 (dd, 2JH5''-H5'=11.3 Hz, 3JH5'-H4'=4.0 Hz, 1H, 
H5''), 3.37 (dd, 2JH5'-H5''=11.3 Hz, 3JH5'-H4'=5.6 Hz, 1H, H5'), 3.76 (ddd, 3JH4'-H5'=5.8 Hz, 
3JH4'-H5''=4.1 Hz, 3JH4'-H3'=2.1 Hz, 1H, H4'), 3.98-4.02 (m, 2H, H2' and H3'), 5.59 (d, 3JH1'-
H2'=3.3 Hz, 1H, H1'), 6.50 (d, 3JV1-V2=13.2 Hz, 1H, vinyl 1), 7.30 (dd, 3JV2-V1=13.3 Hz, 
4JV2-H6=1.2 Hz, 1H, vinyl 2), 7.35 (m, 10H, GePh3 and H6), 7.51 (m, 6H, GePh3). 13C 
NMR (MeOH-d4)  62.56 (C5'), 76.64 and 78.44 (C2' and C3'), 86.95 (C4'), 88.31 (C1'), 
113.75 (C5), 129.34 (GePh3 x 6), 130.01 (GePh3 x 3), 131.49 (vinyl 1), 136.03 (GePh3 x 
6), 138.15 (GePh3 Q x 3), 139.92 (C6), 140.71 (vinyl 2), 151.31 (C2), 173.03 (C4). MS 
(APCI+) m/z 574.8 [MH]+ based on 74Ge.  
1-(-D-erythro-Pentofuranosyl)-5-[(Z)-2-(triphenylgermyl)-ethenyl]uracil (Z-89). A 
saturated solution of MeOH/NH3 (2 mL) was added to a suspension of 83b (33 mg, 0.042 
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mmol) in MeOH (2 mL) and the reaction mixture stirred for 20 h at ambient temperature. 
An additional portion of MeOH/NH3 solution (1 mL) was added and the solution stirred 
for 48 h at ambient temperature. The mixture was concentrated under vacuum and the 
residue chromatographed (dry method, EtOAc) to give Z-89 (15.0 mg, 65%). 1H NMR 
(MeOH-d4)  1.44 (ddd, 2JH2''-H2'=14.2 Hz, 3JH2''-H1'=7.9 Hz, 3JH2''-H3'=6.6 Hz, 1H, H2''), 
1.87 (ddd, 2JH2'-H2''=13.6 Hz, 3JH2'-H1'=5.9 Hz, 3JH2'-H3'=2.7 Hz, 1H, H2'), 3.38 (“d”, 
JAvg=4.4 Hz, 2H, H5' and H5''), 3.70 (“quartet”, 3JAvg=3.8 Hz, 1H, H4'), 3.97 (ddd, 3JH3'-
H2''=6.0 Hz, 3JH3'-H4'=3.3 Hz, 3JH3'-H2'=2.8 Hz, 1H, H3'), 5.81 (dd, 3JH1'-H2''=8.0 Hz, 3JH1'-
H2'=6.0 Hz, 1H, H1'), 6.52 (d, 3JV1-V2=13.3 Hz, 1H, vinyl 1), 7.28 (d, 4JH6-V2=0.9 Hz, H6), 
7.31 (dd, 3JV2-V1=13.3 Hz, 4JV2-H6=1.1 Hz, 1H, vinyl 2), 7.36-7.41 (m, 9H, GePh3), 7.49-
7.54 (m, 6H, GePh3). 13C NMR (MeOH-d4)  40.34 (C2'), 63.01 (C5'), 72.33 (C3'), 86.27 
(C1'), 88.55 (C4'), 115.85 (C5), 129.54 (GePh3 x 6), 130.22 (GePh3 x 3), 131.78 (vinyl 
1), 135.89 (GePh3 x 6), 138.08 (GePh3 Q x 3), 138.19 (C6), 140.79 (vinyl 2), 151.55 
(C2), 164.66 (C4). MS (ESI+) m/z 581.1 [M+Na]+ based on 74Ge.  
5-[(E/Z)-2-(Trimethylgermyl)ethenyl]uridine (E/Z-90). A 0.1 N solution of sodium 
methoxide in anhydrous MeOH (2 mL) was added to E/Z-84a (18.8 mg, 0.025 mmol; 
E/Z, 45:55) and the mixture stirred for 6 h. An additional portion of 0.1N 
NaOMe/MeOH solution was added (0.75 mL) and the solution stirred until the starting 
E/Z-84a was completely consumed. The reaction mixture was carefully neutralized by 
addition of DOWEX 50WX2-200(H+) until moistened pH paper indicated pH6.2. The 
mixture was filtered, and the resin washed with fresh MeOH. The combined filtrate was 
evaporated under reduced pressure and the residue partitioned between Et2O and H2O. 
The organic layer was extensively washed with water. The combined aqueous layers 
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were evaporated under vacuum to yield E/Z-90 (7.0 mg, 71%; E/Z, 42:58). 1H NMR 
(MeOH-d4)  0.27 (s, 5.22H, GeMe3-Z), 0.32 (s, 3.78H, GeMe3-E), 3.84-3.91 (m, 1H, 
H5''-E/Z), 3.95 (dd, 2JH5'-H5''=12.7 Hz, 3JH5'-H4'=2.7 Hz, 0.58H, H5'-Z), 4.05 (dd, 2JH5'-
H5''=12.9 Hz, 3JH5'-H4'=2.4 Hz, 0.42H, H5'-E), 4.18-4.24 (m, 1H, H4'-E/Z), 4.29 (“t”, 
3JAvg=5.0 Hz, 0.58H, H3'-Z), 4.34 (“t”, 3JAvg=5.7 Hz, 0.42H, H3'-E), 4.39-4.44 (m,1H, 
H2'-E/Z), 6.00 (d, 3JH1'-H2'=3.8 Hz, 0.42H, H1'-E), 6.05 (d, 3JH1'-H2'=5.3 Hz, 0.58H, H1'-Z), 
6.36 (d, 3JV1-V2=13.6 Hz, 0.58H, vinyl 1-Z), 6.70 (d, 3JV1-V2=19.0 Hz, 0.42H, vinyl 1-E), 
6.83 (d, 3JV2-V1=19.0 Hz, 0.42H, vinyl 2-E), 6.93 (d, 3JV2-V1=13.6 Hz, 0.58H, vinyl 2-Z), 
7.77 (s, 0.58H, H6-Z), 8.20 (s, 0.42H, H6-E). 13C NMR (MeOH-d4)  -2.89 (GeMe3-E), -
1.17 (GeMe3-Z), 60.14 (C5'-E), 60.98 (C5-Z), 68.90 (C3'-E), 69.83 (C3'-Z), 73.70 (C2'-
Z), 74.13 (C2'-E), 83.98 (C4'-E), 84.72 (C4'-Z), 88.83 (C1'-E), 89.72 (C1'-Z), 113.75 (C5-
E), 115.68 (C5-Z), 132.07 (vinyl 1-E), 134.11 (vinyl 2-Z), 134.67 (vinyl 2-E), 137.60 
(C6-E), 137.83 (C6-Z), 140.81 (vinyl 1-Z), 151.07 (C2-E), 151.64 (C2-Z), 164.60 (C4-E), 
165.34 (C4-Z).  
1-N-Benzyluracil (97). In a flame-dried 100 mL round-bottomed flask uracil (1.7960 g, 
16.02 mmol) was suspended in 1,1,1,3,3,3-hexamethyldisilazane (HMDS) (20 mL) and 
stirred for 10 min under nitrogen. Trimethylsilyl chloride (687.2 mg, 800 L, 6.33 mmol) 
was added via syringe and the resulting mixture refluxed (125 oC, oil bath) for 2 h until it 
became a clear solution. While still hot, the mixture was filtered by gravity and washed 
with fresh 1,2-dichloroethane (1,2-DCE) (25 mL). The liquid and washings were 
collected in a dried 250 mL round-bottomed flask and concentrated in vacuo to give a 
white solid. The solid was dissolved in fresh 1,2-DCE (72 mL) and benzyl bromide (3.29 
g, 2.29 mL, 19.25 mmol) was added followed by I2 (100 mg, 0.39 mmol). The resulting 
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orange solution was then refluxed (92 oC) until TLC analysis revealed no additional 
progress. The hot solution was filtered by gravity and the filtrate washed two times with 
1,2-DCE. The mother liquor was concentrated and thoroughly dried under vacuum to 
give an orange solid. Recrystallization from EtOH gave 97 as a white solid (2.10 g, 65%) 
with data identical as reported.173 1H NMR  4.92 (s, 2H, Ph-CH2), 5.70 (dd, 3JH5-H6=7.9 
Hz, 4JH5-NH=2.2 Hz, 1H, H5), 7.15 (d, 3JH6-H5=7.9 Hz, 1H, H6), 7.27-7.41 (m, 5H, Ph). 
GC-MS (tR 21.90 min) m/z 202 (27, M+), 200 (<1), 91 (100).  
1-N-Benzyl-4-thiouracil (98). Compound 97 (501.1 mg, 2.48 mmol) was placed in a 
flamed-dry round-bottomed flask under a N2 atmosphere and dissolved in dry THF (44 
mL). Previously dried Lawesson’s reagent (1.02 g, 2.52 mmol) was added and the 
resulting suspension heated at 56 oC for about 1 h until TLC showed 95% consumption 
of the substrate 97. The volume of solvent was reduced to half and the solution washed 
with a saturated solution of NaHCO3 and partitioned with EtOAc. The organic phase was 
washed with H2O two times and dried over anhydrous Na2SO4. After removal of the 
volatiles the resulting crude was chromatographed (hexanes/EtOAc, 3:2) to give 98 
(315.0 mg, 65%) as yellow oil of a sufficient purity to be used directly in next step. 1H 
NMR  4.92 (s, 2H, Ph-CH2), 6.36 (d, 3JH5-H6=7.5 Hz, 1H, H5), 6.98 (d, 3JH6-H5=7.5 Hz, 
1H, H6), 7.28-7.33 (m, 2H, Ph), 7.34-7.43 (m, 3H, Ph), 9.86 (br. s, 1H, NH). 13C NMR  
51.87 (Ph-CH2), 113.49 (C5), 128.25, 128.89, 129.30 (Ph), 134.40 (Ph-Q), 138.63 (C6), 
148.42 (C2), 189.75 (C4).  
1-Benzyl-4-(methylthio)-2(1H)-pyrimidinone (99). Compound 98 (314.8 mg, 1.44 
mmol) was dissolved in dry CH2Cl2 (42 mL) and mixed with freshly distilled Et3N (146.2 
mg, 203 L, 1.44 mmol). The resulting yellow solution was stirred for 10 min under N2 
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and methyl iodide (410.4 mg, 180 L, 2.89 mmol) was added via syringe. The reaction 
vessel was covered with aluminum foil and stirred at room temperature for 1.5 h. The 
volatiles were removed under vacuum and the crude dissolved in CH2Cl2 and washed two 
times with H2O. The organic phase was dried over anhydrous Na2SO4 and evaporated to 
dryness to give 99 (320.0 mg, 93%). 1H NMR  2.57 (s, 3H, S-Me), 5.04 (s, 2H, Ph-CH2), 
6.16 (d, 3JH5-H6=6.8 Hz, 1H, H5), 7.22 (d, 3JH6-H5=6.8 Hz, 1H, H6), 7.29-7.40 (m, 5H, 
Ph). 13C NMR  12.85 (S-Me), 52.94 (Ph-CH2), 103.78 (C5), 128.48, 128.49, 129.09 
(Ph), 135.39 (Ph-Q), 143.05 (C6), 154.93 (C2), 177.69 (C4). GC-MS (tR 24.39 min.) m/z 
232 (44, M+), 91 (100).  
4-[18O]-1-N-benzyluracil (100). Compound 99 (248.5 mg, 1.07 mmol) was suspended in 
anhydrous absolute EtOH (6 mL) and stirred at room temperature for 5 min in a screw-
capped glass tube. Isotope enriched H2[18O] (277.0 mg, 250.0 L, 12.5 mmol, 99.2% 18O) 
was added via syringe followed by three drops of concentrated HCl and the mixture was 
heated at 78oC until TLC showed complete conversion to a spot with identical Rf as 
compound 97. The volatiles were removed under vacuum and the residue was dissolved 
in CHCl3 and was washed successively with a saturated solution of NaHCO3 and H2O. 
The volatiles were evaporated and the residue was chromatographed (hexanes/EtOAc, 
2:3) to give 100 (197 mg, 90 %) as a puffy white powder with data identical to the 
reported above for 97, except for GC-MS (tR 21.91 min) m/z 204 (22, M+), 202 (4.4, M-
2), 91 (100). [16O/18O ratio, 15:85; based on comparison of the peak intensities at m/z 
202 (M+,  97) and m/z 204 (M+, 100)].  
1-N-Benzyl-5-iodouracil (101). In a round-bottomed flask 97 (297.6 mg, 1.47 mmol) 
was dissolved in dry CH2Cl2 (30 mL) and stirred under N2 until the solution became 
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clear. Iodine monochloride (ICl) (361.0 mg, 2.22 mmol) was added and the resulting red-
wine solution refluxed (41 oC) until TLC showed complete consumption of 97. The 
reaction mixture was diluted with CH2Cl2 (30 mL) and decolorized with the minimum 
amount of 2% NaHSO3 aqueous solution. The organic phase was washed with H2O (20 
mL) and dried over anhydrous Na2SO4. Removal of the solvent gave compound 101 
(446.4 mg, 93%) as a slightly yellow solid. 1H NMR  4.92 (s, 2H, Ph-CH2), 7.28-7.32 
(m, 2H, Ph), 7.35-7.44 (m, 3H, Ph), 7.59 (s, 1H, H6), 8.42 (br. s, 1H, NH). 13C NMR  
51.59 (Ph-CH2), 68.22 (C5), 128.13, 128.91, 129.33 (Ph), 134.61 (Ph-Q), 148.26 (C6), 
150.42 (C2), 159.93 (C4). GC-MS (tR 25.90 min.) m/z 328 (30, M+), 91 (100), no peak at 
m/z 326 (M-2)+.  
4-[18O]-1-N-benzyl-5-iodouracil (102). Treatment of 100 (256.8 mg, 1.26 mmol) with 
iodine monochloride (ICl) (310.0 mg, 1.91 mmol) as described for 101, afforded 
compound 102 (393.6 mg, 95%) as a slightly yellow solid with data identical to that 
reported above for 101, except for GC-MS (tR 25.90 min.) m/z 330 (24, M+), 328 (5, M-
2), 91 (100). [16O/18O ratio, 17:83; based on comparison of the peak intensities at m/z 
328 (M+, 101) and m/z 330 (M+, 102)].  
1-N-Benzyl-5-((trimethylsilyl)ethynyl)uracil (103). Compound 101 (602.0 mg, 1.83 
mmol) was suspended in freshly distilled Et3N (56 mL) and the mixture degassed for 1 h. 
Trimethylsilylacetylene (723.0 mg, 1.04 mL, 7.36 mmol) was added to the suspension 
followed by (PPh3)2PdCl2 (30 mg, 0.043 mmol) and CuI (22 mg, 0.12 mmol). The 
mixture was then heated at 50 oC until TLC confirmed total consumption of the starting 
101. All the volatiles were removed under vacuum and the brown residue was 
chromatographed (hexanes/EtOAc, 1:1) to give 103 (438.0 mg, 80%) as a pale-yellow 
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solid. 1H NMR  0.21 (s, 9H, SiMe3), 4.92 (s, 2H, Ph-CH2), 7.28-7.32 (m, 2H, Ph), 7.35-
7.43 (m, 3H, Ph), 7.47 (s, 1H, H6), 8.35 (br. s, 1H, NH). 13C NMR  -0.18 (SiMe3), 51.72 
(Ph-CH2), 94.78, 100.14, 100.61 (C5, CC), 128.09, 128.85, 129.29 (Ph), 134.62 (Ph-Q), 
147.06 (C6), 149.74 (C2), 161.01 (C4). GC-MS (tR 26.68 min.) m/z 298 (29, M+), 283 
(29, M-15), 91 (100), no peak at m/z 296 (M-2)+.  
4-[18O]-1-N-Benzyl-5-((trimethylsilyl)ethynyl)uracil (104). Treatment of 102 (388.0 
mg, 1.18 mmol) as described for 103 gave compound 104 (218.0 mg, 62%) as a pale-
yellow solid with data identical to that reported above for 103, except for GC-MS (tR 
26.67 min.) m/z 300 (23, M+), 298 (4, M-2), 285 (23, M-15), 91 (100). [16O/18O ratio, 
14:86; based on comparison of the peak intensities at m/z 298 (M+, 103) and m/z 300 
(M+, 104)].  
1-N-Benzyl-5-ethynyluracil (105). Procedure A. Compound 103 (560.0 mg, 1.88 
mmol) was dissolved in dry THF (32 mL) and the clear solution stirred at 0 oC for about 
20 min. Tetrabutylammonium fluoride (1.88 mL, 1.88 mmol, 1 M in THF) was added via 
syringe and the solution stirred for one hour at 0 oC. The solvent was removed under 
reduced pressure and the resulting yellow crude dissolved in CHCl3 (30 mL) and 
successively washed with saturated NaHCO3 and H2O. After drying the organic phase 
over anhydrous Na2SO4 the oily residue was chromatographed (CH2Cl2/EtOAc, 7:3) to 
give compound 105 (252.5 mg, 60%) containing a little impurity associated to 
tetrabutylammonium fluoride. 1H NMR  3.18 (s, 1H, CCH), 4.93 (s, 2H, Ph-CH2), 
7.27-7.44 (m, 5H, Ph), 7.49 (s, 1H, H6), 8.44 (br. s, 1H, NH). 13C NMR  51.76 (Ph-
CH2), 74.20, 82.40, 99.37 (C5, CCH), 128.20, 128.95, 129.34 (Ph), 134.39 (Ph-Q), 
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147.35 (C6), 149.67 (C2), 161.18 (C4). GC-MS (tR 24.11 min) m/z 226 (19, M+), 91 
(100), no peak at m/z 224 (M-2)+. HRMS calcd for C13H11N2O2 (MH+) 227.08205. Found 
227.08191. 
Procedure B. Compound 103 (645.0 mg, 2.16 mmol) was suspended in MeOH (15 mL) 
and ammonium fluoride (1.04 g, 28.08 mmol) added. The resulting heterogeneous 
mixture was refluxed (60 oC) until TLC confirmed the total consumption of the starting 
103. The reaction mixture was allowed to cool down to ambient temperature and filtered 
by gravity to removed undissolved NH4F. The volatiles were evaporated and the residue 
chromatographed (dry method, CHCl3) to afford 105 (281.0 mg, 57%) as a white solid.  
4-[18O]-1-N-Benzyl-5-ethynyluracil (106). Treatment of 103 (209.0 mg, 0.70 mmol) as 
described in Procedure A, afforded compound 106 (91.5 mg, 58%) as a white powder 
with data identical to the reported above for 105, except for GC-MS (tR 24.12 min) m/z, 
228 (16, M+), 226 (3, M-2), 91 (100). [16O/18O ratio, 14:86; based on comparison of the 
peak intensities at m/z 226 (M+, 105) and m/z 228 (M+, 106)]. HRMS calcd for 
C13H11N2O18O (MH+) 229.08630. Found 229.08594.    
(Z)-1-N-Benzyl-5-(2-(triphenylgermyl)ethenyl)uracil (Z-107).  In a screw-capped glass 
tube 105 (49.7 mg, 0.22 mmol) was dissolved in dry THF (5 mL) and stirred for 20 min 
under N2 at 0 oC. Triphenylgermanium hydride (73.0 mg, 0.24 mmol) and Et3B (265 uL, 
0.265 mmol, 1M in THF) were added and the solution stirred at 0 oC for 7 h (Method B). 
The volatiles were removed under reduced pressure and the resulting bright-yellow liquid 
chromatographed (hexanes/EtOAc, 1:1) to give Z-107 (54.1 mg, 46%). 1H NMR  4.03 
(s, 2H, Ph-CH2), 6.30 (d, 3JV1-V2=13.5 Hz, 1H, vinyl 1), 6.69 (“d”, 3Jo-m=7.0 Hz, Ph-H-
ortho), 6.84 (s, 1H, H6), 7.09 (“t”, 3Jm-o/p=7.5 Hz, Ph-H-meta), 7.16 (“t”, 3Jp-m=7.1 Hz, 
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Ph-H-para), 7.23-7.35 (m, 10H, GePh3 + vinyl 2), 7.37-7.46 (m, 6H, GePh3), 8.51 (br. s, 
1H, NH). 13C NMR  51.21 (Ph-CH2), 113.71 (C5), 128.27 (Ph-CH-ortho), 128.30 (vinyl 
1), 128.44 (Ph-CH-para), 128.76 (GePh3 x6), 129.03 (Ph-CH-meta), 129.47 (GePh3 x 3), 
134.78 (GePh3 x 6), 135.02 (Ph-Q), 136.65 (GePh3 Q x 3), 138.74 (vinyl 2), 141.03 (C6), 
150.18 (C2), 162.53 (C4).  
1-N-Benzyl-5-(2-(triphenylgermyl)acetyl)uracil (108). In a screw-capped glass tube 
105 (50.0 mg, 0.22 mmol) was suspended in dry toluene (5 mL) and the mixture degassed 
using N2 for 50 min. Triphenylgermanium hydride (73.0 mg, 0.24 mmol) and 1,1'-
azobis(cyclohexanecarbonitrile) (catalytic amount) were added and the suspension heated 
at 85 oC for 2 h (TLC showed approximately 80% consumption of 105 relative to a new 
higher moving spot). The volatiles were evaporated under vacuum and the resulting 
yellow oil slowly chromatographed (hexanes/EtOAc, 3:2) to give two fractions. The first 
fraction contained 108 (3.5 mg, 3%) while the second gave an inseparable mixture of 108 
and Z-107 (28.2 mg). Compound 108 had: 1H NMR  3.81 (s, 2H, H8), 4.77 (s, 2H, Ph-
CH2), 7.24-7.40 (m, 14H, GePh3 + Ph-H), 7.48-7.54 (m, 6H, GePh3), 7.79 (br. s, 1H, 
NH), 7.85 (s, 1H, H6). 13C NMR  33.11 (C8), 52.38 (Ph-CH2), 113.30 (C5), 128.30 
(GePh3 x 6), 128.46 (Ph-CH-ortho), 129.09 (Ph-CH-para), 129.34 (Ph-CH-meta), 129.45 
(GePh3 x 3), 134.51 (Ph-Q), 135.15 (GePh3 x 6), 135.29 (GePh3 Q x 3), 149.70 (C2), 
149.88 (C6), 160.68 (C4), 194.30 (C7-ketone). MS (ESI+) m/z 605.0 [M+58]+; MS (EI) 
547.0 (85, M+), 469.0 (24), 305.0 (100). 
4-[18O]-1-N-Benzyl-5-(2-(triphenylgermyl)acetyl)uracil (110). Treatment of 106 (44.5 
mg, 0.20 mmol) as described for 108, afforded two fractions after chromatography 
(hexanes/EtOAc, 3:2). The first fraction contained 110 (3.3 mg, 3%) while the second 
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consists of a mixture of 110 and Z-109 (25.3 mg). Both compounds Z-109 and byproduct 
110 showed identical NMR data as reported above for the unlabeled analogues Z-107 and 
108. However, for compound 110; MS (ESI+) m/z 607.0 [M+58] and MS (EI) m/z 547.1 
(9, M+), 457.1 (28), 305.0 (100).  
1-(2,3,5-Tri-O-acetyl--D-arabinofuranosyl)-5-[(E/Z)-2-(tris(trimethylsilyl)germyl)-
ethenyl]uracil (E/Z-111). A flame-dried 3 neck round-bottomed flask was charged with 
dry and degassed toluene (10 mL) circulating N2. The compound 74 (127.0 mg, 0.322 
mmol) was transferred into the flask and the resulting heterogeneous mixture was stirred 
and degassed for additional 30 min. The suspension was pre-heated up to 90 oC and just 
when all the solid was dissolved, tris(trimethylsilyl)germane (TMS)GeH (115.3 mg, 123 
L, 0.39 mmol) was added via syringe in one portion and fast. A catalytic amount of 1,1'-
azobis(cyclohexanecarbonitrile) was dissolved in degassed toluene (1 mL) and 
transferred to the reaction mixture. The solution was refluxed over 20 min and TLC 
revealed total consumption of 74. The mixture was immediately allowed to stabilize at 
room temperature and concentrated under reduced pressure. The residue was 
chromatographed (hexanes/EtOAc, 3:2) to give E/Z-111 (152.0 mg, 68%, E/Z 4:96). 1H 
NMR  0.20 (s, 25.92H, Ge(TMS)3-Z), 0.24 (s, 1.08H, Ge(TMS)3-E), 2.01 (s, 2.88H, Ac-
Me-Z), 2.10 (s, 2.88H, Ac-Me-Z), 2.11 (s, 0.12H, Ac-Me-E), 2.13 (s, 0.12H, Ac-Me-E), 
2.14 (s, 2.88H, Ac-Me-Z), 2.16 (s, 0.12H, Ac-Me-E), 4.17-4.24 (m, 1H, H4'-E/Z), 4.32-
4.40 (m, 0.04H, H5''-E), 4.34 (dd, 2JH5''-H5'=12.0 Hz, 3JH5''-H4'=5.5 Hz, 0.96H, H5''-Z), 4.38 
(dd, 2JH5'-H5''=12.0 Hz, 3JH5'-H4'=5.2 Hz, 0.96H, H5'-Z), 4.58 (dd, 2JH5'-H5''=11.9 Hz, 3JH5'-
H4'=7.3 Hz, 0.04H, H5'-E), 5.07 (dd, 3J=1.8 Hz, 3J=0.6 Hz, 0.04H, H3'-E), 5.14 (dd, 3JH3'-
H4'=3.8 Hz, 3JH3'-H2'=1.6 Hz, 0.96H, H3'-Z), 5.40 (dd, 3JH2'-H1'=3.5 Hz, 3JH2'-H3'=1.0 Hz, 
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0.04H, H2'-E), 5.47 (dd, 3JH2'-H1'=3.8 Hz, 3JH2'-H3'=1.7 Hz, 0.96H, H2'-Z), 6.16 (d, 3JH1'-
H2'=3.9 Hz, 0.96H, H1'-Z), 6.28 (d, 3JV1-V2=13.5 Hz, 0.96H, vinyl 1-Z), 6.36 (d, 3JH1'-
H2'=3.5 Hz, 0.04H, H1'-E), 6.63 (d, 3JV1-V2=18.7 Hz, 0.04H, vinyl 1-E), 6.86 (d, 3JV2-
V1=18.5 Hz, 0.04H, vinyl 2-E), 6.90 (dd, 3JV2-V1=13.5 Hz, 4JV2-H6=1.4 Hz, 0.96H, vinyl 2-
Z), 7.29 (d, 4JH6-V2=1.4 Hz, 0.96H, H6-Z), 7.52 (s, 0.04H, H6-E), 9.00 (br. s, 1H, NH-Z). 
13C NMR  1.73 (Ge(TMS)3-E), 1.95 (Ge(TMS)3-Z), 20.66, 20.88, 20.96 (Ac-CH3-Z), 
63.07 (C5'-Z), 74.95 (C2'-Z), 76.46 (C3'-Z), 80.71 (C4'-Z), 85.40 (C1'-Z), 116.09 (C5-Z), 
133.88 (vinyl 2-Z), 134.11 (vinyl 1-Z), 136.20 (C6-Z), 149.59 (C2-Z), 161.95 (C4-Z), 
168.86, 169.71, 170.56 (Ac-C=O). MS (APCI+) m/z 688.9 [MH]+ based on 74Ge.  
5-[(Z)-2-(tris(trimethylsilyl)germyl)ethenyl]-2',3',5'-tri-O-p-toluoyl-uridine (Z-112). 
A solution of 82a (38.0 mg, 0.061 mmol) and (Me3Si)3GeH (21.6 mg, 23 L, 0.074 
mmol) in dry THF (4 mL) was treated according to Method B (with progressive warming 
from -78 oC to 0 oC) for 6 h. The volatiles were removed under vacuum and the oily 
residue was chromatographed (hexanes/EtOAc, 3:2) to give Z-112 (27.5 mg, 61%). 1H 
NMR  0.16 (s, 27H, Ge(TMS)3), 2.39 (s, 6H, p-Tol-Me), 2.40 (s, 3H, p-Tol-Me), 4.62 
(dd, 2JH5''-H5'=11.5 Hz, 3JH5''-H4'=4.7 Hz, 1H, H5''), 4.65-4.71 (m, 1H, H4'), 4.73 (dd, 2JH5'-
H5''=11.5 Hz, 3JH5'-H4'=3.0 Hz, 1H, H5'), 5.90-5.96 (m, 3H, H1'/H2'/H3'), 6.17 (d, 3JV1-
V2=13.5 Hz, 1H, vinyl 1), 6.79 (dd, 3JV2-V1=13.5 Hz, 4JV2-H6=1.1 Hz, 1H, vinyl 2), 7.14 (d, 
3Jo-m=7.6 Hz, 2H, p-Tol-H), 7.17 (d, 3Jo-m=7.6 Hz, 2H, p-Tol-H), 7.19-7.24 (m, 3H, p-
Tol-H + H6), 7.82 (d, 3Jo-m=8.2 Hz, 4H, p-Tol-H), 7.93 (d, 3Jo-m=8.2 Hz, 2H, p-Tol-H). 
13C NMR  1.93 (Ge(TMS)3), 21.84, 21.85 (p-Tol-Me), 63.84 (C5'), 71.11 and 74.17 (C2' 
and C3'), 80.59 (C4'), 92.15 (C1'), 116.92 (C5), 126.07, 126.23, 126.87 (p-Tol-Q), 
129.28, 129.36, 129.93, 129.98, 130.04 (p-Tol-CH), 132.77 (vinyl 1), 133.78 (vinyl 2), 
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137.46 (C6), 144.20, 144.47, 144.66 (p-Tol-Q), 149.55 (C2), 162.14 (C4), 165.33, 
165.39, 166.30 (p-Tol-C=O). MS (ESI+) m/z 939.1 [M+Na]+ based on 74Ge.  
(Z)-2-(4-Methylphenyl)-1-[tris(trimethylsilyl)silyl]ethene (116b). Method C (Radical 
hydrosilylation of alkynes). (Me3Si)3SiH (0.31 mL, 248 mg, 1 mmol) was added in one 
portion via a syringe to a degassed solution of 115b (0.13 mL, 116 mg, 1 mmol) in dry 
benzene (3 mL) at ambient temperature under N2 atmosphere. The AIBN (83.8 mg, 0.50 
mmol) was then added and the resulting solution was heated (oil bath, 85 °C) for 3 h or 
until the alkyne was consumed (GC). The volatiles were evaporated in vacuo and the oily 
residue was flash chromatographed (hexanes) on silica gel to give 116b (336 mg, 92%) 
as a colorless oil: 1H NMR δ 0.16 (s, 27H), 2.37 (s, 3H), 5.82 (d, J=14.5 Hz, 1H), 7.16 (d, 
J=7.8 Hz, 2H), 7.22 (d, J=7.8 Hz, 2H), 7.40 (d, J=14.5 Hz, 1H); 13C NMR δ 1.4, 21.3, 
123.1, 128.1, 129.0, 137.1, 137.8, 146.6; 29Si NMR d -88.33 [s, Si(SiMe3)3], -11.67 [s, 
Si(SiMe3)3]; GC-MS: (tR 22.12 min) m/z 364 (6, M+), 174 (100). HRMS Calcd for 
C18H36Si4 (M+): 364.1894. Found: 364.1896. 
(Z)-2-(4-Methoxyphenyl)-1-[tris(trimethylsilyl)silyl]ethene (116c). Treatment of 115c 
(0.13 mL, 136 mg, 1 mmol) with (Me3Si)3SiH (0.31 mL, 248 mg, 1.0 mmol) and AIBN 
(84 mg, 0.5 mmol) by method C gave 116c (308 mg, 81%) as a colorless oil: 1H NMR  δ 
0.17 (s, 27H), 3.84 (s, 3H), 5.80 (d, J=14.4 Hz, 1H), 6.87 (d, J=8.7 Hz, 2H), 7.33 (d, 
J=8.7 Hz, 2H), 7.38 (d, J=14.4 Hz, 1H); 13C NMR δ 1.4, 55.5, 113.8, 121.9, 129.4, 133.5, 
146.1, 159.1; MS m/z 380 (10, M+), 174 (100). Anal. Calcd for C18H36OSi4 (380.82): C, 
56.77; H, 9.53. Found: C, 56.37; H, 9.78. 
(Z)-2-(4-Trifluoromethylphenyl)-1-[tris(trimethylsilyl)silyl]ethene (116d). Treatment 
of 115d (0.16 mL, 170 mg, 1 mmol) with (Me3Si)3SiH (0.31 mL, 248 mg, 1 mmol) and 
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AIBN (84 mg, 0.50 mmol) by method C gave 116d (334 mg, 80%) as a colorless oil: 1H 
NMR  δ 0.16 (s, 27H), 6.09 (d, J=14.6 Hz, 1H), 7.45 (d, J=14.6 Hz, 1H), 7.47 (d, J=8.2 
Hz, 2H), 7.60 (d, J=8.2 Hz, 2H); 13C NMR δ 1.35, 124.37 (q, J=272.0 Hz), 125.40 (q, 
J=3.8 Hz), 128.15, 128.36, 129.35 (q, J=32.6 Hz), 144.24, 144.98; 19F NMR  δ -62.45 (s); 
MS m/z 418 (3, M+), 174 (100). Anal. Calcd for C18H33F3Si4 (418.79): C, 51.62; H, 7.94. 
Found: C, 51.58; H, 8.15. 
(E)-2-Phenyl-1-[tris(trimethylsilyl)silyl]ethene (117a). The vinyl silane (Z)-116a178 
(350 mg, 1 mmol), (Me3Si)3SiH (0.15 mL, 124 mg, 0.5 mmol), Rh(COD)2BF4 (40.7 mg, 
0.1 mmol), PPh3 (52.5 mg, 0.2 mmol) and NaI (22.5 mg, 0.15 mmol) were placed into a 
screw-capped glass tube. The reaction mixture was heated with stirring at 60 oC for 18 h. 
The volatiles were evaporated and the residue [GC-MS: 117a/116a (E/Z, 88:12; tR 21.04 
min, Z, tR 21.33 min, E) m/z 350 (10, M+), 174 (100)] was chromatographed (hexanes) to 
give 117a178,203 (273 mg, 78%): 1H NMR  0.19 (s, 27H), 6.47 (d, J=18.8 Hz, 1H), 6.91 
(d, J=18.8 Hz, 1H), 7.23 (t, J=7.2 Hz, 1H), 7.33 (t, J=7.3 Hz, 2H), 7.39 (d, J=7.3 Hz, 
2H); 29Si NMR  (THF-d8)  -85.30 [s, Si(SiMe3)3], -14.34 [s, Si(SiMe3)3]. HRMS Calcd 
for C17H34Si4 (M+): 350.1738. Found: 350.1741. 
(E)-2-(4-Methylphenyl)-1-[tris(trimethylsilyl)silyl]ethene (117b). Alkyne 115b (116 
mg, 0.127 mL, 1.0 mmol), Rh(COD)2BF4 (40.7 mg, 0.1 mmol), PPh3 (52.5 mg, 0.2 
mmol), NaI (22.5 mg, 0.15 mmol)] and (Me3Si)3SiH (0.37 mL, 297 mg, 1.2 mmol) were 
placed under nitrogen in a screw-capped glass tube and the resulting mixture was heated 
with stirring at 60 oC for 20 h. The volatiles were evaporated and the residue [GC-MS: 
117b/116b (E/Z, 9:1); tR 22.12 min, Z; 22.39 min, E] was chromatographed (hexanes) to 
give 117b (298 mg, 82%): 1H NMR δ 0.19 (s, 27H), 2.36 (s, 3H), 6.39 (d, J=18.8 Hz, 
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1H), 6.83 (d, J=18.8 Hz, 1H), 7.16 (d, J=7.9 Hz, 2H), 7.24 (d, J=7.8 Hz, 2H); 13C NMR δ 
1.1, 21.4, 121.4, 126.1, 129.4, 136.6, 137.5, 145.5; 29Si NMR d -83.41 [s, Si(SiMe3)3], -
12.49 [s, Si(SiMe3)3]; GC-MS: (tR 22.39 min) m/z 364 (10, M+), 174 (100). HRMS Calcd 
for C18H36Si4 (M+): 364.1894. Found: 364.1898. 
The vinyl silane (Z)-116b (1.06 g, 2.92 mmol), (MeSi)3SiH (0.435 mL, 342 mg, 
1.375 mmol), RhCl(PPh3)3 (112 mg, 0.275 mmol) and NaI (61.6 mg, 0.42 mmol) were 
place into a screw-capped glass tube. The reaction mixture was heated with stirring at 75 
oC for 54 h. The volatiles were evaporated and the residue [GC-MS: 117b/116b (E/Z, 
99.5:0.5)] was chromatographed (hexanes) to give 117b (987 mg, 93%) as colorless oil. 
(E)-2-(4-Methoxyphenyl)-1-[tris(trimethylsilyl)silyl]ethene (117c). The vinyl silane 
(Z)-116c (381 mg, 1 mmol), (Me3Si)3SiH (0.15 mL, 124 mg, 0.5 mmol), Rh(COD)2BF4 
(40.7 mg, 0.1 mmol), PPh3 (52.5 mg, 0.2 mmol) and NaI (22.5 mg, 0.15 mmol) were 
placed into a screw-capped glass tube. The reaction mixture was heated with stirring at 
60 oC for 18 h. The volatiles were evaporated and the residue [GC-MS: 117c/116c (E/Z, 
92:8; tR 22.02 min, Z, tR 22.34 min, E) m/z 380 (15, M+), 174 (100)] was 
chromatographed (hexanes) to give 117c (338 mg, 89%): 1H NMR δ 0.25 (s, 27H), 3.84 
(s, 3H), 6.29 (d, J=18.8 Hz, 1H), 6.87 (d, J=18.8 Hz, 1H), 6.89 (d, J=8.8 Hz, 2H), 7.35 
(d, J=8.8 Hz, 2H); 13C NMR δ 1.0, 55.4, 114.0, 119.6, 127.2, 132.4, 145.0, 159.3. AP-
ESI-HRMS Calcd for C18H36ONaSi4 (MNa+): 403.1735. Found: 403.1739.  
(E)-1,2-Diphenylethene (118a). Method D (Pd-catalyzed cross-coupling of vinyl 
TTMS-silanes with NaOH as base). A solution of NaOH (60 mg, 1.5 mmol) and H2O2 
(30% solution, 0.15 mL, 1.5 mmol) in deionized H2O (1.5 mL) were added to a stirred 
solution of 117a (175 mg, 0.5 mmol) in THF (15 mL) at ambient temperature. After 15 
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min, iodobenzene (84 μL, 153 mg, 0.75 mmol), Pd(PPh3)4 (58 mg, 0.05 mmol) and 
tetrabutylammonium fluoride (1M/THF, 1.5 mL, 1.5 mmol) were added and the resulting 
brownish mixture was heated at 55 oC (oil bath) for 10 h. The volatiles were evaporated 
and the residue was partitioned (H2O/CHCl3). The aliquot of the organic layer was 
subjected to GC-MS and/or 1H NMR analysis in order to establish the overall 
stereochemistry. The organic layer was dried (MgSO4), evaporated and chromatographed 
(hexanes) to give (E)-118a (74 mg, 83%) with data identical to commercial sample: GC-
MS (tR 17.9 min, E) m/z 180 (100, M+). 
Treatment of 117a (35 mg, 0.10 mmol) with bromobenzene (16 μL, 23.6 mg, 0.15 
mmol) by method D gave (E)-118 (12 mg, 67%). 
Analogous treatment of 117a (35 mg, 0.10 mmol) with iodobenzene (17 μL, 31 
mg, 0.15 mmol) by method D (without TBAF) gave (E)-118a (13.5 mg, 75%). 
Analogous treatment of 117a (35 mg, 0.10 mmol) with bromobenzene (16 μL, 23.6 
mg, 0.15 mmol) by method D (without TBAF) gave (E)-118a (9 mg, 50%). Also, 
biphenyl (1%; e.g., 2% consumption of bromobenzene) was detected: GC-MS (tR 11.3 
min) m/z 154 (100, M+). 
Method E (Pd-catalyzed cross-coupling of TTMS-silanes with KOSiMe3 as base).  
KOSiMe3 (38.5 mg, 0.3 mmol) and H2O2 (30% solution, 31 μL, 0.30 mmol) were added 
to a stirred solution of 117a (35 mg, 0.10 mmol) in THF (3 mL) at ambient temperature. 
After 20 min, iodobenzene (17 μL, 31 mg, 0.15 mmol) and Pd(PPh3)4 (11 mg, 0.01 
mmol) were added and the resulting mixture was heated at 55 oC (oil bath) for 10 h.  
Aqueous work-up and purification as described in method D gave (E)-118a (11 mg, 
60%). 
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(E/Z)-1,2-Diphenylethene (118a). Treatment of 116a178 (35 mg, 0.10 mmol) with 
bromobenzene (16 μL, 23.6 mg, 0.15 mmol) by method D gave 118a (E/Z, 40:60; 15 mg, 
82%) with data identical to commercial sample: GC-MS (tR 15.1 min, Z; tR 17.9 min, E) 
m/z 180 (100, M+). HRMS Calcd for C14H13 (MH+): 181.1073. Found: 181.1079. 
Analogous treatment of 116a (35 mg, 0.10 mmol) with bromobenzene (16 μL, 23.6 
mg, 0.15 mmol) by method D (without TBAF) gave 118a (E/Z, 25:75; 10 mg, 55%). 
Also, biphenyl (3%; e.g. 6% consumption of bromobenzene) was detected (GC-MS). 
(E)-1-(4-Methylphenyl)-2-phenylethene (118b). Treatment of 117b (36.5 mg, 0.10 
mmol) with iodobenzene (17 μL, 31 mg, 0.15 mmol) by method D gave (E)-118b (14 
mg, 72%) with data as reported:23 1H NMR δ 2.22 (s, 3H), 6.92 (d, J=18.1 Hz, 1H), 6.98 
(d, J=18.1 Hz, 1H), 7.03 (d, J=7.9 Hz, 2H), 7.13 (t, J=7.3 Hz, 1H), 7.22 (t, J=7.4 Hz, 
2H), 7.30 (d, J=8.1 Hz, 2H), 7.39 (d, J=7.9 Hz, 2H), GC-MS (tR 19.6 min) m/z 194 (100, 
M+). 
(E/Z)-1-(4-Methylphenyl)-2-phenylethene (118b). Treatment of 116b (364 mg, 1.0 
mmol) with iodobenzene (0.17 mL, 306 mg, 1.5 mmol) by method D gave 118b204 (E/Z, 
3:97; 175 mg, 90%): GC-MS (tR 16.8 min, Z; tR 19.6 min, E) m/z 194 (100, M+). HRMS 
Calcd for C15H15 (MH+): 195.1174. Found: 195.1179. (Z)-118b had: 1H NMR δ 2.20 (s, 
3H), 6.43 (s, 2H), 6.92 (d, J=7.9 Hz, 2H), 7.03 (d, J=7.9 Hz, 2H), 7.11-7.20 (m, 5H). 
Treatment of 116b (36.5 mg, 0.10 mmol) with bromobenzene (16 μL, 23.6 mg, 
0.15 mmol) by method D gave 118b (E/Z, 30:70; 17 mg, 86%).  
Analogous treatment of 116b (36.5 mg, 0.10 mmol) with iodobenzene (17 μL, 31 
mg, 0.15 mmol) by method D (without TBAF) gave 118b (E/Z, 15:85; 12 mg, 61%). 
Identical coupling with bromobenzene (0.15 mmol) gave 118b (E/Z, 20:80; 8 mg, 40%).   
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Treatment of 116b (36.5 mg, 0.10 mmol) with iodobenzene (17 μL, 31 mg, 0.15 
mmol) by method E gave 118b (E/Z, 25:75; 11.6 mg, 60%).  Identical coupling with 
bromobenzene (0.15 mmol) gave 118b (E/Z, 10:90; 9 mg, 48%).  
Analogous treatment of 116b (36.5 mg, 0.10 mmol) with iodobenzene (17 μL, 31 
mg, 0.15 mmol) by method E [with addition of TBAF (0.3 mmol) as described in method 
D] gave 118b (E/Z, 2:98; 15.7 mg, 81%).  
Analogous treatment of 116b (36.5 mg, 0.10 mmol) with iodobenzene by method 
D [using aqueous NaF (12.6 mg, 0.3 mmol) instead of TBAF] gave 118b (E/Z, 40:60; 
11.6 mg, 60%). 
Analogous treatment of 116b (36.5 mg, 0.10 mmol) with iodobenzene by method 
D [using Pd2(dba)3 (9.2 mg, 0.01 mmol ) instead of Pd(PPh3)4 and without addition of 
TBAF] gave 118b (E/Z, 25:75; 10 mg, 52%). 
(E)-1-(4-Methoxyphenyl)-2-phenylethene (118c). Treatment of 117a (35 mg, 0.10 
mmol) with 4-methoxyiodobenzene (35 mg, 0.15 mmol) by method D gave (E)-118c204 
(14 mg, 79%): 1H NMR δ 3.84 (s, 3H), 6.90 (d, J=8.2 Hz, 2H), 6.98 (d, J=16.4 Hz, 1H), 
7.07 (d, J=16.4 Hz, 1H), 7.24 (t, J=7.3 Hz, 1H), 7.34 (t, J=7.9 Hz, 2H), 7.44-7.51 (m, 
4H); 13C NMR δ 55.3, 114.1, 126.2, 126.6, 127.2, 127.7, 128.2, 128.6, 130.1, 137.6, 
159.2; MS m/z 210 (100, M+). 
Treatment of 117c (35 mg, 0.10 mmol) with bromobenzene (16 μL, 23.6 mg, 0.15 
mmol) by method D gave (E)-118c (13 mg, 63%). 
(E/Z)-1-(4-Methoxyphenyl)-2-phenylethene (118c). Treatment of 116c (38 mg, 0.10 
mmol) with bromobenzene (16 μL, 23.6 mg, 0.15 mmol) by method D gave E/Z-118c204 
(E/Z, 9:91; 20 mg, 97%): GC-MS (tR 19.0 min, Z; tR 21.6 min, E) m/z 210 (100, M+). 
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HRMS Calcd for C15H14O (M+ + H): 211.1123. Found: 211.1124. (Z)-118c had: 1H NMR 
δ 3.81 (s, 3H), 6.50 ("s", 2H), 6.79 (d, J=8.4 Hz, 2H), 7.20-7.31 (m, 7H); 13C NMR δ 
55.6, 114.0, 127.3, 128.6, 129.2, 129.2, 130.1, 130.2, 130.6, 138.0, 159.1. 
(E)-1-(4-Trifluoromethylphenyl)-2-phenylethene (118d). Treatment of 117a (35 mg, 
0.10 mmol) with 4-iodo-α,α,α-trifluorotoluene (22 μL, 41 mg, 0.15 mmol) by method D 
gave (E)-118d205 (22.3 mg, 90%): 1H NMR δ 7.12 (d, J=16.3 Hz, 1H), 7.22 (d, J=16.3 
Hz, 1H), 7.31 (t, J=7.3 Hz, 1H), 7.39 (t, J=7.3 Hz, 2H), 7.34 (d, J=7.3 Hz, 2H), 7.61 (br. 
s, 4H); 19F NMR δ -62.90 (s); MS m/z 248 (100, M+). 
(E/Z)-1-(4-Trifluoromethylphenyl)-2-phenylethene (118d). Treatment of 116d (42 mg, 
0.10 mmol) with bromobenzene (16 μL, 23.6 mg, 0.15 mmol) by method D gave E/Z-
118d205 (E/Z, 55:45; 17 mg, 70%). HRMS Calcd for C15H11F3 (M+ + H): 249.0891. 
Found: 249.0883. (Z)-118d had: 1H NMR δ 6.62 (d, J=12.3 Hz, 1H), 6.75 (d, J=12.3 Hz, 
1H), 7.20-7.35 (m, 5H), 7.41 (d, J=7.8 Hz, 2H), 7.50 (d, J=7.8 Hz, 2H); 19F NMR δ-
62.98 (s); MS m/z 248 (100, M+). 
(E)-1-(4-n-Butylphenyl)-2-(4-methylphenyl)ethene (119b). Treatment of 117b (50 mg, 
0.14 mmol) with 4-n-butyl-1-iodobenzene (36 mL, 54 mg, 0.21 mmol) by method D gave 
(E)-119b (20 mg, 59%): 1H NMR  0.97 (t, J=7.3 Hz, 3H), 1.40 (sextet, J=7.4 Hz, 2H), 
1.60-1.68 (m, 2H), 2.39 (s, 3H), 2.65 (t, J=7.7 Hz, 2H), 7.08 (s, 2H), 7.19 and 7.20 (2  d, 
J=8.2 Hz, 2H), 7.43 and 7.45 (2  d, J=8.2 Hz, 2H); 13C NMR  13.9, 21.2, 22.4, 33.6, 
35.4, 126.3, 127.71, 127.72, 128.7, 129.4, 134.8, 135.0, 137.3, 142.4; GC-MS (tR 24.3 
min) m/z 250 (70, M+), 207 (100). HRMS Calcd for C19H22 (M+): 250.1721. Found: 
250.1728. 
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(E/Z)-1-(4-n-Butylphenyl)-2-(methylphenyl)ethene (119b). Treatment of 116b (52 mg, 
0.14 mmol) with 4-n-butyl-1-iodobenzene (36 mL, 56 mg, 0.21 mmol) by method D gave 
E/Z-119b (E/Z, 24:76; 22 mg, 61%): GC-MS (tR 21.5 min, Z; 24.3 min, E) m/z 250 (70, 
M+), 207 (100). (Z)-119b had: 1H NMR  0.94 (t, J=7.3 Hz, 3H), 1.37 (sextet, J=7.5 Hz, 
2H), 1.57-1.65 (m, 2H), 2.34 (s, 3H), 2.59 (t, J=7.8 Hz, 2H), 6.55 (s, 2H), 7.06 (d, J=8.1 
Hz, 4H), 7.17-7.22 (m, 4H); 13C NMR  14.0, 21.3, 22.4, 33.5, 35.4, 128.2, 128.7, 128.8, 
128.9, 129.49, 129.58, 134.5, 134.7, 136.2, 141.3. HRMS Calcd for C19H22 (M+): 
250.1721. Found: 250.1728. 
(E)-1-(4-Methylphenyl)-2-(naphtha-1-yl)ethene (120b). Treatment of 117b (35 mg, 
0.096 mmol) with 1-iodonaphthalene (22 mL, 37 mg, 0.14 mmol) by method D gave (E)-
120b206 (16 mg, 70%): 1H NMR  2.42 (s, 3H), 7.16 (d, J=16.0 Hz, 1H), 7.25 (d, J=8.0 
Hz, 2H), 7.50-7.60 (m, 5H), 7.77 (d, J=7.2 Hz, 1H), 7.82 (d, J=8.2 Hz, 1H), 7.87 (d, 
J=15.9 Hz, 1H), 7.90 (d, J=7.5 Hz, 1H), 8.26 (d, J=8.0 Hz, 1H); 13C NMR  21.3, 123.5, 
123.8, 124.8, 125.7, 125.8, 126.0, 126.6, 127.9, 128.6, 129.5, 131.4, 131.7, 133.8, 134.9, 
135.2, 137.7; GC-MS (tR 25.8 min) m/z 244 (98, M+), 229 (100). HRMS Calcd for C19H16 
(M+): 244.1252. Found: 244.1253. 
Analogous treatment of 117b (55 mg, 0.15 mmol) with 1-iodonaphthalene (33 mL, 
58 mg, 0.22 mmol) by method D (without TBAF) gave (E)-120b (17 mg, 46%). 
Analogous treatment of 117b (55 mg, 0.15 mmol) with 1-bromonaphthalene (31 
mL, 46 mg, 0.22 mmol) by method D gave (E)-120b (18 mg, 48%). 
(E/Z)-1-(4-Methylphenyl)-2-(naphtha-1-yl)ethene (120b). Treatment of 116b (50 mg, 
0.14 mmol) with 1-iodonaphthalene (31 mL, 52 mg, 0.21 mmol) by method D gave E/Z-
120b206 (E/Z, 15:85; 25 mg, 73%): GC-MS (tR 23.1 min, Z; 25.8 min, E) m/z 244 (98, 
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M+), 229 (100). (Z)-120b had: 1H NMR  2.26 (s, 3H), 6.83 (d, J=12.2 Hz, 1H), 6.92 (d, 
J=8.1 Hz, 2H), 7.01 (d, J=8.1 Hz, 2H), 7.03 (d, J=12.2 Hz, 1H), 7.35-7.42 (m, 2H), 7.48-
7.55 (m, 2H), 7.80 (d, J=7.7 Hz, 1H), 7.88-7.92 (m, 1H), 8.09-8.14 (m, 1H); 13C NMR  
21.2, 125.0, 125.6, 125.9, 126.0, 126.4, 127.4, 127.6, 128.4, 128.8, 129.0, 131.6, 131.9, 
133.7, 133.9, 135.6, 136.9. HRMS Calcd for C19H16 (M+): 244.1252. Found: 244.1253. 
Analogous treatment of 116b (41 mg, 0.11 mmol) with 1-bromonaphthalene (24 
mL, 35 mg, 0.17 mmol) by method D gave E/Z-120b (E/Z, 27:73; 14 mg, 51%). 
Analogous treatment of 116b (41 mg, 0.11 mmol) with 1-bromonaphthalene (24 
mL, 35 mg, 0.17 mmol) by method D (without TBAF) gave E/Z-120b (E/Z, 17:83; 8 mg, 
30%). 
(Z)-2-(4-Methylphenyl)-1-[tris(trimethylsiloxy)silyl]ethene (124). Treatment of 116b 
(50 mg, 0.14 mmol) with 1-iodonaphtalene (22 mL, 35 mg, 0.14 mmol) by method D 
[without TBAF, 2 h, NaOH (5 equiv.)] and column chromatography (hexanes) gave 124 
(4 mg, 7%) and E/Z-120b (E/Z, 7:93; 4 mg, 12%). Compound 124 had: 1H NMR  0.07 
(br s, 27H), 2.36 (s, 3H), 5.50 (d, J=15.5 Hz, 1H), 7.12 (d, J=7.9 Hz, 2H), 7.21 (d, J=15.5 
Hz, 1H) 7.44 (d, J=8.0 Hz, 2H); 29Si NMR  -66.0 [s, Si(OSiMe3)3], 7.94 [s, 
Si(OSiMe3)3]; GC-MS (tR 17.60 min) m/z 412 (6, M+), 175 (100); HRMS Calcd for 
C18H37O3Si4 (MH+): 413.1814. Found: 413.1823. 
Triallyl(phenyl)germane (125). In a flame-dried round-bottom flask a solution of 
trichloro(phenyl)germane (250 mg, 160 mL, 0.976 mmol) in Et2O (2 mL) was treated 
with allylmagnesium bromide (3.1 mL, 3.12 mmol, 1 M solution in Et2O) added 
dropwise for 20 min at 0 oC. After 1 h stirring at 0 oC the reaction mixture was refluxed 
(38 oC) overnight. The reaction was allowed to cool to room temperature and quenched 
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with NH4Cl at 0 oC. The organic layer was separated and the aqueous layer extracted with 
Et2O (2x5 mL). The combined extracts were washed with water and brine and dried over 
anhydrous MgSO4. The crude mixture was concentrated in vacuo and chromatographed 
(hexanes) to give 125 (227 mg, 85%) as clear oil. 1H NMR  2.04 (d, J=8.3 Hz, 6H), 4.89 
(d, J=10.0 Hz, 3H), 4.95 (d, J=16.9 Hz, 3H), 5.88 (m, 3H), 7.38 (m, 3H), 7.47 (m, 2H). 
13C NMR  19.54, 113.67, 127.99, 128.74, 133.87, 134.84, 137.95. GC-MS (tR 19.1 min) 
m/z 273 (33, M+), 151 (100); (tR 16.2 min) m/z 233 (89, M+-41), 151 (100). 
Diallyl(diphenyl)germane (126). Treatment of a solution of dichloro(diphenyl)germane 
(1.0 g, 0.707 mL, 3.359 mmol) in Et2O (2 mL) as reported for 125 afforded compound 
126 (980 mg, 94%) as clear oil. 1H NMR  2.27 (dt, J=8.3, 1.0 Hz, 4H), 4.90 (dq, J=9.2 
Hz, 1.7 Hz, 2H), 4.95 (d, J=16.9 Hz, 2H), 5.90 (m, 2H), 7.39 (m, 6H), 7.49 (m, 4H). 13C 
NMR  20.08, 114.12, 128.08, 128.90, 134.48, 134.62, 137.12. GC-MS (tR 22.3 min) m/z 
269 (100, M+-41), 227 (29), 151 (80).  
Allyl(triphenyl)germane (127). Treatment of a solution of chloro(triphenyl)germane 
(260.0 mg, 0.77 mmol) in Et2O (2 mL) with allylmagnesium bromide as reported for 125 
(mixing at room temperature instead of 0 oC) afforded compound 127 (245.0 mg, 92%) as 
white solid. 1H NMR  2.52 (d, J=8.1 Hz, 2H), 4.90 (dq, J=10.0 Hz, 1.0 Hz, 1H), 5.00 
(dq, J=16.9 Hz, 1.6 Hz, 1H), 5.95 (m, 1H), 7.40 (m, 9H), 7.51 (m, 6H). 13C NMR  
21.24, 114.50, 128.18, 129.02, 134.53, 135.02, 136.55. GC-MS (tR 24.5 min) m/z 305 
(100, M+-41), 227 (14), 151 (23). 
Treatment of a solution of allyltrichlorogermane (855 mg, 560 mL, 3.886 mmol) 
in Et2O (2 mL) with phenylmagnesium bromide (4.0 mL, 4.02 mmol, 3 M solution in 
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Et2O) following the procedure described above for 125 gave compound 127 (590 mg, 
44%). 
1-Allyl-4-butylbenzene (128a). 1-butyl-4-iodobenzene (45.1 mg, 29.4 L, 0.174 mmol) 
was added to a solution of tris(allyl)phenylgermane 125 (43.0 mg, 0.16 mmol) and 2 M 
NaOH (1.0 mL, 2.0 mmol) in 1,4-dioxane (5 mL). The reaction mixture was stirred for 15 
min at ambient temperature and Pd(OAc)2 (5 mg, 0.022 mmol) was added. The reaction 
mixture was heated at 95 oC for 16 h. The resulting mixture was quenched with 20 mL of 
water and the aqueous layer was extracted with Et2O. The combined organic layers were 
dried over Na2SO4 and the solvent evaporated under reduced pressure. Purification of the 
crude by column chromatography (hexanes) gave an unseparable mixture of 128a and 
129a (17 mg, 60%, 88:12; based on 1H NMR). GC-MS: (tR 11.9 min, 128a; tR 12.7 min, 
129a) m/z 175 (M+1, 7), 174 (M+, 44), 131 (100), 117 (55), 91 (42). 1H NMR  0.95 (t, 
J=7.4 Hz, 2.64H), 0.96 (t, J=7.3 Hz, 0.36H), 1.38 (sextet, 2H), 1.58-1.64 (m, 2H), 2.17 
(s, 0.36H), 2.61 (t, J=7.8 Hz, 1.76H), 2.63 (t, J=7.7 Hz, 0.24H), 3.39 (d, J=6.8 Hz, 
1.76H), 5.06 (m, 0.12H), 5.08 (dq, J=10.3 Hz, 1.0 Hz, 0.88H), 5.11 (dq, J=17.0 Hz, 1.7 
Hz, 0.88H), 5.36-5.38 (m, 0.12H), 5.99 (ddt, J=16.9 Hz, 10.1 Hz, 6.7 Hz, 1H), 7.11-7.15 
(m, 4H), 7.17 (d, J=8.2 Hz, 0.24H), 7.42 (d, J=8.2 Hz, 0.24H). 
1-Allylnaphthalene (128b). 1-iodonaphthalene (43.8 mg, 25.2 L, 0.17 mmol) was 
added to a solution of tris(allyl)phenylgermane 125 (42.8 mg, 0.16 mmol) and 2 M 
NaOH (1.0 mL, 2.0 mmol) in 1,4-dioxane (5 mL). The reaction mixture was stirred for 15 
min at ambient temperature and Pd(OAc)2 (5 mg, 0.022 mmol) was added. The reaction 
mixture was heated at 95 oC for 16 h. The resulting mixture was quenched with 20 mL of 
water and the aqueous layer was extracted with Et2O. The combined organic layers were 
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dried over Na2SO4 and the solvent evaporated under reduced pressure. Purification of the 
crude by column chromatography (hexanes) gave an unseparable mixture of 128b and 
129b (18 mg, 67%, 90:10; based on 1H NMR). GC-MS: (tR 13.4 min, 129b; tR 14.3 min, 
128b) m/z 169 (M+1, 14), 168 (M+, 100), 167 (M-1, 89), 153 (M-15, 91), 141 (26). 1H 
NMR  2.2 (s, 0.3H), 3.83 (d, J=6.3 Hz, 1.8H), 5.08-5.12 (m, 0.1H), 5.09-5.15 (m, 1.8H), 
5.40-5.44 (m, 0.1H), 6.14 (ddt, J=16.8 Hz, 10.1 Hz, 6.7 Hz, 0.9H), 7.30-7.38 (m, 1H), 
7.47-7.56 (m, 3H), 7.72-7.78 (m, 1H), 7.83-7.89 (m, 1H), 8.02-8.08 (m, 1H). 
Hexaphenyldigermoxanes (138). Tetracyanoethylene (41.4 mg, mmol) was added to a 
stirred solution of allyl(triphenyl)germane 127 (99.5 mg, 0.29 mmol) in acetonitrile (8 
mL) under nitrogen atmosphere. The resulting mixture was heated at 82 oC until TLC 
analysis showed complete consumption of the starting germane 127. An aqueous solution 
of NaOH (3 mL, 1 M solution) was added and the resulting brown solution stirred for 
additional 3 h at 82 oC. The mixture was concentrated under vacuum and the reaction 
mixture partitioned between EtOAc and H2O to give a brown solid which yielded a white 
solid (55.0 mg, 61%; m.p. 180 oC, uncorrected) after washing with MeOH. 1H NMR δ 
7.24-7.31 (m, 6H), 7.37 (tt, J=7.6 Hz, 1.2 Hz, 3H), 7.43-7.49 (m, 6H). 13C NMR  128.0, 
129.37, 134.42, 137.54. 
1-Phenylnaphthalene (139a). TBAF (1M/THF, 0.56 mL, 0.56 mmol) was added to a 
stirred solution of chlorodimethyl(phenyl)germane (143; 30.0 mL, 30 mg, 0.14 mmol), 1-
iodonaphthalene (22.5 μL, 39 mg, 0.16 mmol) and Pd2(dba)3 (6 mg, 0.013 mmol) in 
toluene (3.0 mL) at ambient temperature under nitrogen atmosphere. The resulting 
brownish mixture was heated at 100 oC (oil bath) for 12 h. The volatiles were evaporated 
and the residue was partitioned (H2O/CH2Cl2). The organic layer was dried (MgSO4), 
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evaporated and purified by column chromatography (hexane) to give 139a207  (26.6 mg, 
93%) followed by 141a207 [1.7 mg, 4%, 8% consumption of the iodonaphthalene; GC-
MS (tR 25.02 min) m/z 254 (100, M+)]. Compound 139a had: 1H NMR δ 7.41-7.58 (m, 
9H), 7.89 (d, J=8.2Hz, 1H), 7.91-7.96 (m, 2H) ; 13C NMR δ 125.5, 125.9, 126.15, 126.18, 
127.1, 127.4, 127.8, 128.4, 130.2, 131.8, 134.0, 140.4, 140.9; GC-MS (tR 19.87 min) m/z 
204 (100, M+). 
Method F (Pd-catalyzed cross-coupling of chloro(phenyl)germanes with TBAF).  
TBAF (1M/THF, 0.98 mL, 0.98 mmol) was added to a stirred solution of 
dichlorodiphenylgermane (144; 30.0 mL, 42 mg, 0.14 mmol), 1-iodonaphthalene (22.5 
μL, 39 mg, 0.16 mmol) and Pd2(dba)3 (6 mg, 0.013 mmol) in toluene (3.0 mL) at ambient 
temperature under nitrogen atmosphere. The resulting brownish mixture was heated at 
100 oC (oil bath) for 12 h. The volatiles were evaporated and the residue was partitioned 
(H2O/CH2Cl2). The organic layer was dried (MgSO4), evaporated and purified by column 
chromatography (hexane) to give 139a (17.1 mg, 30%) followed by 141a (8.0 mg, 20%). 
Treatment of 144 (30.0 mL, 42 mg, 0.14 mmol) with iodonaphthalene (45 μL, 78 
mg, 0.31 mmol) by Method F gave 139a (31.1 mg, 55%) and 141a (17.6 mg, 22%). 
Treatment of chlorotriphenylgermane (145; 47.5 mg, 0.14 mmol) with 
iodonaphthalene (22.5 μL, 39 mg, 0.16 mmol) by Method F gave 139a (10.0 mg, 12%) 
and 141a (17.4 mg, 43%). 
Treatment of 145 (47.5 mg, 0.14 mmol) with iodonaphthalene (45 μL, 78 mg, 
0.31 mmol) by Method F gave 139a (30.0 mg, 35%) and 141a (18.7 mg, 24%). 
Treatment of 145 (47.5 mg, 0.14 mmol) with iodonaphthalene (67.5 μL, 117 mg, 
0.46 mmol) by Method F gave 139a (33.7 mg, 39%) and 141a (35.0 mg, 30%). 
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Treatment of 145 (47.5 mg, 0.14 mmol) with bromonaphthalene (70 μL, 99 mg, 
0.46 mmol) by Method F gave 139a (24%) and 141a (15%) based on GC/MS analysis of 
the crude reaction mixture. 
Treatment of 146 (24.0 mL, 35.9 mg, 0.14 mmol) with iodonaphthalene (22.5 μL, 
39 mg, 0.16 mmol) by Method F gave 139a (23.1 mg, 81%) and 141a (1.5 mg, 4%). 
Treatment of 146 (24.0 mL, 35.9 mg, 0.14 mmol) with bromonaphthalene (22.3 
μL, 33 mg, 0.16 mmol) by Method F gave 139a (23.4 mg, 82%). 
Method G (Pd-catalyzed cross-coupling of chloro(phenyl)germanes with TBAF and 
added water).    TBAF (1M/THF, 0.98 mL, 0.98 mmol) was added to a stirred solution 
of 144 (30.0 mL, 42 mg, 0.14 mmol), 1-iodonaphthalene (22.5 μL, 39 mg, 0.16 mmol), 
water (100 μL, 5.7 mmol) and Pd2(dba)3 (6 mg, 0.013 mmol) in toluene (3.0 mL) at 
ambient temperature under nitrogen atmosphere. The resulting brownish mixture was 
heated at 100 oC (oil bath) for 12 h. The volatiles were evaporated and the residue was 
partitioned (H2O/CH2Cl2). The organic layer was dried (MgSO4), evaporated and purified 
by column chromatography (hexane) to give 139a (24.0 mg, 42%) followed by 141a (1.3 
mg, 3%). 
Treatment of 144 (30.0 mL, 42 mg, 0.14 mmol) with iodonaphtalene (45 μL, 78 
mg, 0.31 mmol) by Method G gave 139a (50.8 mg, 89%) and 141a (6.3 mg, 8%). 
Treatment of 144 (30.0 mL, 42 mg, 0.14 mmol) with bromonaphthalene (45 μL, 
66 mg, 0.31 mmol) by Method G [H2O; 30 μL, 1.7 mmol] gave 139a (27.0 mg, 48%) and 
141a (4.5 mg, 6%). 
Treatment of 145 (47.5 mg, 0.14 mmol) with iodonaphthalene (22.5 μL, 39 mg, 
0.16 mmol) by Method G gave 139a (14.3 mg, 17%) and 141a (7.1 mg, 18%). 
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Treatment of 145 (47.5 mg, 0.14 mmol) with iodonaphthalene (45 μL, 78 mg, 
0.31 mmol) by Method G gave 139a (51.1 mg, 60%) and 141a (7.0 mg, 9%). 
Treatment of 145 (47.5 mg, 0.14 mmol) with iodonaphthalene (67.5 μL, 117 mg, 
0.46 mmol) by Method G gave 139a (75.0 mg, 88%) and 141a (7.0 mg, 6%). 
Treatment of 146 (24.0 mL, 35.9 mg, 0.14 mmol) with iodonaphthalene (22.5 μL, 
39 mg, 0.16 mmol) by Method G gave 139a (27.4 mg, 96%) and 141a (1.0 mg, 2.5%). 
4-Phenylanisole (139b). Treatment of 144 (30.0 mL, 30 mg, 0.14 mmol) with 4-
iodoanisole (60.0 mL, 60 mg, 0.31 mmol) by Method G at 115 oC gave 139b80 (43.8 mg, 
85%) followed by 141b207 [5.2 mg, 8%, GC-MS (tR  20.81 min) m/z 214 (100, M+)]. 
Compound 139b had: 1H NMR δ 3.86 (s, 3H), 7.98 (d, J=7.8 Hz, 2H), 7.31 (t, J=7.8 Hz, 
1H), 7.42 (t, J=8.6 Hz, 2H), 7.50-7.58 (m, 4H); 13C NMR δ 55.5, 114.4, 126.8, 126.9, 
128.3, 128.9, 134.0, 141.0, 159.3; GC-MS (tR 17.41 min) m/z 184 (100, M+).  
3-(Trifluoromethyl)biphenyl (139c). Treatment of 144 (30.0 mL, 42 mg, 0.14 mmol) 
with 1-iodo-3-(trifluoromethyl)benzene (44.6 mL, 84.8 mg, 0.31 mmol) by Method G 
gave 139c (42.0 mg, 68%) followed by 141c208 [16.0 mg, 18%; GC-MS (tR 12.58 min) 
m/z 290 (100, M+)]. Compound 139c had: 1H NMR δ 7.38-7.64 (m, 7H), 7.78 (d, J=7.4 
Hz, 1H), 7.85 (br. s, 1H); 13C NMR δ 124.07 (q, 3J=3.2 Hz), 124.11 (q, 3J=3.2 Hz), 124.4 
(q, 1J=272.2 Hz), 127.4, 128.2, 129.2, 129.4, 130.6, 131.3 (q, 2J=32.5 Hz), 134.0, 142.2; 
GC-MS (tR 12.84 min) m/z 222 (100, M+).  
4-Acetylbiphenyl (139d). Treatment of 144 (30.0 mL, 42 mg, 0.14 mmol) with 4-
iodoacetophenone (75.8 mg, 0.31 mmol) by Method G gave 139d (5.5 mg, 10%) 
followed by 141d209  [4.5 mg, 6%; GC-MS (tR 24.80 min) m/z 238 (30, M+)]. Compound 
139d had: 1H NMR δ 2.64 (s, 3H), 7.41 (t, J=7.2 Hz, 1H), 7.48 (t, J=7.7 Hz, 2H), 7.63 (d, 
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J=6.7 Hz, 2H), 7.69 (d, J=7.2 Hz, 2H), 8.04 (d, J=8.4 Hz, 2H); 13C NMR δ 26.8, 127.35, 
127.4, 128.4, 129.0, 129.1, 136.0, 140.0, 145.9, 197.9; GC-MS (tR 19.41 min) m/z 196 
(45, M+). 
(E)-1,2-Diphenylethene (139e). Treatment of 144 (30.0 mL, 42 mg, 0.14 mmol) with β-
bromostyrene (E/Z, ~85:15; 40.0 mL, 105 mg, 0.31 mmol) by Method F gave 139e210 
(2.5 mg, 5%), 141e [8.6 mg, 13%; GC-MS (tR  22.02 min) m/z 206 (100, M+)] and 
biphenyl207 [5.4 mg, 50%; GC-MS (tR 12.89 min) m/z 154 (100, M+)]. Compound 139e 
had: 1H NMR δ 7.14 (s, 2H), 7.29 (tt, J=7.3 Hz, 1.5 Hz, 2H), 7.39 (t, J=8.0 Hz, 4H), 7.54 
(d, J=7.2 Hz, 4H); 13C NMR δ 126.7, 127.8, 128.8, 128.9, 137.5; GC-MS (tR 17.93 min) 
m/z 180 (100, M+). 
2-Methyl-5-phenylthiophene (139f). Treatment of 144 (30.0 mL, 42 mg, 0.14 mmol) 
with 2-iodo-5-methylthiophene (37 mL, 70 mg, 0.31 mmol) by Method G gave 139f211 
(3.0 mg, 6%), 141f212 [5.0 mg, 8%; GC-MS (tR 16.74 min) m/z 194 (100, M+)] and 
biphenyl207 [5.4 mg, 25%; GC-MS (tR 12.89 min) m/z 154 (100, M+)]. Compound 139f 
had: 1H NMR δ 2.52 (s, 3H), 6.74 (dd, J=3.5 Hz, 0.8 Hz, 1H), 7.12 (d, J=3.5 Hz, 1H), 
7.21-7.28(m, 1H), 7.36 (t, J=8.0 Hz, 2H), 7.56 (d, J=8.0 Hz, 2H); 13C NMR δ 15.6, 123.0, 
125.7, 126.3 127.1, 128.9, 134.9, 139.6, 142.2; GC-MS (tR 15.03 min) m/z 174 (100, M+). 
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5. CONCLUSION 
 The stereoselective synthesis of novel 2',3',5'-tri-O-acetyl and 2',3',5'-O-p-toluoyl 
protected 5-[2-(tris(trimethylsilyl)germyl)ethenyl]uridine analogues was achieved via 
radical-promoted hydrogermylation of 5-alkynyl substrates with 
tris(trimethylsilyl)germane (TTMS-germane). These novel uridine analogues modified at 
carbon-5 were efficiently prepared using both thermally-induced radical addition 
(Method A) and Et3B-promoted hydrogermylation (Method B) with similar yields. The 
hydrogermylation with the bulky TTMS-germane using Et3B, as a low-temperature 
radical initiator, occurred stereoselectively via anti addition yielding exclusively the Z-
vinylgermane. On the other hand, the use of thermal radical initiation utilizing 1,1'-
azobis(cyclohexanecarbonitrile) (ACCN) gave predominantly the Z-isomer (E/Z, 4:96). 
The preference for the anti-addition of radicals to terminal alkynes by Et3B-promoted 
hydrogermylation was also confirmed when 5-alkynyl uridine analogues were treated 
with less-reactive organogermanium hydrides, such as Ph3GeH, Me3GeH, and Bu3GeH. 
The stereoselectivity for the kinetic Z-isomer was found to increase when bulkier germyl 
hydrides [Me3GeH (E/Z, 40:60), Bu3GeH (E/Z, 6:94), Ph3GeH (pure Z)] were 
employed. Also, the hydrogermylation showed better yields when more reactive aryl-
substituted germanes (40-60%) were utilized instead of alkyl-substituted germyl 
hydrides (30-45%). 
 During the hydrogermylation of several 5-ethynyluridine precursors with Ph3GeH 
at higher temperatures (0 oC vs -78 oC) in addition to the desired vinylgermane product, 
an unexpected byproduct which was tentatively assigned as a 5-[2-
(triphenylgermyl)acetyl]uridine analogue was also observed. In order to investigate the 
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formation of such 5-(-germyl)acetyl uridine derivatives, the 18O-labeled 4-[18O]-1-N-5-
ethynylbenzyluracil was synthesized from the 5-iodouracil precursor using established 
procedures. The hydrogermylation of the 18O-labeled 5-ethynyluracil with Ph3GeH 
employing thermal-radical initiation (Method A) also gave the corresponding 18O-labeled 
5-(-germyl)acetyl uracil derivative. 
 We demonstrated that conjugated and non-conjugated vinyl 
tris(trimethylsilyl)silanes undergo Pd-catalyzed cross-coupling with aryl iodides and 
bromides under aqueous oxidative conditions in the presence of sodium hydroxide with 
or without fluoride activation. Contrary to (E)-silanes, which undergo coupling with 
retention of stereochemistry, coupling of (Z)-silanes occurred with lower stereoselectivity 
giving an E/Z mixture of products. The best stereoselectivity was achieved when either 
aryl iodides or electron-rich TTMS-silanes were used. Under the oxidative coupling 
conditions neither reductive self-coupling of the halides nor oxidative homocoupling of 
the vinyl TTMS-silanes were observed.  The tris(trimethylsilyl)silanes remained intact 
under typical conditions employed in the coupling of dimethylsilanols (bases such as 
KOSiMe3), thus making stable and readily accessible vinyl TTMS-silanes alternative 
substrates ("masked" silanols) for the Hiyama coupling. Hydrogen peroxide is assumed to 
chemoselectively cleave SiSi bond(s) generating active silanol/siloxane species that 
undergo coupling in the presence of base. The silanol/siloxane intermediates were 
observed when the progress of the reaction of vinyl TTMS-silanes with H2O2/base was 
monitored by 29Si NMR. The (Z)-2-(4-methylphenyl)-1-[tris(trimethylsiloxy)silyl]ethene 
was isolated from the coupling reaction mixture and characterized by spectroscopic 
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techniques, supporting the proposed oxygen insertion in the presence of such oxidative 
coupling conditions. 
 The ability of novel allyl(phenyl)germanes to transfer the phenyl groups via Pd-
catalyzed cross-coupling with aryl iodides was explored in the presence of fluoride ions, 
base, or a base/H2O2 combination. However, instead of the formation of expected biaryls, 
the transfer of the allyl groups from the germane precursor was observed using aqueous 
NaOH and several Pd catalysts. A Heck arylation mechanism was proposed based on the 
formation of regioisomeric mixtures of allylated products. In order to force the transfer of 
the phenyl groups from the allyl(phenyl)germanes precursors, the selective cleavage of 
the Ge-C(allyl) bond was explored by treatment with tetracyanoethylene (TCNE). A one-
pot cleavage/hydrolysis sequence afforded hexaphenyldigermoxane which was able to 
undergo Pd-cross-coupling with 1-iodonaphthalene in the presence of fluoride ions. 
We have demonstrated that arylchlorogermanes undergo Pd-catalyzed cross-
couplings with aryl halides in the presence of TBAF in wet toluene to afford biaryl 
products. One chloride ligand on Ge center allows efficient activation by fluoride to 
promote transfer of up to three aryl groups from germane. The methodology shows that 
organogermanes can render a coupling efficiency comparable to the more established 
stannane and silane counterparts. Our coupling methodology (TBAF/”moist” toluene) 
was also found to promote transfer of multiple phenyl groups from analogous 
chloro(phenyl)silanes and chloro(phenyl)stannanes. The study of the activation of 
chloro(phenyl)germanes with TBAF by 19F NMR led to the observation of typical peaks 
for tetravalent monofluorogermanes ( -204 ppm) and difluorogermanes ( -163 ppm), as 
  153
well as, other signals tentatively assigned to pentavalent fluorogermanates around  -148 
ppm and  -120 ppm.  
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